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Employing a novel anti-pUL17 antibody I have resolved details of the 
physical relationship between the minor capsid protein, pUL17, and the herpes 
simplex virus (HSV-1) capsid and tegument layers.  I helped demonstrate that 
pUL17 binds externally and multivalently to the capsid, fulfilling a structural role 
and potentially explaining its function in DNA encapsidation as well.   
   Immunoprecipitation assays illustrated interactions of pUL17 with 
capsid proteins VP5 and pUL25 as well as tegument proteins VP11/12 and 
VP13/14.  A pUL17/ pUL25 capsid-independent complex was detected upon 
capsid-deficient infection.  In wild-type infection, this complex could also be 
detected independently of capsid.  Immunofluorescence studies revealed 
pUL17 and pUL25 co-localization in wild-type infection; moreover, proper 
localization was co-dependent.  While pUL25-deficient infection yielded a 
unique mis-localization of pUL17, the mis-localization phenotype of pUL25 in 
the absence of pUL17 resembled pUL25 mis-localization without VP23 and 
VP5.  
Deletion of capsid proteins but not all DNA cleavage and packaging 
proteins increased cytoplasmic concentrations of pUL25 and pUL17 though 
overall protein levels appeared depressed in immunostaining.  This 
observation coupled with poor pUL25 immunoprecipitation from these mutant 
viruses, suggests that pUL25/pUL17 may undergo conformational changes.  
Also, cytoplasmic localization of pUL25 seems to occur at least in part through 
Crm-1 nuclear export machinery.   
Additional immunoprecipitation studies revealed interactions with 
VP11/12 and VP13/14.  pUL17 was in turn immunoprecipitated with anti-
VP13/14 antibody.  Nickel matrix purification of pUL17 from a pUL17 C-terminal 
His-tagged virus also enhanced VP13/14 co-elution independently of VP16.  A 
VP13/14 and pUL17 immunofluorescence time course demonstrated co-
localization in the replication compartment, cytoplasm, and both nuclear and 
plasma membranes.  VP11/12 may mediate cytoplasmic VP13/14-pUL17 
interaction.  Upon transfection VP13/14 and pUL17 were found to co-localize in 
cytoplasmic puncta only when VP11/12 was expressed. 
I also probed for functional roles of pUL17 including intranuclear capsid 
transport, DNA-binding, and ATP hydrolysis.  All essential encapsidation 
proteins, including pUL17 were assayed by time-lapse microscopy for effects 
on intranuclear motility of GFP-VP26-labeled capsids.  No single protein was 
concluded to deter capsid dynamics, indicating intranuclear capsid movement 
does not reflect encapsidation and does not require encapsidation proteins.  
Additionally, pUL17 was found to bind to pac-1-containing DNA and may have 
ATPase activity.    
 
 
  
BIOGRAPHICAL SKETCH 
 
In 1996 as an undergraduate student at Washington University, Luella 
Scholtes began her research career studying genetics of plant pathogenesis in 
Dr. Barbara Kunkel’s laboratory.  She received a Bachelor of Arts degree from 
Washington University in 1997 and continued her studies for the following two 
years in Saint Louis University’s Cellular and Molecular Regulation Master’s 
degree program where she researched plant-nematode molecular interactions 
under the Chairman of the Department of Biology, Dr. Robert Bolla.  In 1999, 
she carried on  research in parasitology studying Leishmania at Washington 
University’s School of Medicine under the guidance of Dr. Stephen Beverley, 
Chairman of the Department of Molecular Microbiology.  She arrived at Cornell 
University in 2002 in pursuit of her Ph.D. from the department of Microbiology 
under the mentorship of Dr. Joel Baines and completed her Ph.D. work in 
2009. 
 iii
  
 
 
 
 
 
 
 
 
 
This work would not have been possible without the support and 
encouragement of my husband, family, and friends.  Most especially I would 
like to recognize my parents who have made many sacrifices throughout their 
lives to allow me opportunities that they themselves never had.     
 iv
 ACKNOWLEDGEMENTS 
I would like to thank the NIH, for the Virology Training Grant which supported 
many years of this work as well as Dr. Colin Parrish and Sachiko Funaba for 
their efforts in maintaining this support.  
 v
 TABLE OF CONTENTS 
Biographical Sketch……………………..…………………………………………..iii 
Dedication……..……………………………………...……………………………...iv 
Acknowledgements……………………………………………………………….....v 
Table of Contents………….………………………..……………….………….......vi 
List of Figures…………….………………………………………………………….vii 
List of Tables………………………………….……………...…………………....... x 
List of Abbreviations………………………….…………………...………………...xi 
List of Symbols……………………………….………………………...…………..xiii 
Preface………………………………………….…………………………………...xix 
Chapter I.  Introduction……………………..……………………………….……... 1 
Chapter II.  Herpes Simplex Virus 1 DNA Packaging Proteins Encoded by UL6, 
UL15, UL17, UL28, and UL33 Are Located on the External Surface of the Viral 
Capsid……………………………………………………….……………………… 71 
Chapter III.  The minor capsid proteins pUL17 and pUL25 associate 
independently of capsid or capsid triplex assembly………………………….…87 
Chapter IV.  pUL17 binds a DNA fragment with the HSV packaging site.…..118   
Chapter V.  The essential protein encoded by UL17 of herpes  
virus 1 bridges capsid and tegument proteins ……….………………...……. .128 
Chapter VI.  Inhibition of DNA Packaging does not abrogate intranuclear 
capsid movement………………………………………………………………….166 
Chapter VII.  Conclusion……………….…………………..……………...……..198 
Bibliography………………………………………………………………………..201 
 vi
 LIST OF FIGURES 
 
Figure 1.1  Conserved structure of Herpesviridae virions……………...…........ 3   
Figure 1.2  Schematic layout of HSV genome ………………………………...... 5   
Figure 1.3  Protein-binding interactions in attachment and penetration………. 8   
Figure 1.4  Conformational change in gD N-terminus………………..………...15 
Figure 1.5  Arrangement of primary amino acid sequence of gH ………….... 19 
Figure 1.6  Structural similarity between HSV gB and VSV G proteins……... 21 
Figure 1.7  Virion entry by fusion at the plasma membrane……….…...…….. 23 
Figure 1.8  Virion entry by endocytosis…………….…………...………………. 24 
Figure 1.9  Correlative motion analysis…………………………………………. 28 
Figure 1.10  Three-dimensional HSV capsid reconstruction…………….…… 33 
Figure 1.11  Capsid assembly………………………………………………….... 35 
Figure 1.12  Proteolytic processing of UL26 and UL26.5 gene products…..…36 
Figure 1.13  The C-Capsid Specific Complex…………………………………...46 
Figure 1.14  Two pathways of egress with 2-step envelopment……...….……52 
Figure 1.15  Electron micrographs of capsid egress forming a  
double-membrane vesicle…………………...…………………………...………. 53 
Figure 1.16  Capsid passage through nuclear pores………………………….. 55 
 
Figure 2.1  Chicken anti-pUL17 antibody immunoblotting……..……….…..… 76 
Figure 2.2  Capsid electron micrographs labeled with various antibodies...... 81 
Figure 2.3  ImmunoEM labeling of pUL17 upon infection……………………... 85 
 
Figure 3.1  Co-immunoprecipitation with pUL17 in F and capsid deletion 
viruses………………………………………………………...…………….……….96 
 vii
 Figure 3.2  Reciprocal immunoprecipitation of pUL17 with anti-pUL25……….99 
Figure 3.3  Immunoblot of whole cell lysates from infected cells…………….101  
Figure 3.4  Co-localization of pUL17/pUL25 and co-dependent localization..103 
Figure 3.5  Peripheral nuclear aggregates in delta 25 infection contain 
pUL17 and completely assembled capsids……………………………………..106 
Figure 3.6  Immunostaining of pUL17 and pUL25 with cleavage and 
packaging or capsid mutant viruses……………………………...……………..108 
Figure 3.7  Wild-type localization of pUL17, pUL25 in delta15 infected cell...111 
Figure 3.8  The effects of blocking Crm-1 nuclear export in delta 32…...…..113   
Figure 3.9  Cells co-expressing pUL17 and pUL25…………………………….115 
 
Figure 4.1  Electrophoretic mobility shift assay (EMSA) of pac-1- 
containing DNA with purified pUL17-His………………………………..………122 
Figure 4.2  Electrophoretic mobility shift assay of pUL17-His and 
uninfected cell lysate samples…………………………………………………..124 
 
Figure 5.1  UL17 sequences in different HSV-1 strains………………….…...140 
Figure 5.2  Anti-His immunoprecipitation from pUL17-His-infected cells…...142 
Figure 5.3  Co-immunoprecipitation of proteins with pUL17 specific 
antibody………………………………………………………………………...….143 
Figure 5.4  Co-immunoprecipitation of proteins with anti-VP13/14 
antibody……………………………………………………………………...…….148 
Figure 5.5  Affinity co-purification of VP13/14 and pUL17……………….…,.,150 
Figure 5.6  Immunofluorescence staining time-course from infection 
with an HA-tagged VP13/14 virus…………………………………..…………..152 
Figure 5.7  Co-localization of pUL17 and VP13/14………...……………...…..155 
 viii
 Figure 5.8.  Immunofluorescent staining of singly and co-expressed 
pUL17,  VP13/14-HA, and VP11/12-FLAG…………………..…..………...…..157 
Figure 5.9  VP11/12-FLAG, VP13/14-HA, and pUL17 triple transfection.…..159 
Figure 5.10.  Immunogold electron microscopy with HA-specific antibody…161 
 
Figure 6.1  GFP-VP26 capsid isolation ………………………………………...177 
Figure 6.2  Confocal immunofluorescence of purified GFP-VP26 
capsids……………………………………………………………………………..179 
Figure 6.3  Time-lapse microscopy of BAC-derived GFP-VP26 
recombinant virus………………………………………………………………...180 
Figure 6.4  Time-lapse microscopy of GFP-VP26 delta 17 infection…..…...182 
Figure 6.5  Time-lapse microscopy of delta 17 infection in pJB193 cells…..184 
Figure 6.6  Time-lapse microscopy of delta 25 infection in pJB193 cells…..185 
Figure 6.7  Time-lapse microscopy of delta 6 infection in pJB193 cells…....186 
Figure 6.8  Time-lapse microscopy of delta 15 infection in pJB193 cells…..187 
Figure 6.9  Time-lapse microscopy of delta 28 infection in pJB193 cells…..188 
Figure 6.10  Time-lapse microscopy of delta 33 infection in pJB193 cells....189 
Figure 6.11  Converging assemblons in delta 17 infection of pJB193 cells..190 
Figure 6.12  ATPase assay of purified pUL17-(His)……………………..……192 
Figure 6.13  ATP hydrolysis in the presence of pUL17-His antibodies,,……194 
Figure 6.14  ATP hydrolysis with pUL17-His, Stu-2, and non-specific 
purified proteins……………………..………………..………………,,…………196 
 ix
 LIST OF TABLES 
 
Table 2.1  Percent capsids Immunolabeled with monospecific antisera…..... 79 
Table 5.1  MALDI-TOF results…………………………………………….....… 146 
 
 
 
 x
 LIST OF ABBREVIATIONS 
 
3-OST 3-O-sulfotransferase 
32P radioactive phosphorous isotope 
35S radioactive sulfur isotope 
A alanine     
A adenine 
AMP-PNP adenosine 5’-(β,γ-imido) tri-phosphate 
ATP adenosine tri-phosphate 
BAC bacterial artificial chromosome 
BDM 2,3-butanedione monoxime 
BFLA bafilomycin A 
BHV/BoHV bovine herpes virus 
bps base pairs 
BSA bovine serum albumin 
C carboxyl 
C3(b) complement protein 
CaCl2 calcium chloride 
CCSC C-capsid specific complex 
cDNA complementary deoxyribonucleic acid 
CHO Chinese hamster ovary 
CKII casein kinase II 
Cm chloramphenicol 
CMV cytomegalovirus 
CNS central nervous system 
Cos cohesive 
 xi
 CPE cytopathic effects 
CS chondroitin sulfate 
D aspartate 
dH2O distilled water 
DIG detergent insoluble glycolipid 
DMEM Dulbecco’s modified Eagle’s medium 
DNA deoxyribonucleic acid 
DR direct repeat 
DTT dithiolthreitol 
E glutamic acid 
E. Coli Escherichia coli 
EBV Epstein-Barr virus 
ECL electrochemiluminescence 
EDTA ethylenediaminetetraacetic acid 
EHV equine herpes virus 
EM electron microscopy 
EMSA electrophoretic mobility shift assay 
ER endoplasmic reticulum 
FACS fluorescence-activated cell sorter 
FITC fluorescein isothiocynate 
Fig figure 
fmole femtomole 
G glycine 
G guanine 
g- glycoprotein 
GAG glycosaminoglycan 
 xii
 GFP green fluorescent protein 
gp gene product 
GST glutathione-S transferase 
H (2A, 3, 4) histone (2A, 3, 4) 
HA hemagglutinin 
His histidine 
HIV human immune-deficiency virus 
HR heptad repeat 
HRP horse radish peroxidase 
HS heparan sulfate 
HSV (1/2) herpes simplex virus (serotype 1/2) 
Hve (A/B/C) herpesvirus entry protein (A/B/C)  
HVEM herpes virus entry mediator 
Hyg hygromycin 
ICP infected cell protein 
Ig immunoglobulin 
IHF integration host factor 
INM inner nuclear membrane 
IR inner repeat 
ITLV infectious laryngotracheitis virus 
K lysine 
Kan kanamycin 
kb kilobase 
KCl potassium chloride 
Kd dissociation constant 
kD(a) kilodalton 
 xiii
 KSHV Karposi’s sarcoma herpes virus 
L leucine 
LAP lamin-associated protein 
LAT latency activated transcript 
LMN (A/C) lamin (A/C) 
M  Molar 
MALDI-TOF MS  matrix-associated laser desorption 
  Ionization-time of flight mass spectrometry 
MAP microtubule associated protein 
MDV Marek’s disease virus 
Mg2+ magnesium 
MHC major histocompatibility complex 
ml milliliter 
mM millimolar 
MOI multiplicity of infection 
Mr relative molecular weight  
mRNA messenger ribonucleic acid 
mw molecular weight 
N amino 
NaCl sodium chloride 
NaH2PO4 sodium phosphate (monobasic) 
Na2HPO4 sodium phosphate (dibasic) 
Na3VO4 sodium vanadate 
NBCS newborn calf serum 
ND10 nuclear domain 10 
Ni++ nickel 
 xiv
 Ni-NTA nickel-nitrotriacetic acid 
NLS nuclear localization signal 
nM nanomolar 
nm nanometer 
NPC nuclear pore complex 
ORF  open reading frame 
Ori (S/L) origin of replication (S/L) 
ONM outer nuclear membrane 
p probability 
pac packaging  
PAGE polyacrylamide gel electrophoresis 
PBS(T) phosphate buffered saline (with Tween) 
PFD pro-fusion domain 
PFU plaque-forming units 
PG phosphoglycan 
pH power of hydrogen 
PI-3 phospho-inositol-3 
PK (A/C) protein kinase (A/C) 
pmole picomole 
PMSF phenymethanesulphonylfluoride 
PNK polynucleotide kinase 
PRR1 poliovirus-related receptor 1 
PrV pseudorabies virus 
R purine 
RFP red fluorescent protein 
RIPA radioimmunoprecipitation assay 
 xv
 RNA ribonucleic acid 
rpm revolutions per minute 
RSC rabbit skin cell 
SDS sodium dodecyl sulfate 
STE sodium Tris EDTA 
T threonine 
T thymine 
TAE Tris-acetate EDTA 
TBE Tris boric acid EDTA 
TAP tandem-affinity purification 
TGN trans-Golgi network 
TLC thin-layer chromatography 
TLR toll-like receptor 
TNFR tumor necrosis factor receptor 
TR terminal repeat 
Ub unique region b 
Uc unique region c 
UL unique sequence long 
US  unique sequence short 
μg microgram 
μm micrometer 
V volts 
vhs virus host shut-off 
VP viral protein 
VSV vesicular stomatitis virus 
VZV varicella-zoster virus 
 xvi
 w/v weight/volume 
Zn2+ zinc 
 
 
 
 xvii
 LIST OF SYMBOLS 
 
α alpha/ immediate-early 
α anti- 
β beta/ early 
δ delta 
Δ deletion 
γ gamma/ late 
λ lambda phage 
‘ prime 
% percent 
0C degrees Celsius 
- null 
Å angstrom 
R resistant 
 xviii
  xix
PREFACE 
 
“Life is like a box of chocolates, Forrest, you never know what you are going to 
get…”   -Forrest Gump, 1995 
 
Thinking back on when I began my dissertation research project with 
very few clues in the literature, many more questions than answers, and no 
experience in virology, it is amazing to see both the scientific and personal 
evolution and development that has taken place.   
When choosing to work on pUL17, I remember being drawn by the 
adventure of not knowing where this project would take me.  Like being given 
only a handful of pieces to an intricate puzzle, it is difficult to guess what form 
will actually take place.  Determining the roles that this protein plays has 
certainly been challenging.  The nearly unrestricted possibilities of 
investigation allowed me to ask a wide variety of questions.  Although many of 
these pursuits were unsuccessful, in the end we have formed new ideas about 
the structural and functional roles of pUL17 and the process has been 
invaluable to my development. 
Science research really is like a box of chocolates, and in the pages 
that follow I have selected my favorite varieties to share. 
  CHAPTER I: 
 
INTRODUCTION 
 
Introduction: 
 Viruses of the herpesviridae can infect both humans and animals.  
HSV-1, or herpes simplex virus serotype 1, is a member of the alpha 
herpesvirus subfamily of the Herpesviridae family.  They are divided into three 
classes: the alpha-, beta- and gammaherpesviruses.  The alphaherpesviruses 
are characterized by their destruction of their host cell (CPE, cytopathic effects 
including multi-nucleated giant cells) and can form syncytia, or fused cells, in 
certain cell lines that is mediated by insertion of viral proteins into the host cell 
plasma membrane (104, 225).  Members of each class can infect humans, 
namely: (alphaherpesviruses) HSV-1, HSV-2, and varicella zoster virus (VZV); 
(betaherpesviruses) roseolovirus and cytomegalo virus (CMV); 
(gammaherpesviruses) Epstein-Barr virus (EBV) and Karposi’s Sarcoma 
herpesvirus (KSHV).  
 
Clinical Effects: 
 Clinical symptoms of HSV infection range from oral and genital lesions 
to corneal blindness and encephalitis.  Most commonly HSV-1 causes oral 
herpetic lesions in contrast to the primarily urogenital lesions seen from HSV-2 
infection.  However, the two viruses are remarkably similar in sequence and it 
is clear that cross-transmission occurs (68); HSV-1 can be isolated from 
urogenital lesions and HSV-2 is sometimes found in oral lesions . 
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  Initially, HSV targets mucosal epithelial cells in which a lytic cycle of 
infection takes place.  Progeny of the lytic round of infection are either 
released into the extracellular space, or are transmitted directly through a cell-
cell spread mechanism into neighboring epithelial cells.  Extracellular particles 
may re-infect locally or at a distance from their origin.  Released virus particles 
target either more epithelial cells for additional rounds of lytic infection, or 
neurons, the cellular reservoir for latent HSV infection.  Once harbored in a 
neuron, HSV can either remain latent, or can spread through the CNS through 
synaptically-linked neurons.  Transneuronal spread through the CNS may 
cause fatal, HSV-induced encephalitis. 
 Herpesviruses are unique in establishing a true molecular latency in 
infected neurons.  The molecular mechanism of HSV latency is poorly 
understood; however, it is clear that viral transcription is nearly completely 
abolished save LATs, or latency associated transcripts.  These transcripts 
along with the immediate early protein, ICP0, play a role in re-activation to a 
lytic infection from the latent state. 
 
Virion organization: 
 All herpesviruses share the same general architecture; the virion is 
composed of four main layers: envelope, tegument, capsid, and genome 
(Figure 1.1).  The outermost layer is a lipid bi-layer envelope that the virion 
acquires as it leaves an infected cell.  The envelope contains a variety of 
virally encoded glycoproteins that are crucial for the virion’s ability to enter 
another cell.  Beneath the envelope lies an asymmetric, proteinaceous layer 
unique to herpes viruses coined the tegument.  Proteins in this compartment  
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Figure 1.1 Conserved structure of Herpesviridae virions.  Virions 
consist of four main layers: envelope, tegument, capsid, and genome.  
(Taken from 
http://bioinfo.bact.wisc.edu/themicrobialworld/hsv1struc.jpg) 
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perform a wide range of functions that enhance success of replication.  Much 
of the virus’ strategic actions such as giving preference to viral gene 
expression over that of the host and evading immune system detection are 
carried out by these proteins.  The tegument lies between the envelope and 
the capsid.  The capsid is a structure used to transport the genetic material of 
herpesviruses to and from their location of replication, the nucleus.  The 
central domain is exclusively made up of a double-stranded DNA genome 
which encodes all the proteins essential for infection. 
   
Genome: 
 The highly-structured 152 kilobase-pair HSV genome is divided into 2 
unique coding regions coined the unique long (UL) stretching 108 kilobase 
pairs and the unique short (US) containing 13 kilobase pairs (Figure 1.2).  
Each of these regions is flanked by inverted repeats.  Repeated sequences 
flanking the UL and US components are designated the IRL and IRS for inner 
repeats long and short.  This terminology is necessary to distinguish the inner 
repeats from a separate set of repeated sequences, the terminal repeats, TRL 
and TRS that are located at the outermost regions of the genome.  It is not 
entirely clear in exactly what manner HSV uses these many repeated 
sequences, but it is proposed that the inner repeats and terminal repeats offer 
HSV a recombination competent landscape, which may play a crucial role in 
the virus’ replication strategy.   
Another repeat-containing region called the a sequence has a more 
clearly understood role in HSV replication.  The a sequence separates the 
inner repeats, IRL and IRS, and is also partially present at each of the terminal  
  5
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ends (168).  A 20 base pair direct repeat (DR1) defines the ends of the a 
sequence (168).  A sequences also contain two regions of unique sequence 
Ub and Uc that are divided by a series of directly repeated sequence.  Within 
the unique stretches of the a sequence there are two distinct packaging 
elements (pac sites), pac1 present in Ub and pac2 in Uc (60, 232).  
Electrophoretic mobility-shift assays using a Ub oligonucleotide as probe DNA 
suggest that a putative HSV terminase protein, pUL28, recognizes and binds 
to single-stranded pac1 DNA (2).  This interaction is specific for pac1 as 
samples using a Uc fragment containing pac2 are not altered in electrophoretic 
mobility (2).  Mutant Uc oligonucleotides failed to bind to, or bound less 
efficiently to purified UL28 protein, demonstrating specific recognition of the 
pac1 sequence within the Uc oligonucleotide.  Additional experiments found 
this protein-DNA interaction to be DNA structure specific as only the more 
slowly migrating DNA species indicative of structured DNA were altered when 
protein was added (2).  This evidence supports the hypothesis that pUL 28 
recognizes a specific HSV sequence to aid in proper cleavage of concatemeric 
genomic DNA at a single genome-length and subsequent packaging into 
capsids.  Although the exact roles of HSV’s many repeats are not known, it is 
likely that studies of these genomic structural elements will further elucidate 
HSV’s mechanism of genomic replication. 
 
Entry/attachment: 
After HSV virions exit an infected cell, they target another epithelial cell 
by attaching to host cell-surface glycosaminoglycans (GAGs) that serve as 
receptors and support fusion to the host membrane.  The mechanisms of 
 6
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attachment and fusion (penetration) make use of host cell receptors and co-
receptors, respectively, which are contacted by viral envelope glycoproteins 
(Figure 1.3).  There is redundancy in these interactions contributed by both the 
virus and the host cell making if difficult to identify essential components of 
attachment.  The HSV virion displays 12 glycoproteins on its surface, many of 
which facilitate entry (reviewed in (30, 108, 116, 204).  GAG chains are 
commonly found on various cell surface proteoglycans (PG) thus presenting 
HSV with multiple attachment receptors.  For example, the GAG chains of 
both heparin sulfate (HS) and chondroitin sulfate (CS) can function in HSV cell 
surface attachment (153).  Cells devoid of all GAGs show lower infectivity, but 
still do not completely abolish HSV entry, highlighting HSV’s mechanistic 
versatility (226). 
The kinetics of HSV entry initially determined that the process could be 
broken down into at least three phases: initial attachment, stable attachment, 
and penetration (155).  Attachment stages can be differentiated from 
penetration by temperature control.  Attachment, unlike penetration, still 
occurs at 40C, leaving virions in an arrested state on the host cell surface.  
Extracellular, unattached virions can be inactivated by low pH and washed 
away.  Studies deleting either viral glycoprotein gC or gB showed decreased 
attachment and infectivity, and deletion of both gC and gB severely hampered 
infectivity (91, 134, 227).  It has been proposed that attachment through gC 
and gB functions primarily to bring the viral envelope into close enough 
proximity to the host cell membrane to allow for penetration.   
 Substantial evidence shows gC binds to heparan sulfate to initiate 
attachment.  Heparan sulfate or heparin was first determined to be the 
receptor of HSV-1 and HSV-2 in assays that blocked infection by competing 
  8
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 for heparan sulfate binding (276).  Subsequent studies used Chinese hamster 
ovary (CHO) cells that are deficient in the synthesis of GAGs to assay HSV 
attachment (142).  Virus binding to these mutant cells was severely impaired 
(219).  Glycoprotein C has been shown to bind heparin.  Virions deficient in gC 
showed decreased ability to bind heparan sulfate receptors at the cell surface.  
Of those particles that could bind, penetration was also impaired (111, 227, 
256).  Additionally, in vitro affinity chromatography experiments determined 
that both gC and gB can bind heparin Sepharose (112).  Binding is thought to 
occur through electrostatic interactions between positively-charged 
glycoprotein domains and negatively-charged heparan sulfate moieties.  
Mutational studies mapped the heparin binding domain of gC to charged 
amino acid residues in an antigenic site (152, 255).  An antigenic region, 
determined by reactivity to various monoclonal antibodies, is externally 
displayed, thus it must be accessible in the proteins native form, making this 
portion of the protein a likely candidate for receptor binding.  Mutations of 
specific amino acids within two distinct regions of gC decreased attachment, 
and synthetic peptides of the two regions also inhibited infection (255).   
 Glycoprotein C can also bind C3b, a component of the host immune 
response complement pathway (84).  Infection with HSV induces the display of 
complement C3 receptor, on epithelial cell surfaces (46).  C3b receptors are 
normally present on human blood cell surfaces and function to inhibit 
complement activation through accelerating the decay of C3b convertase 
enzymes or to opsonize pathogens targeted with C3b.  Binding of gC to C3b 
appears to occur independently of entry and is thought to promote immune 
evasion by neutralizing C3b.         
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 Glycoprotein B has similar properties to gC in that it can also bind to 
HSPG.  Although gC plays a significant role, some infectivity remains upon 
infection with a gC null virus, indicating that HSV has other sources of 
attachment.  Upon glycoprotein C-null virus infection, absence of heparan 
sulfate was found to further attenuate infectivity, thus it was determined that 
HSV was able to bind multiple attachment proteins (110).  Deletion analysis of 
gB revealed an N-terminal poly-lysine rich domain critical for interaction of gB 
with heparan sulfate (134).  Additionally, double mutant recombinant viruses 
(gC-/gB-) are more severely attenuated than either single mutant (110, 134).  
Since the effects of gC and gB are additive, these results argue for 
independent functions of both glycoproteins.  Although the contribution of gC 
in HSV-1 attachment appears to be more significant than gB, the reverse 
importances of the roles for these proteins have been shown upon HSV-2 
infection (43, 134). 
 The role of gB in HSV attachment is less clear than that of gC.  Studies 
show that gB, unlike gC, is essential for HSV infection despite the dispensable 
role of heparan sulfate in infection (29).  Therefore, gB must also have a role 
outside of its interactions with HSPG or CSPG because both proteoglycans 
are not essential for HSV entry.  A compilation of data suggests gB may bind 
another, yet unidentified receptor (20).  Soluble HSPG analogs were used to 
competitively block binding and cell lines lacking either HSPG only or HSPG 
and CSPG were also assayed for binding.  In both cases, the abrogation was 
enough to block attachment of gC completely; however, blockage of gB 
attachment was incomplete (20).  It is possible that gB’s binding to HSPG 
might preface a second interaction with a more specific receptor, or gB may 
just have the ability to bind multiple receptors. 
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  Curiously, gB fractionates into detergent-insoluble glycolipid-enriched 
(DIG) membranes called lipid rafts.  Lipid rafts are cholesterol-rich 
microdomains of the plasma membrane that function to organize membrane 
proteins and perform signal transduction in response to external stimuli.  The 
possibility that HSV uses lipids rafts in entry has been suggested (31); 
however, studies failed to show any known HSV penetration receptors (HVEM 
or nectin-1) or other HSV glycoproteins (gC, gD, gH) in DIG fractions (21).  
The search to identify another receptor for gB to explain its essential role in 
HSV replication and clarify its interactions with lipid rafts is still underway.   
 
Entry/penetration: 
 Attachment is the first step in entry, and is thought to cause a loose 
association between the viral envelope and the host cell membrane, possibly 
the result of the virion tumbling around the host cell surface.  Following 
attachment, a more specific interaction between viral fusion protein gD and a 
host cell co-receptor promotes penetration, the second stage of viral entry, via 
envelope fusion to the plasma membrane.  The mechanism of entry is still not 
entirely clear because, like attachment, penetration is also complicated by 
multiple mechanisms, the redundancy of HSV glycoprotein functions, and the 
variety of cells that can be infected.  
 gD has several receptors; the two best-studied that allow entry in all 
clinical isolates tested (129) are HVEM (Herpes Virus Entry Mediator) or HveA 
(herpesvirus entry protein A) and nectin-1 or HveC (herpesvirus entry protein 
C).  The original receptor names, TNFRSF14 and poliovirus receptor-related 
protein 1 (PRR1), were based on protein family membership, but have since 
been renamed HVEM (HveA) and nectin-1 (HveC), respectively.  HVEM 
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 (HveA), a member of the tumor necrosis factor receptor (TNFR) family 
mediates entry of most strains of HSV-1 and HSV-2 (170).  In contrast, nectin-
1 (HveC), a cell-cell adhesion protein and a member of the (IG) 
immunoglobulin superfamily, appears more permissive, as it promotes fusion 
of many alpha herpes viruses including HSV-1, HSV-2, BHV, and PrV (51, 92).  
HveC binds to each gD species with different affinity (51).  Curiously, the 
HVEM (HveA) and nectin-1 (HveC) receptor proteins are structurally unrelated 
and their expression patterns are distinct.  Although both are expressed in 
epithelial cells and fibroblasts, only nectin-1 is present on neurons, arguing for 
the importance of nectin-1 as the HSV receptor on neuronal cells.  HVEM 
(HveA) is expressed on other cell types such as liver, lung, kidney, spleen, 
and peripheral blood leukocytes, but any role for these cells in HSV infection is 
not yet clear.  However, it has been suggested that HVEM’s lymphoid tropism 
may aid HSV in preventing apoptosis (91).  
 A third receptor, nectin-2 (HveB) another member of the immunoglobin 
superfamily, binds HSV, but unlike the aforementioned receptors, nectin-2 
differentiates between HSV-1 and HSV-2, allowing HSV-2 fusion in all strains 
but only limited HSV-1 fusion (267).  Nectin-2, like nectin-1, also binds PrV gD 
but unlike nectin-1 does not bind BHV gD (267) and certain gD amino-terminal 
point mutants, rid1 and rid2 bind exclusively to nectin-2 .  Nectin-2 also has a 
splice variant (nectin-2 delta) in which the ectodomain is identical to nectin-2 
but the transmembrane and cytoplasmic domains are altered.  The nectin-2 
delta isoform, unlike the full-length nectin-2, also allows binding of BHV (161).  
gD amino-terminal point mutants such as rid1 and rid2 can enter only through 
interactions with nectin-2 (170). 
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 A fourth, non-protein receptor of gD, sulfate-modified heparan sulfate, 
was identified when a cDNA screen showed 3-O-sulfotransferase-3B was 
capable of conferring susceptibility to CHO (Chinese hamster ovary) cells, 
which are naturally resistant to HSV infection (221, 249).  Multiple isoforms of 
3-OST-3 from mouse or human can render CHO cells susceptible, indicating 
that a 3-O-sulfate modification of HS by multiple enzymes is sufficient to allow 
entry.  An oligosaccharide library derived from 3-OST modified HS was 
reacted with gD to reveal one particular octasaccharide of HS critical for the 
interaction (146).  The Kd determined for the octasaccharide’s interaction with 
gD was 10-fold higher than that of complete HS with gD, possibly due to 
multiple gD binding sites (146).  The crystal structure of gD supports this result 
and proposes two potential binding sites for 3-O-sulfated HS, one very near 
the HveA binding site (33).  Others confirmed a role of 3-O-sulfated HS in HSV 
entry demonstrating cell-cell fusion in a luciferase reporter gene fusion assay 
using glycoproteins B, D, H, and L (248).  Taken together, these data indicate 
that 3-O-sulfated HS can be sufficient as a receptor for HSV fusion despite not 
being essential for entry.   
gD is also essential for HSV entry (143).  Infection is blocked in the 
presence of either soluble gD or anti-gD antibodies.  Conceptually, the 
sequence of the gD ectodomain can be divided into two functional domains, 
the N (amino)-terminal domain containing receptor binding sites (amino acids 
1-260) and the C (carboxy)-terminal pro-fusion domain (PFD) encompassing 
amino acids 260-310.  In pull-down experiments using a GST (glutathione S-
transferase) tagged pro-fusion domain, multiple sites in the carboxy terminal 
half (PFD) of gD were concluded to interact with a truncated amino-terminus of 
gD in the absence of gD receptor binding (89).  However, GST-gD PFD was 
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 not able to pull-down longer truncations of gD, presumably because they 
retained internal PFD that were blocking accessibility of GST-gD.  The 
presence of either HVEM or nectin-1 soluble receptor precluded the self-
interaction of gD, leading to the hypothesis that gD folds back on itself forming 
a “closed” structure, which has since been confirmed by structural data (33) 
(Figure 1.4).  In the presence of receptor, a conformational change is triggered 
such that gD self-interactions are lost in exchange for receptor-binding 
interactions (89).  Thus it has been suggested that this “open” conformation of 
gD may trigger fusion between HSV envelop and the host cell plasma 
membrane. 
Crystal structures of both gD alone as well as gD bound to HVEM have 
been determined, and comparison indicates a conformational change occurs 
upon binding (33).  This is a common trend in virology throughout many 
viruses including influenza, HIV, and Ebola, which all encode similar fusion 
peptides that are triggered during fusion to undergo a conformational change 
(reviewed in (270)).  In gD an amino-terminal region containing the receptor 
binding domain remains flexible in the unbound state but changes into a 
hairpin loop with a long alpha helix when gD was bound to HveA (33).  
However, a mutant gD with an engineered di-sulfide bond intended to stabilize 
the hairpin loop structure was insufficient to induce fusion indicating that 
additional factors are needed (50).  This suggests that either gD is not the 
fusogenic molecule of HSV, or that it acts in concert with another essential 
glycoprotein either gH/gL or gB to initiate fusion. 
Despite the revelation of gD’s structure and the HVEM binding site, the 
exact nectin-1 binding domain remained elusive.  It is clear that the binding 
domains of HVEM and nectin-1 are overlapping, since each receptor in soluble 
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Figure 1.4  Conformational change in gD N terminus.  (A) hairpin loop 
shown in red is in “closed” conformation in receptor-bound conditions. (B) 
“open” conformation of gD in unliganded state (33) 
 form can block entry through the other.  Also, some gD monoclonal antibodies 
can prevent binding by both receptors.  However, other gD monoclonal 
antibodies will specifically block HVEM or nectin-1, indicating that although 
these two receptors may share overlapping binding domains on gD, at least 
part of the binding sites is distinct.  Connolly et al propose a nectin-1 specific 
interaction region of gD (50).  Point mutations of gD at amino acid 38 and at 
other amino acids positioned locally on the same surface disrupted nectin-1 
binding.  This proposed “hot spot” for nectin-1 binding is located adjacent to 
the HVEM binding site of gD (50). 
The minimal set of glycoproteins required for HSV fusion is composed 
of gB, gD, gH and gL.  However, in the absence of any one of the proteins 
binding still occurs, presumably through gC, but penetration does not.  In 
infected cells, gH and gL form a heterodimer in which each in the absence of 
the other is not trafficked properly to ultimately be displayed at the plasma 
membrane, or incorporated into exiting virions (117, 125).  The 
transmembrane domain of gH, retains the protein in the ER in the absence of 
gL; whereas gL is secreted without gH.  The interaction domain of each of 
these proteins has been mapped, and not surprisingly, mutants of gL that 
disrupt the gH binding domain are deficient in penetration.  However, deletions 
of gL outside of the gH-binding region which retained gH-gL protein-protein 
interactions yet failed in fusion assays elucidated a proposed chaperone 
domain in gL (125).  Thus, the current model suggests after protein synthesis, 
gH and gL interact so that gL can ensure proper folding of gH.  Glycoprotein 
H, in turn, anchors the complex to cytoplasmic membranes where upon 
budding, both are integrated onto the virion so that they can aid in penetration 
of the virion into another cell. 
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 Immunoprecipitation studies found that a complex containing gB, gD, 
gH, and gL and HVEM receptor could be detected only transiently after 
infection.  At zero minutes post infection, the complex could not be 
immunoprecipitated, and similarly, by 30 minutes post infection the complex 
had dissociated (94).  Transfection of expression plasmids of gD, gB, gH, and 
gL demonstrated that this complex could be reconstituted in the absence of 
any other viral proteins (7).  Immunoprecipitation studies from infection with 
recombinant viruses deleted for each of the essential entry glycoproteins or 
from selective transfection of various expression plasmids attempted to order 
the sequence of protein interactions.  Both experimental approaches 
concluded that interaction of gD with HVEM receptor initiated complex 
formation and was paramount for other protein-protein interactions (7, 94).  
Following gD recognition of receptor, gB is added, and subsequent to and 
dependent on gB integration, gH and gL are incorporated to complete the 
complex (94). 
Recent evidence suggests either gB or gH, rather than gD, is the HSV 
fusion protein and that gD’s role is primarily in attachment.  Currently, most 
reports claim gH as HSV’s candidate fusion protein; support for this is drawn 
from many properties of gH.  The ectodomain of gH has a hydrophobic alpha 
helix located internally in the peptide that is positionally conserved in all 
herpesviruses (95).  Furthermore, a swapping experiment replacing the entire 
HSV gH protein with the gH protein of VZV sustains viral replication, indicating 
the functional conservation as well (95).  Additionally, mutations within this 
alpha helix confer loss of infectivity and loss of cell-cell syncytia formation.  
Also, supplementing defective gH with gp41 or G, the HIV or VSV fusion 
protein, respectively, partially restores infectivity (95). 
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 One of the strongest pieces of evidence suggesting gH bears the fusion 
peptide, is its ability to form a coiled-coil structure through heptad repeats 
(Figure 1.5) (96).  In addition to the conformational change of fusion proteins 
previously discussed with respect to gD, another canonical structural feature 
of class 1 viral fusion proteins is the formation of an alpha-helical coiled-coil 
through protein multimerization.  Influenza virus, for example, uses a trimer of 
coiled-coil hemagglutinin (HA) alpha helices in the form of a hairpin to 
effectively form a six-helix bundle (28).   
Peptide modeling predicted amino acid substitutions of two residues of 
heptad repeat 1 (HR1), E450G and L453A, would abolish coiled-coil formation.  
This virus created by site-directed mutagenesis demonstrated loss of 
infectivity, inability to complement a gH deletion, and cell-cell fusion despite 
proper functioning of gL as indicated by heterodimer formation, gH folding, and 
gH localization (96).  Similar mutational analyses were later done with a 
second, downstream heptad repeat 2 (HR2); mutations created based off of a 
model design to either increase or decrease the likelihood of coiled-coil 
formation.  The effects of the alterations on fusion paralleled the proteins 
ability to form the structure (97).  Synthetic peptides mimicking HR1 and HR2 
were found to bind one another; moreover, competition with HR1 or HR2 
peptides inhibited fusion in a dose-dependent manner, though curiously the 
HR1 synthetic peptide induced inhibition was specific for HSV-1 and had no 
effect on HSV-2 infection (97).  This inhibition of infection could be reversed 
with the simultaneous presence of both HR1 and HR2 synthetic peptides (97).   
Taken together, these data indicate the coiled-coil formation of HR1 
and HR2 is independently important for infectivity.  Additionally, HR1 and HR2 
most likely interact with one another.  Individual gH HR sequences may form 
 18
  19
 
 
 
 
 
 
 
 
 
 
 
 
 
.
Figure 1.5  Arrangement of primary amino acid sequence of gH.  SS, signal 
sequence; C, cysteine; HR, heptad repeat; TM, transmembrane domain; 
FP, candidate internal fusion peptide (93) 
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coiled coils that can structurally result in a hairpin loop.  Whether gH’s self-
interactions are capable of creating a canonical six-helix bundle, or whether 
interactions with another glycoprotein, perhaps the hairpin of gD, are 
necessary to complete HSV fusion machinery remains unclear.  Yet it is 
certain that the complexity of glycoproteins needed to execute fusion, gB, gD, 
gH and gL, makes HSV different from other class 1 fusion viruses.   
Most recently, the structure of gB suggests that the gB ectodomain 
shares structural properties with the fusion protein G of Vesicular Stomatitis 
Virus (VSV) (Figure 1.6), a rhabdovirus with a single stranded RNA genome, 
as well as the fusogenic gp64 protein of Baculovirus, thus leading to its 
designation as a class III fusion protein (105).  Historically, fusion proteins 
were divided into either class I fusion peptides or class II fusion peptides.  
Class I fusion proteins are characterized by their conserved three-stranded 
coiled-coil “spike” structure and amino-terminal fusion peptides.  In contrast, 
class II fusion proteins are structurally less pronounced and maintain a single 
internal fusion loop.  The newest category of fusion protein merges qualities of 
both class I and class II proteins.  Class III proteins form three-stranded coiled 
coils but also carry an internal fusion loop; however, the hydrophobic fusion 
loops of class III proteins vary slightly from class II in that they are bipartite. 
Previous studies have shown that gB interacts with cells through a 
receptor that is independent of HS and CS, and bound gB protein is sufficient 
to block subsequent entry (20).  Mutations in the potential internal fusion loop 
of gB were found to block or impair entry to cells just like the wild-type gB 
protein, implying the receptor binding domain was not altered upon mutation of 
the potential fusion loop (105).  However, these fusion loop mutant gB proteins 
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could not bind liposomes (105).  These data suggest that gB, like gH, may 
also be an HSV fusion protein.  Whether or not these two proteins act in 
concert, or individually remain unknown.    
The field of HSV entry is further complicated by the debate on where 
penetration takes place.  Originally, dogma based on electron micrographs 
presented HSV fusion solely at the plasma membrane (88) (Figure 1.7).  A 
more recent study performing cryo-electron tomography has documented 
fusion intermediates thus providing a clearer picture of envelope fusion (154).  
Although the plasma membrane undoubtedly can be a site of penetration, 
other studies indicate that this simplistic viewpoint does not represent a 
complete perspective on HSV entry pathways.  Many variables such as the 
cell type, energy requirements, and pH determine the use of different 
pathways of virus uptake. 
Electron micrographs of enveloped HSV particles in cytoplasmic, 
vesicular compartments less than 30 minutes after infection, strongly argue 
that HSV can make use of the endocytic pathway (187) (Figure 1.8).  Entry by 
endocytosis may also be called internalization, a stage that is temporally and 
spatially distinct from penetration.  Internalized particles have been taken up 
within the cell, but still technically reside in an extracellular environment within 
vesicles.  Cytoplasmic, endocytosed virions have been readily observed in 
HeLa cells and CHO cells bearing nectin-1, and also occasionally found in 
Vero cells, albeit at a much lower frequency (187).  The endocytic pathway as 
a route of entry clearly appears to be cell type-specific as cytoplasmic, naked 
capsids are not observed in HeLa and nectin-1 expressing CHO cells, and 
conversely most virus entry in Vero cells results in naked capsids, indicative of  
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Figure 1.8  Virion entry by endocytosis (187). 
 fusion at the plasma membrane (88).  Endocytosis of HSV into cells appears 
to occur very quickly.  In protease protection assays accessible virus had a 
half-life of only 9 minutes, and within 30 minutes, nearly all virus was 
endocytosed (188).  Concomitant envelope loss was also shown (188). 
Endocytosis of HSV into HeLa and CHO cells does not require gD but 
does require compartment acidification.  In the absence of gD-receptor binding 
and penetration, CHO cells still take up particles though these are sent to the 
lysosome for degradation.  Thus gD/ligand binding is not required for 
endocytosis (187).  To determine whether or not acidification of the endocytic 
vesicle was needed for viral fusion, cells were treated with bafilomycin A, 
buffering weak base ammonium chloride, or the ionophore monensin, all of 
which disrupt organelle acidification.  Under these conditions, penetration was 
again blocked (187, 188).  It still remains unclear as to whether or not 
endocytosis of HSV is clathrin-mediated.  Other viral glycoprotein mutants 
were analyzed for functional differences between the entry and endocytic 
pathways, but gC was still found to be non-essential and gB, gD, gH, and gL 
were required suggesting a similar mechanism of penetration in both direct 
fusion and the endocytic pathway of viral entry (188). 
 In vitro binding requirements of HSV have also been investigated using 
binding assays in which liposomes are tested for fusion to HSV by 
characteristic migration in a sucrose gradient.  These studies have also 
determined that mildly acidic pH (5.0-5.3) is necessary for virions to bind 
HVEM-bearing liposomes (268).  When the assay was performed at neutral 
pH virtually undetectable levels of fusion were observed resulting in all 
liposomes present in the top fraction of the sucrose gradient (268).  
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 Unexpectedly, nectin-1 proved ineffective in mediating binding in all assays 
regardless of conditions (268).   
 In order to address the biological significance of HSV endocytosis in 
relevant primary cells, neurons and epidermal keratinocytes have been 
studied.  Only in keratinocytes, not neurons, did HSV enter through the 
endocytic pathway (186).  Internalization could be disrupted by 
lysosomotrophic agents suggesting that low-pH is a prerequisite for entry in 
these cells (186) . Treatment with isoflavone genistein, an inhibitor of cellular 
protein tyrosine kinases reduced transport of endocytosed HSV indicating a 
signaling requirement for capsid transport (186).  It is not surprising that 
neurons do not demonstrate the same need, as fusion has been shown to 
occur at the plasma membrane in these cells (151). 
    Milne et al. recently proposed a third, pH–independent endocytic route 
of internalization.  Employing mouse cancer cells (B78H1 cells) which normally 
do not express any HSV receptors and a derived B78C10 cell line expressing 
the human nectin-1 protein, the role of gB in entry was assayed.  Virus was 
applied to both cell types, cross-linked with BS3 (an agent not permeable to 
the plasma membrane), and immunoprecipitated with anti-gB antibody.  Entry, 
as determined by protection from the cross linking agent, was determined to 
be both receptor (nectin-1) dependent and energy dependent (167).  
Ultrastructural images demonstrated internalization of particles in membrane 
invaginations specifically with B78C10 (receptor-expressing) not B78H1 cells 
(167).  These data are similar to those of Nicola et al., who first reported 
endocytic uptake of HSV (187).  In contrast to the findings of Nicola et al, 
however, fusion after endocytosis was bafilomycin A1 (BFLA) and ammonia 
chloride-resistant suggesting internalization in these cells proceeds in a pH-
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 independent manner (167).  Whether penetration occurs in the endocytic 
vesicles or at a later stage such as in the phagolysosome has not been 
directly addressed, although the lack of low pH requirement for fusion argues 
that fusion may occur relatively early in the endocytic pathway. 
 
Capsid transport: 
Membrane fusion, or penetration, releases the capsid and allows 
tegument proteins to be exposed to the cytosol.  The tegument layer is 
composed of approximately 20 structural proteins including VP1/2 (UL36), 
pUL37, VP11/12 (UL46), VP13/14 (UL47), VP16 (UL48), VP22 (UL49), pUS3 
(US3) and pUL17 (UL17) (214, 235).  Electron microscopic time course studies 
showed a collection of densely staining material, proposed to arise from 
tegument proteins, formed at the cytoplasmic surface of the plasma 
membrane, near naked capsids after entry (224).  It’s thought that most 
tegument proteins dissociate from the capsid upon entry (164).  The 
mechanism and regulation of tegument protein dissociation is poorly 
understood but has been hypothesized to occur through dephosphorylation 
events.  Phosphorylation of virion-associated tegument proteins VP1/2, 
VP13/14, VP16, and VP22 was observed for each protein with at least one of 
the following kinases: CKII, PKA, or PKC (171).  In a PrV correlative motion 
study, analysis by sequential imaging was used to compare positioning of 
capsids labeled with RFP-VP16 to any signal arising from individually labeled 
GFP-tegument proteins (150) (Figure 1.9).  By this method, it was concluded 
that outer tegument proteins VP16, VP13/14, and VP22 dissociate from the 
capsid within an hour of entering sensory neurons (150).  In contrast, both 
RFP-pUL36 and RFP-pUL37 were associated with the capsid through axon 
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Figure 1.9  Correlative motion analysis.  PrV GFP-fusion tegument proteins 
and RFP-labeled capsids demonstrate retention of VP1/2 and UL37 protein 
and dissociation of VP16, VP13/14, and VP22.  (R=RFP, capsid; G=GFP, 
tegument protein)  (150) 
 transport (150).  Tegument protein labeling via immunoelectron microscopy 
corroborated and expanded these results to demonstrate the loss of pUL11 
and retention of pUS3 (101).  These experiments clearly highlight the 
temporal/special specificity of tegument dissociation.   
Released tegument proteins are free to diffuse throughout the cytosol 
or may be targeted to particular cellular locations.  Many of these proteins 
serve regulatory functions of gene expression which will be discussed later.  
Conversely, tegument proteins that remain capsid-bound are needed for 
transport through the cytoplasm or to gain access to the nucleus.   
  The capsid-bound tegument proteins attach to microtubules and take 
advantage of a host cell transport motor, dynein, to bring the capsid to the 
microtubule organizing center (66, 224).  The capsid’s association with 
microtubules was first demonstrated by immunofluorescence microscopy 
staining for capsid and tubulin proteins (224).  Signal from anti-capsid 
antibodies was consistently found approximately 50 nm from the microtubule 
(224).  This correlation supports the prediction that HSV utilizes host cell motor 
proteins for cytoplasmic transport.   
 Less is known about the transport of particles entering the host cell 
through endocytosis.  It is presumed that HSV uses a hybrid of transport 
mechanisms, trafficking of the endosome as well as capsid transport 
subsequent to penetration, both of which employ dynein-mediated 
anterograde transit on microtubules.  When cells were treated with 
wortmannin, a phospho-inositol-3 (PI3) kinase inhibitor, capsids from 
endocytosed particles failed to reach the nucleus whereas capsids in Vero 
cells (in which HSV enters by envelope fusion at the plasma membrane) were 
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 distributed at the periphery of the nucleus (188).  This suggests a role for the 
cellular kinase in transport of endocytosed particles.  
 It is believed that capsids dock at the nuclear pore within two hours of 
entry (224).  By electron microscopy, the naked capsid has been observed 
tethered to the nuclear pore complex (NPC) through cytosolic fibers (224).  
The capsid, averaging 125 nm in diameter (216), is too large to enter through 
the nuclear pore complex, which excludes particles greater than 26 nm; 
therefore the capsid must trigger an uncoating event while docked at the NPC 
to release and inject the double-stranded DNA genome into the nucleus, 
leaving the empty capsid in the cytoplasm.  Two HSV proteins that have been 
shown to interact with each other (49), VP1/2, encoded by the UL36 open 
reading frame, and pUL25, have also been implicated in uncoating the 
genome.  Infection with temperature-sensitive mutants of each of these 
proteins halted the release of the genome as did treatment with a serine-
cysteine protease inhibitor (14, 121, 199). Additionally, pUL25 interacts with 
nuclear pore proteins (nucleoporins), CAN/Nup214 and hCG1, which may act 
as receptors to tether the capsid at the NPC (193).  pUL36 has been shown to 
be proteolytically cleaved around the time of entry and thus it may act as the 
substrate for the required serine-cysteine protease (121). 
 
Transcription and replication: 
 Shortly after infection, HSV proteins set up a replication compartment in 
the nucleus to host viral DNA replication and capsid assembly that is defined 
by localization of replication proteins such as ICP8 the ssDNA binding protein.  
This compartment forms from multiple sites adjacent to ND10 structures that 
grow and converge (242).   The replication compartment becomes large, 
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 encompassing most of the nucleus, with a lobed, asymmetric design.  As 
infection progresses the infected nucleus increases two-fold in size, a process 
that is dependent upon expression of two HSV late genes, UL31 and UL34 
(169, 223).  Possibly as a consequence of replication compartment expansion, 
host chromatin is condensed and displaced to the periphery of the nucleus 
(169).  Marginalized chromatin is a potential barrier that capsids must 
overcome to egress from the nucleus.  
 After viral DNA enters the nucleus it initiates a transcriptional cascade 
that is designed to promote, in order, the transcription of regulatory proteins, 
replication proteins, and structural proteins (reviewed in (235)).  A transcription 
transactivator protein, VP16, present in the HSV virion initiates transcription of 
5 immediate early genes, ICP0, ICP4, ICP22, ICP27 and ICP47 (15).  Unlike 
the other immediate early genes, ICP47, does not appear to be a major 
transcriptional regulator, but instead acts to down-regulate MHC class I 
presentation of viral antigen as a means of immune system evasion (280).  
Many of the immediate early proteins are multifunctional; together they act to 
regulate and co-ordinate viral transcription of immediate early (α), early (β), 
and late (γ) genes. 
Upon transcription of early genes synthesis of new viral DNA takes 
place in the replication compartment (56, 200).  HSV replication is a 
complicated process that is still not fully understood.  The HSV genome 
contains 3 origins of replication, two copies of an OriS sequence and one copy 
of an OriL sequence; however, in cultured cells both OriS sites are 
dispensable (118).  Despite HSV having access to host machinery for double-
stranded DNA replication, the virus still encodes a helicase (UL5), an origin-
binding protein (UL9), a primase (UL52), a DNA polymerase (UL30), a 
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 processivity factor (UL41), and a single-stranded DNA binding protein (UL29, 
ICP8), so it is clear that its replication strategy is different from that of the host.  
Initial DNA replication is thought to use a theta structure and subsequent 
rounds of replication mimic some bacteriophage by using a rolling circle 
mechanism (24).  Additionally, it is proposed that DNA recombination events 
play a role in replication, through the combination of an alkaline nuclease 
(UL12) and the single-stranded DNA binding protein (UL29, ICP8) that act in a 
similar fashion to the phage λ Red recombination system (205).  The product 
of replication is known to be a concatemer of many genomes connected end-
to-end in both linear and branched arrangements. 
 
Capsid assembly: 
Only after new DNA has been synthesized are late genes transcribed 
efficiently.  The transcription of late genes promotes the production of 
structural components necessary to build the icosahedral capsid.  Capsid 
assembly takes place in the nucleus with the aid of a scaffolding protein, pre-
VP22a (UL26.5, ICP35), around which 11 pentamers and 150 hexamers of 
VP5 (UL19, ICP5) and one dodecamer of pUL6 all associate to form a T=16 
icosahedral shell (216, 288) (Figure 1.10).  Limiting concentrations of pre-
VP22a protein can result in a decrease in the capsid size (181).  
Transient co-expression of the major capsid and scaffolding proteins 
suggests the two associate in the cytoplasm to promote transport of VP5 into 
the nucleus (185).  After entry into the nucleus, VP5 monomers self-assemble 
into multimers.  The multimers are in two forms, pentamers and hexamers, 
both of which are integrated into the capsid shell (253, 262).  Preassembled 
structures called triplexes each composed of a single VP19C (UL38) and two  
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.
Figure 1.10  Three-dimensional HSV capsid reconstruction.  Resolution at 
2.5 nm.  (a) Views looking from various points of symmetry.  (b) Capsid 
proteins are false colored such that VP5 molecules are red (hexons) and 
orange (pentons), triplex complexes (containing 2 copies of VP23 and  a 
single copy of VP19c) are green, and VP26 (blue) capping the tops of 
hexons is shown only on the right half of the capsid (116) 
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molecules of VP23 (UL18) link the VP5 hexamers (183, 228, 251).  The 
scaffold, VP5, and triplex proteins are the minimum set of proteins required to 
make capsids (Figure 1.11).  Each of these proteins has been expressed in 
baculovirus and co-infection with these expression vectors is sufficient to build 
HSV capsids (116, 239).  Additionally, it has been shown that capsids can 
assemble in vitro from mixed cell lysates from the individual baculoviruses 
(180).   
VP21 and VP24, auto-proteolytic products of the UL26 (protease) gene, 
and VP26 (the product of UL35) complete the capsid, although these proteins 
are not essential for assembly in the baculovirus system (116, 239) (Figure 
1.12).  VP26 molecules adorn the top of the VP5 hexamers, protruding 
outward from the capsid (287).   Neither capsid assembly nor tegumentation 
require the presence of VP26 (42), although viral propagation is more efficient 
with VP26 (239, 244).  
Capsid assembly results in an immature form called the procapsid.  
Procapsids differ from the mature form, known as C capsids, in that (i) they 
are more round, not angular, in structure (ii) the non-proteolytically processed 
scaffolding protein is retained in their shells, and (iii) the genome has not been 
packaged (reviewed in (116)).  Mutations in proteins necessary for DNA 
packaging have allowed two distinct capsid types, A and B, either precursors 
or abortive forms of the maturation process, to be identified (3, 132, 158, 195, 
196, 218, 241, 243, 281).  The scaffold protein, pre-VP22a, in A capsids is 
cleaved by a UL26-encoded protease yielding VP22a and a 25 aa peptide, 
which are expelled, but no genome is inserted, thus resulting in an empty, 
angularized capsid.  In contrast, in B capsids the pUL26 protease again
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Figure 1.12 Proteolytic processing of UL26 and UL26.5 gene products (116). 
 cleaves the scaffold, but VP22a is retained, leaving no opportunity for DNA 
packaging to occur (98, 178).  Of all of the capsid forms, C capsids are 
preferentially recognized at the inner nuclear membrane and undergo primary 
envelopment (196).  The site of capsid assembly and DNA packaging is 
controversial.  It has been hypothesized to occur in nuclear compartments 
called assemblons that are defined as peripheral nuclear aggregates 
containing capsid proteins including ICP35, ICP5 and VP19c (266), as well as 
throughout the replication compartment (132). 
  
DNA encapsidation: 
 Capsids must encounter the genomic concatemer located in the 
replication compartment for the process of DNA cleavage and packaging to 
take place.  New capsids are pre-formed and subsequently packed with DNA.  
HSV-1 is considered to be an example of sequential rather than concerted 
packaging and assembly.  There are seven viral proteins (pUL6, pUL15, pUL17, 
pUL25, pUL28, pUL32, and pUL33) that are essential to form correctly 
encapsidated HSV genomes.  Deletion or truncation of any of these packaging 
proteins apparently does not disturb capsid construction or replication of new 
viral genomes; however, these mutants fail to incorporate nascent viral 
genome into capsids, and all except the UL25 mutant fail to sever the 
replication concatemer into single-unit genomes (3, 132, 158, 195, 241, 243, 
281).   
 
Bacteriophage double-stranded DNA encapsidation:  
 Similar cleavage and packaging mechanisms are understood for 
double-stranded DNA bacteriophages such as P22, T4, T7, and λ.  Since 
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 phage generally utilize simpler mechanisms than eukaryotic viruses, most 
studies of packaging mechanisms have been performed on phage.  Although 
there are many virus-specific variations, the fundamental strategies provided 
by early phage packaging research have largely directed HSV cleavage and 
packaging models.  Like HSV, phage also use a protein complex referred to as 
the terminase that works in combination with the portal, a multimer present on 
only one vertex of the capsid shell, to bind DNA, translocate the genome, and 
cleave the encapsidated genome from the concatemeric replication product. 
In Salmonella P22 phage, gene product 3 (gp3) and gene product 2 
(gp2) are thought to constitute the small and large subunits of the packaging 
terminase, respectively.  gp3 recognizes a 22 base pair “pac” site on P22 
genomic DNA to initiate packaging (35, 275).  Electron microscopy studies 
show gp3 self-assembles into a nonameric ring with a channel that non-
specifically binds to the DNA backbone through electrostatic interactions 
(177).  The other terminase component, gp2, provides both endonuclease 
activity and also the motor force to drive the packaging reaction via ATP 
hydrolysis.  It was hypothesized that a symmetry mismatch between the portal 
protein, gp1, and the five-fold symmetry axis of the capsid shell may be 
exploited to provide packaging force through portal rotation with respect to the 
capsid (109, 119).  However, subsequent studies with another T-even 
bacteriophage, T4, have strongly refuted this model.  First, T4 portal fusion 
mutants designed to prevent rotation failed to inhibit phage assembly (16).  
Second, the resolved structure of the T4 packaging ATPase was observed to 
be similar to that of other helicases, which suggests that DNA translocation 
may be a repeated process of binding and releasing the DNA (236).  This is 
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 often referred to as the inch-worm model.  Translocation of the genome 
continues uni-directionally and is processive. 
Bacteriophage T4, also carries out strictly headful packaging of new 
genomes through the use of a two-part terminase complex; in this phage DNA 
packaging is not terminated or initiated by recognition of specific DNA 
sequence.  Instead, the terminase large subunit, gp17, is responsible for 
random cleavage of the genomic DNA (22).  Purified gp17 protein has been 
shown to possess single-stranded DNA binding, double-stranded DNA binding 
and endonuclease activity; the presence of Mg2+ and gp16 control the mutual 
exclusion of these two properties (4, 5, 83).  The gp17 protein also binds to the 
capsid portal (gp20)(144), and generates the force behind the packaging 
reaction via hydrolysis of ATP (139).  The terminase small subunit, gp16, does 
not hydrolyze ATP (145), but enhances the ATPase activity of gp17 (139, 
203).   
In contrast, in T7, a T-odd phage, packaging studies give no indication 
of headful packaging.  Instead, cleavage takes place at uniquely recognized 
terminal genomic sites and the placement of the sequence in the concatemer 
dictates the length of the genome inserted into the capsid.  T7 cleavage is 
executed in a staggered fashion in the genomic junction region of the 
concatemer leaving terminal 5’ overhangs of DNA.  Each end is then filled by 
DNA polymerase using the shorter 3’ strand as a primer for synthesis resulting 
in a completely double-stranded genome with duplication of directly repeating 
terminal ends.  Although it is through another mechanism, the end result is 
similar to packaging 102% of the genomic DNA length as seen with T4 phage. 
Phage λ, has yet another mechanism for DNA cleavage and packaging.  
Phage λ's cleavage and packaging mechanism is arguably more similar to that 
 39
 of T7 in that a particular 200 base pair region defined as a CosN site is the 
target of cleavage.  The λ terminase is composed of the two proteins gpNu1 
(small subunit) and gpA (large subunit) that form a hetero-oligomer.   First, 
gpNu1 binds a 16 base pair repeated sequence, the R element, that is present 
in three copies in a cosB site sub-region to initiate the packaging reaction 
(220).  Then the dimer of gpNu1 interacts with its terminase counterpart, gpA 
(250).  Sequence-specific binding of gpNu1 positions gpA so that it may 
introduce two site-specific symmetric nicks 12 base pairs apart at the cosN 
cleavage site (114).  Terminase binding to the R element through gpNu1 is 
augmented by ATPase activity in contrast to the strict requirement of ATP for 
gpA to recognize the cosN site (113).  The cleavage and packaging 
mechanisms of phage lambda are unique in that the cleavage reaction is 
supported by a host (E. coli) protein IHF, or Integration Host Factor (128).  It 
seems this protein is exploited by λ phage to bind and bend the phage DNA at 
the cos site, possibly priming it for cleavage or for gpNu1 recognition.    
The endonucleolytic activity of gpA (212) with the aid of gpA’s helicase 
ability removes preceding bases in the 12 base pair cosN region, thereby 
generating single-stranded 5’ overhangs, or “sticky” ends.  These ends have 
also been called “cos” ends for their cohesive property because cleavage of 
two consecutive cos sites in the concatemer creates unpaired overhangs that 
complement one another and can re-ligate.  Both terminase proteins possess 
ATPase activity.  gpA uses ATP hydrolysis to promote both its endonucleolytic 
cleavage and helicase functions.  It is still unclear in what manner the ATP 
hydrolysis of gpNu1 is used.  It has been shown that gpA also interacts with 
gpB, the portal protein, to initiate the packaging reaction (279). 
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 Although many viruses share the common need to package 
concatemeric DNA and most retain homologous functional properties of 
terminase proteins, there clearly are many different mechanisms by which this 
can be achieved.  Each of the four bacteriophages mentioned above appears 
to have both similar and unique properties in its cleavage and packaging 
strategies.  P22 and T4, for example, use a “headful” packaging mechanism.  
After initiation of DNA translocation, these phage continue to package DNA 
beyond the length of a single genome until the capsid head has reached 
maximum capacity.  For P22, this results in approximately 104% of the 
genome being incorporated into each new virion (34).  By introducing more 
than a single unit-length genome into the capsid, this mechanism may provide 
a safety net in the duplicated terminal sequence to compensate for any 
incomplete coding sequences or missing promoter regions potentially 
generated from cleavage.  T4 is considered to use a strictly headful 
mechanism since no sequence markers for packaging have been reported.  In 
contrast, P22 also uses headful packaging, as indicated by the length of 
packaged DNA, yet this phage has pac sites for terminase recognition.  With 
this headful packaging strategy, the portal (gp3 and gp20, respectively) serves 
not only as the DNA conduit, but also as a pressure sensor to monitor the 
capsid head’s capacity.  The headful DNA packaging model is also supported 
by a three-dimensional asymmetrical reconstruction of the crystal structure of 
P22 DNA encapsidation.  The structure indicates that packaged DNA is coiled 
against the coat protein in the phage head interior and presses against the 
portal protein, potentially providing the signal that the capsid is full (133, 177).  
This is in contrast to T7 and lambda phage packaging in which both termini of 
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 the genome are specifically marked with direct repeats or cos sites to ensure 
encapsidation of an appropriate size DNA molecule (119).   
 
HSV DNA encapsidation proteins:   
Unlike its phage counterparts, the HSV terminase may be composed of 
more than two viral proteins.  In HSV three proteins, pUL15, pUL28, and 
pUL33, form a packaging terminase complex (19).  Protein-protein interactions 
among these terminase proteins have been more clearly defined through co-
immunoprecipitation experiments.  The results indicate that pUL15 and pUL33 
are incapable of interacting directly with each other, even though both pUL33 
and pUL15 can each directly interact with pUL28 (277).  Therefore, it seems 
that the association of pUL15 with pUL33 can only be observed through 
interactions with pUL28 (277). The protein complex is formed in the cytoplasm, 
and transport of pUL15/ pUL28 into the nucleus appears to be dependent upon 
a pUL15 nuclear localization signal (278).  pUL28 and pUL15 are suggested to 
serve the respective roles of DNA binding and energy production necessary 
for DNA encapsidation to parallel phage terminase systems.  The role of 
pUL33, however, is less clear, although it has been demonstrated to 
strengthen the interaction between pUL15 and pUL28 and thus may serve as 
an accessory component to the complex (277). 
In vitro, pUL28 binds the single-stranded, structured pac1 sites in a 
sequence-specific manner (2).  Nascent genomes are first cleaved at the UL 
terminus; this is the genomic end which first enters the capsid through the 
dodecameric ring of pUL6 (32, 182, 252).  This combined with the 
understanding of the atypical DNA binding-properties of pUL28 lends to the 
 42
 hypothesis that pUL28 recognizes the pac1 site at the US terminal end and is 
responsible for this second cleavage event of the packaging reaction.   
Additionally pUL15 shares homology with the ATPase domain of T4 
terminase protein gp17 (54).  The putative ATPase domain of pUL15 is 
predicted by two conserved nucleotide binding protein motifs, GKT and DE, 
coined Walker A and B boxes respectively (67, 265). 
 Of HSV packaging proteins, pUL6 was found to form a portal through 
which the nascent genome can enter the capsid.  Electron microscopy studies 
showed that pUL6 formed a ring and was most commonly found only on a 
single vertex of capsids (182).  Quantitative western blots and scanning 
transmission electron microscopy indicated a 12-mer forms the pUL6 ring 
(182).  Additionally, pUL6 has been shown to interact with at least two of the 
HSV terminase proteins, pUL15 and pUL28 (278).  It is widely accepted that 
genomic HSV DNA enters the capsid through the portal ring, however, any 
additional mechanical roles of pUL6 in capacity sensing, energy generation, or 
DNA binding are currently unclear.  A three-dimensional asymmetric 
reconstruction of P22 phage shows the structure of the virion at 17 angstroms 
(133).  Although this is a relatively low-resolution structure determination, the 
asymmetric reconstruction provides information about the unique vertex of the 
portal, which is eliminated when icosahedral averaging is used to derive the 
structure.  This asymmetric structure containing the portal (gp1) in the context 
of the virion reveals significant conformational differences from the crystal 
structure of the portal alone.  It appears as if the conformational change in gp1 
may be an indicator of a fully packaged virion.  In HSV it is unclear if pac site 
recognition is all that is needed to maintain uniform insertion of complete 
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 genomes into capsid or if pUL6 may additionally serves as a headful 
packaging indicator. 
Thus, the roles of four of the seven genes essential for proper HSV 
DNA cleavage and packaging can be attributed to the roles these proteins play 
in forming the terminase and portal structures; each have analogs in phage 
packaging mechanisms.  However, homologs of the remaining 3 remaining 
essential genes, UL32, UL25, and UL17 exist only in other herpesviruses and 
their functions in DNA encapsidation have yet to be clearly defined. 
Similar to the other HSV packaging proteins, pUL32 is essential for 
construction of C capsids (132).  The primary sequence of UL32 predicts 
putative N-linked glycosylation sites, and aspartyl protease and zinc-binding 
motifs (39).  Although no biochemical function of this protein has yet to be 
reported, purified, native, UL32 protein as well as a Histidine-tagged UL32 
protein expressed in baculovirus were both capable of binding zinc (39).  
Deletion of this gene results in the production of only B capsids, does not alter 
the rate of viral DNA replication, and does not allow for the cleavage of the 
genomic concatemers (132).  Originally pUL32 was reported to localize 
exclusively to the cytoplasm (39), which obscures any direct role of this protein 
in cleavage and packaging, but in later studies performed with an antibody 
against a tagged fusion UL32 protein, both in infected and transfected cells 
some pUL32 was found in the nucleus although the predominant staining of 
pUL32 still remained cytoplasmic (132).  The nuclear pUL32 was present within 
the replication compartment but absent from presumed nucleoli.   Deletion of 
UL32 caused mislocalization of assembled capsids early in infection (132).  
This lead to the hypothesis that pUL32 was needed for capsid localization to 
the replication compartment.  In the proposed (Weller) model, pre-assembled 
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 capsids are brought to the replication compartment either by a direct or 
indirect interaction with pUL32 in order for cleavage and packaging to occur in 
the replication compartment (132).  This is in direct opposition to the model 
proposed by Ward et al that suggested capsid maturation and packaging 
occurs in assembly structures located at the periphery of the replication 
compartment (266). 
 pUL25 and pUL17 are present on the external face of C capsids in a 
proposed heterodimer coined the C Capsid-Specific Complex (CCSC) (254).  
This structure, present on C capsids, extends radially from each of the five-fold 
points of symmetry of VP5 pentons passing between hexons of VP5 and 
above triplex complexes (254)(fig 1.13). 
pUL25 like the other cleavage and packaging proteins is essential for 
optimal formation of C capsids, however, UL25 stands alone in that deletion of 
this gene results in a higher ratio of A to B capsids (158).   Additionally, upon 
deletion of UL25 HSV still retains its ability to cleave concatemeric DNA (158) 
and allows for some DNA packaging to occur, though much less efficiently 
(approximately 20-fold) compared to wild-type HSV-1 infection (231).  
Genomes propagated in UL25 deletion virus-infected cells undergo cleavage 
at both genomic termini, but in southern blots of DNAse-resistant viral DNA the 
two ends are disproportionally represented indicating the US terminus 
specifically is degraded presumably from failure to be encapsidated (231).  
These data suggest that pUL25 plays a later role in cleavage and packaging 
than do the other proteins of this class.  It has been proposed that pUL25 may 
act as a gate to close the portal after packaging in order to keep the genome 
contained within the capsid. 
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Figure 1.13 The C-Capsid Specific Complex.  CyroEM and three-
dimensional reconstruction of the pUL17/pUL25 heterodimer (magenta) 
present on C capsids (B, C, E, F) but not A capsids (A, D).  Panel F 
shows the optimal fit of a pUL25 fragment in ribbon structure within the 
heterodimer (254). 
  In another alphaherpesvirus, pseudorabies virus (PrV), the UL25 gene 
product is not required for DNA cleavage or encapsidation, yet, the protein is 
absolutely essential for viral replication (124).  DNA-containing C capsids are 
retained in the nucleus upon infection with pUL25-lacking PrV (124).  Instead 
of being required for cleavage and packaging, electron microscopy of PrV 
UL25- infection shows an accumulation of nucleocapsids throughout the 
nucleus and at the inner nuclear membrane as well as a void of cytoplasmic 
capsids and extracellular virions all indicating pUL25 is necessary for nuclear 
egress (124).  The presence of light particles in the cytoplasm also ensures 
that the effect is specific to primary envelopment as secondary envelopment is 
still functional in the absence of pUL25.  The different phenotype of the PrV 
mutant compared to its HSV homolog may reflect subtle differences in 
replication strategy between these viruses.   Presumably, this indicates that 
pUL17 in PrV is capable of sealing the packaged capsid independent of pUL25, 
and that pUL25 may recognize markers for primary envelopment.  Whether or 
not the same role for pUL25 in primarily envelopment exists in HSV infection 
has not been clearly established, although it has been shown as an 
attachment point for the inner tegument proteins (49). 
HSV pUL25 is not associated with the procapsid and may be added on 
to maturing capsids in a pUL17-dependent manner (245).  Purified UL25 
protein was able to bind to UL25-null capsids (179).  Studies analyzing protein 
components of B capsids purified from UL17-null virus infection showed 
depleted levels of pUL25 suggesting that pUL17 is required for efficient 
incorporation of pUL25 in B capsids (245).  The reciprocal experiment 
detecting protein levels of pUL17 present on B capsids from UL25- infection 
resulted in a two-fold reduction of pUL17 (245).  Combined, these data lead to 
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 the hypothesis that pUL25 may stabilize pUL17’s association with capsids.  
However, it is not clear why pUL17 stabilization through pUL25 would be 
necessary since pUL17 associates with the procapsid prior to addition of 
pUL25 in capsid maturation (246).  Regardless, these effects suggest roles for 
pUL25 and pUL17 in capsid structure and maturation that may produce indirect 
effects on the cleavage and packaging process.  
 The mechanisms of regulation of DNA packaging, tegumentation, and 
nuclear egress remain elusive.  However, studies investigating the quantity of 
pUL25 and pUL17 assembled onto various capsid types as well as into the 
virion suggest that both proteins are continually built upon the capsid, and 
capsid-bound protein concentrations may aid to regulate these processes.  
Protein levels of assembled pUL25 have been shown to be minimal on 
procapsids, intermediate on B capsids, and highest on C capsids with an 
overall 15-fold difference between procapsids and C capsids (217).  In a 
separate study, quantitative western blot analysis indicated approximately 20 
copies of pUL25 were present per single B capsid, 45 copies per A capsid, and 
75 copies per C capsid (179).  When the incorporation of pUL17 protein was 
analyzed, both A and B capsids were determined to have similar amounts of 
pUL17 whereas C capsids indicated approximately two-fold increase (246).  
The addition of pUL25 and pUL17 correlates with the CCSC (pUL17/pUL25) 
being detectable by cryoelectron microscopy specifically on C capsids, not on 
A capsids (179, 246, 254) in which pUL25 may be less uniformly structured. 
 The gene most recently shown to be essential for DNA cleavage and 
packaging, UL17, is an open reading frame that is predicted to encode a 
protein of 74,577 daltons (703 amino acids) and that resides in the intron of 
UL15 (214).  UL17 has no significant homology to any other cellular or viral 
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 proteins other than UL17 homologs of other herpesviruses.  The first antibody 
to pUL17, a polyclonal rabbit antibody from DNA immunization reported by 
Salmon et al reacted with two proteins with molecular weights of 72,000 
daltons and 77,000 daltons.  Subsequently another polyclonal rabbit antibody 
from a fusion protein immunization that reacted only with a viral protein of 
78,000 daltons was reported (99).  These data suggest that pUL17 protein 
exists in multiple forms in infected cells. 
pUL17 was observed to be essential for viral replication based on the 
evidence that UL17 deletion mutants could not form viral plaques on wild-type 
(Vero) cells (11).  Since UL17 lies within the intron of another essential gene, 
UL15, deletion of UL17 proves an additional challenge.  A UL17 mutant virus 
replacing UL15 exon I with the entire cDNA was constructed in order to control 
for effects on splicing of UL15 (214).  Although mutants of UL17 were unable to 
grow on wild-type (Vero) cells, these mutants sustained growth on cells 
designated G5 that were derived from transformed Vero cells engineered to 
incorporate a 16.2 kb EcoRI fragment containing viral genes UL16 to UL21 
from the KOS strain of HSV-1 (62).  When compared to another mutant 
bearing a premature stop codon in UL17 made in the wild-type virus, 
supplementing with the UL15 cDNA made no difference in the mutant 
phenotype of UL17.     
Cells infected with a UL17 deletion virus were shown to be deficient in 
cleavage of concatemeric DNA by BamHI southern blot probed with an S 
fragment probe (214).  This probe will bind to the US terminal BamHI fragment 
(“S”) generated only in cleaved genomic DNA.  In uncleaved, concatemeric 
DNA this probe will instead recognize the larger, uncleaved S-P fragment.  
UL17-null virus grown on complementing cells (providing pUL17 in trans) 
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 restored the cleavage required to regenerate the S fragment (214).  With this 
method, Salmon et al showed both that cleavage was prevented in UL17-null 
infected cells, but also that replication of genomic DNA remained unaltered 
(214). 
A defect in genomic DNA packaging was also confirmed by thin-section 
electron microscopy of UL17-null infected cells (214).  Akin to most other 
cleavage and packaging mutants, deletion of UL17 caused accumulation of B 
capsids only.  However, deletion of UL17 produced aggregates of capsids at 
the periphery of the nucleus, a unique phenotype (241) revealed by 
immunostaining with a monoclonal antibody, 8F5, that specifically recognizes 
an epitope on hexons of assembled capsid (253).  In contrast to capsids in 
wild-type infected cells where mature capsids are dispersed throughout the 
replication compartment, the capsid aggregates formed upon UL17-null 
infection were excluded from the replication compartment (241).  From these 
data, pUL17 has been proposed to transport capsids from assemblons to the 
replication compartment.   
  The cellular localization of the UL17 protein in HSV-1 and HSV-2 has 
been assayed by indirect immunofluorescence with two different antibodies 
both against a UL17-His fusion proteins (99) (figure 3.4).  In one report pUL17 
co-localized with VP5 and ICP35 to assemblons at late times in infection (99) 
in contrast  to the punctate localization throughout the replication compartment 
presented in this work (figure 3.4).   
 
Egress pathway debate: 
After mitigating the lamina barrier, capsids must pass through both the 
inner and outer nuclear membrane.  Multiple, diverse pathways of egress have 
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 been hypothesized and a sustained debate ensued.  The most evidence has 
accumulated for the de-envelopment/re-envelopment pathway which will be 
discussed in greater detail below in “Nuclear Egress/Primary Envelopment and 
“Nuclear Egress/Secondary Envelopment” (Fig 1.14).  This route of egress 
was originally proposed by Stackpole in the late 1960’s but because of its 
complexity was not embraced at the time (229).  In this model, capsids bud 
through the inner nuclear membrane (INM) obtaining a primary envelope as 
they enter into the periplasmic space.  Exit from this space is thought to occur 
through a fusion event of the primary envelope with the outer nuclear 
membrane (ONM) (de-envelopment).  This route of nuclear egress produces 
unenveloped, cytoplasmic capsids.  Stackpole hypothesized these 
unenveloped cytoplasmic capsids would subsequently obtain their final, 
secondary envelope (re-envelopment) by budding through a cytoplasmic 
membrane such as the Golgi or an endosome (163) and ultimately HSV virions 
exit the cell through the secretory pathway.  This model suggests that a 
primary tegument is acquired in budding at the inner nuclear membrane, but 
the final tegument is built in the cytoplasm rather than the nucleus.   
There three main alternative pathways have been proposed.  The first 
variation of the de-envelopment/re-envelopment pathway suggests capsids 
bud through the inner nuclear membrane and these enveloped capsids leave 
the perinuclear space in an outer nuclear membrane-derived vesicle (102) 
(Figure 1.14, Figure 1.15).  In this model, the outer nuclear membrane and 
virion envelope fuse to release unenveloped capsids into the cytoplasm, 
where they can bud into trans-Golgi network cisternae and exit through the 
secretory system.  This pathway variant is the most closely related to the  
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Figure 1.15   Electron micrographs of capsid egress forming a double-
membrane vesicle.  Budding through the inner and outer nuclear 
membrane in concert (C-F).  Vesicularization at the outer leaflet of the 
nuclear membrane (G).  Potential fusion between the PrV envelope and 
outer vesicular membrane (H) (102). 
 accepted de-envelopment/re-envelopment pathway in that it also suggests two 
steps of envelopment. 
 Data arguing for another route of egress through dilated nuclear pores 
have been presented (271).  This model proposes a pathway in which holes 
large enough for the passage of capsids (>140nm) exist in the nuclear 
membrane late in infection (271, 272).  This route offers capsid egress without 
requiring inner or outer nuclear membrane interactions.  In quantitative 
analysis of electron micrographs, Wild et al. found capsids were readily 
capable of budding into any membrane from the cytoplasmic side, whereas 
the occurrence of nuclear capsids budding into the inner nuclear membrane 
was rarely observed (271).  Using fast freezing electron microscopy 
preparation, HSV capsids were seen in the openings of dilated nuclear pores 
(271) (Figure 1.16).  Also, HSV budding into the perinuclear space was 
reported to originate from both the nuclear as well as the cytoplasmic side.  In 
the dilated nuclear pore model, Wild et al propose HSV uses two pathways to 
obtain an envelope.  Naked cytoplasmic capsids can either bud into Golgi 
cisternae, or bud back into the periplasmic space, which is continuous with the 
ER and Golgi, or into another part of this continuum.  Thickening of the nuclear 
membrane proximal to the capsid was found to correlate with budding.  This 
was observed in both the inner (rarely) and outer nuclear membrane, arguing 
capsids can bud from either the nuclear or cytoplasmic side into the 
perinuclear space (140).  The thickening of the outer nuclear membrane was 
not attributed to the remains of a primary envelope after fusion because the 
length of thickened membrane was insufficient to cover the perimeter of the 
HSV capsid.   
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Figure 1.16  Capsid passage through nuclear pores.  Cryo-FESEM (A-B) 
TEM images of capsids in proximity to various-sized dilated nuclear pores 
in BoHV-infected MDBK cells (C-H) n=nucleus, c=cytoplasm (271).  
  Intracisternal passage of capsids to the Golgi is supported by the 
presence of capsids within the RER cisternae.  However, if these enveloped 
capsids are fusion competent as indicated by the presence of gB, gC and gD 
in the perinuclear capsids, then another protein(s) must be preventing fusion 
during intralumenal transport.  It has been speculated that gK, gM, UL20, 
pUL31, or pUL34 might serve this anti-fusogenic role.   
A third alternate route of egress that held popularity for some time also 
suggested that only a single step of envelopment was necessary for egress. 
This model proposed capsids were enveloped at the inner nuclear membrane 
and then passed through the perinuclear space/ER continuum into the Golgi.  
This model also requires that the membrane originally obtained from budding 
at the inner nuclear membrane is maintained and the capsid leaves through 
the secretory system.  Simplicity made this proposed pathway attractive, and 
experimental support came from the finding that perinuclear virions were 
infectious and that the Golgi was required for virion egress (257).  However, 
for the following reasons there is currently little backing for this pathway and 
some of the alternatives described above.   
Firstly, cytoplasmic capsids, both enveloped and unenveloped, have 
been observed by electron microscopy.  Also through live cell microscopy, 
capsid transport on neuronal axons as well as through the cytoplasm of 
infected mammalian cells has been observed.  Only one of the three alternate 
pathways presented, direct egress to the cytoplasm through the nuclear pore, 
anticipates the existence of unenveloped particles throughout the cytoplasm. 
Secondly, many other reports have failed to notice the dilated nuclear 
pores that Wild presents, and capsid envelopment has been documented in 
the vicinity of intact nuclear pores (166).  In Wild’s study nuclear pore size 
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 variation ranged from 140 nm to 1900 nm late in bovine herpesvirus (BoHV-1) 
infection of MDCK cells and often showed nuclear membrane extensions 
(blebbing) associated with the expanded pores (271).  Such gross alterations 
of the nuclear membrane suggest fixation artifacts although the authors did not 
see dilated nuclear pores in uninfected cells indicating the effects were 
specific to infection.  Due to the rapid disintegration of infected MDCK cells, 
the authors prepared rapid-freeze substitution EM samples of infected cells 
and uninfected cells and examined them at low temperatures (140).  This 
technique offers better preservation of membranes and high temporal and 
special resolution through arresting cellular processes in nanoseconds.  Only 
infected cells demonstrated the enlarged nuclear pores and therefore the 
phenomenon was attributed specifically to cytopathic effects and not to a 
technical artifact.   
Thirdly, budding was seen, albeit at a low frequency, upon MDCK 
infection with BoHV-1 despite the presence of expanded nuclear pores.  
Electron micrographs of HSV also provide clear images of capsids budding 
through the inner nuclear membrane and into the perinuclear space in close 
proximity to seemingly intact nuclear pores (162).  The low frequency of 
budding observed in Wild’s assay may reflect the rapidity with which INM 
budding is executed rather than its likelihood.  Perinuclear enveloped particles 
have also been seen fusing to the outer nuclear membrane (100).   
Of the alternate pathways, only the INM/ONM double membrane 
particle is proposed to go through two steps of envelopment.  All of the single-
step routes of transport imply tegument is assembled as the capsid fulfills its 
only budding step or within the ER-Golgi.  However, this model fails to explain 
why (i) tegument proteins have a cytoplasmic distribution, (ii) the phospholipid 
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 content of virions differs from that of perinuclear particles (163, 258), and (iii) 
proteins such as pUL31 and pUL34 have been detected in perinuclear virions 
but not in final virions. 
Much of the confusion over the mechanism of egress is a result of 
technical limitations.  Although electron microscopy offers a clear picture of 
ultrastructural localization at a given point in time, it does not offer any 
information about directional progression through time.  In a snap-shot view a 
particle budding towards the nucleus from the cytoplasm appears identical to a 
particle leaving the nucleus after fusion or de-envelopment.  Also, observing 
only a single point in time, it is not possible to differentiate between successful 
and aberrant particles. Although a number of studies have been published, a 
consensus of the route of HSV egress still has not been reached. Perhaps 
egress is more complex than expected in that multiple pathways exist to 
maximize viral success in various cell types or environments. 
 
Nuclear egress/primary envelopment:  
The most popular model of HSV capsid egress involves INM budding, 
de-envelopment at the ONM, and re-envelopment in the Golgi or other 
cytoplasmic membrane (Figure 1.14).  Other alphaherpes virus including PrV, 
ITLV (infectious laryngotracheitis virus), and EHV (equine herpes virus) are 
thought to use this pathway.  It suggests that a primary tegument is acquired 
in budding at the inner nuclear membrane, but the final tegument is built in the 
cytoplasm rather than the nucleus. 
Since C capsids are preferentially enveloped at the inner nuclear 
membrane, it is clear that something must distinguish these from other 
immature A and B capsids that remain within the nucleus, and yet this 
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 mechanism is still unknown.  It is unclear whether a capsid component or 
proteins in the tegument are involved in the process of assembly or whether 
they are only added to capsids after nuclear egress and envelopment (164, 
165, 266).  However, recent studies suggest that some tegument proteins may 
be added to the capsid within the nucleus.  US3 has been shown on both 
perinuclear and extracellular virions (209).   Additionally, the pUL36 and pUL37 
tegument proteins have recently been found to co-purify with intranuclear 
capsids, and pUL41 has been detected on intranuclear B and C capsids (27, 
202).  Moreover, despite its cytoplasmic localization, the VP11/12 (UL46) 
tegument protein was found to interact with purified nucleocapsids as well as 
to fractionate with capsids when virions were stripped of their envelopes, 
suggesting its interaction with the capsid (174).   
Capsids that are selected for nuclear exit must pass first through a layer 
of condensed host chromatin, then through a network of nuclear structural 
proteins, and finally through two layers (inner and outer) of nuclear membrane 
to finally arrive in the cytoplasm.  Immunofluorescence studies assaying 
chromatin distribution late in infection found that host cell chromatin (as 
indicated by an antibody against histone H1) became fragmented in the 
nuclear periphery by 18 hours post infection, forming channels into which ICP8 
(infected cell protein 8), a marker of HSV replication compartments, extended 
(222).  No co-localization between the chromatin and replication compartment 
markers was seen, suggesting discrete compartmentalization.  This led to the 
hypothesis that after marginalizing host cell chromatin, HSV also manipulates 
the compacted structures at the nuclear periphery to allow capsids access to 
the inner nuclear membrane.  When two HSV late genes, UL31 and UL34, 
were each singly deleted from the virus, infections no longer exhibited nuclear 
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 expansion nor produced channels in the condensed chromatin; instead, a 
continuous layer of chromatin lined the inner rim of the nuclear membrane 
(222).  Repair of the missing gene into each of these mutant viruses restored 
the fragmentation of chromatin late in infection, indicating the observed 
phenotypes were specific for the mutations created.  Taken together, these 
data suggest pUL31 and pUL34 actively manipulate the distribution of 
marginalized chromatin late in infection to allow passage of capsids toward the 
inner nuclear membrane (222).   
Chromatin is only one of many barriers obstructing the capsids access 
to the nuclear membrane.  Structural proteins, such as lamins, normally offer 
mechanical support to maintain the integrity, size, and shape of the nucleus.  
Lamins self-associate in multiple ways.  First, they have a coiled-coil domain 
that facilitates dimer formation.  Second, these dimeric, skeletal proteins are 
linked in a head-to-tail fashion to create a support network of filaments that lie 
interior to the inner nuclear membrane.  There are three lamin genes 
expressed in vertebrates, LMNB1, LMNB2, and LMNA.  LMNB1 encodes only 
a single gene product, lamin B1.  In contrast, LMNB2 encodes both lamin B2 
and B3 proteins, and LMNA produces four lamins proteins, A, AΔ10, C1 and 
C2, through alternate splicing of the LMNA transcript (115).  Each of these 
products can be categorized as one of two types of lamins, A or B type.  
Studies transfecting truncated lamin A show disruption of lamin A/C 
localization but not of lamin B, suggesting that the two types of lamins are 
independent (115). 
It has been proposed that the lamin network, the lamina, must be 
disassembled or disrupted by exiting nucleocapsids to permit egress (192).  
Lamins are only a subset of the structural proteins present in the complex 
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 lamina that includes emerin and other lamin binding proteins such as lamin-
associated protein (LAP2) and lamin B receptor.  Capsid penetration of this 
complex layer uses components of a cellular system intended for lamina 
disruption.  Normal host cell processes such as mitosis and apoptosis also 
require dismantling of the nuclear lamina; disassembly can be accomplished in 
various ways.   In mitosis, induced host cell kinases such as (cdc2) can 
phosphorylate components of the lamina (lamin proteins and LAPs, including 
emerin) to promote the necessary reversible filament depolymerization (77, 
81, 106).  In contrast, apoptosis utilizes both depolymerization by PKCδ and 
caspase 6 cleavage to permanently destroy the nuclear lamina (52). 
 In order to transport capsids out of the nucleus, HSV induces 
progressive lamin disruption which can be seen in lamin A/C immunostaining.  
Mock-infected cells show smooth, uniform lamin A/C staining surrounding the 
nucleus, but infected cells reveal punctate staining leaving gaps along the 
nuclear rim.  Redistribution of LAP2 as well as lamin A/C was observed late in 
infection and this allowed expansion of the replication compartment to the 
nuclear membrane (222).  Two protein products of HSV late genes, pUL31 and 
pUL34, both present only on the perinuclear virion (209) were found to be 
essential for this redistribution to occur (222).   
 UL34 encodes a type II membrane phosphoprotein that upon infection 
or transfection resides in the nuclear envelope.  pUL31 is a nuclear matrix-
associated phosphoprotein (40); however, its membrane localization in 
infected and transfected cells is influenced by the presence of pUL34 (208).  In 
the absence of pUL34, pUL31 is entirely mis-localized and stains 
predominantly within the nucleus.  In contrast, in the absence of pUL31, some 
pUL34 can still be detected at the nuclear rim, but pUL34 is also spread out in 
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 the replication compartment, and in the perinuclear region.  Direct interaction 
of the two proteins in vitro has been shown with GST-fusion pull down 
experiments and co-localization assays (208).  The region containing amino 
acids 137-181 in the UL34 protein is essential for this interaction with pUL31 
(141).  
In addition to each of the UL31 and UL34 proteins influencing the 
localization of the other, the nuclear membrane localization of both proteins 
can also be altered by a viral kinase encoded by US3.  In the absence of pUS3, 
pUL31 and pUL34 form punctate accumulations along the nuclear rim (208).  
Like pUL31 and pUL34, pUS3 is also present in the inner nuclear membrane, 
closely associated with pUL34 (209).  pUS3 exerts its kinase activity on both 
UL31 and UL34 proteins as well as other, unrelated viral proteins such as pUS9 
and ICP22 and many other cellular substrates including emerin and lamins 
(122, 136, 172).  It is thought that lamin A/C phosphorylation by pUS3 
regulates lamina disruption through conformational changes thus in effect 
perforating the barrier to capsid egress (23, 172, 207).  Studies in PrV 
revealed that capsids accumulate within nuclear membrane invaginations in 
cells infected with the US3-null virus (264).  Thus far, phosphorylation of pUS9 
and ICP22 by pUS3 has not shown any relevance to inner nuclear membrane 
recognition for capsid budding.  Instead, these pUS3 substrates most likely aid 
in other pUS3 functions such as capsid de-envelopment at the outer nuclear 
membrane or prevention of apoptosis. 
Remarkably, despite their roles in gaining access to the nuclear 
membrane, neither pUL31 nor pUL34 is strictly essential for replication though 
both UL31 and UL34 deletion viruses produce many fewer virions.  UL34 
deletion virus is attenuated at least 3 orders of magnitude for growth when 
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 compared to wild-type viral titers (211).  Deletion of UL31 lowered virus output 
by 1-3 logs depending on the cell line (41).  Specifically, electron microscopy 
revealed that either UL31 or UL34 deletion viruses produce an accumulation of 
unenveloped capsids at the interior of the nuclear membrane (208). These 
observations also suggest pUL31 and pUL34 are crucial for nuclear egress.  
 
Tegument: 
The tegument, analogous to the matrix of other viruses, is an 
asymmetrical network of at least 20 proteins with various functions (162).  The 
innermost layer, the layer most proximal to the capsid shell, is composed of 
the product of HSV’s largest ORF, UL36, which encodes VP1/2 (159), pUL37, 
and pUS3; these are believed to be the first tegument proteins added to the 
capsid (285).  The external capsid proteins, pUL17 and pUL25, may also be 
considered part of the tegument.  This conclusion is supported by the 
presence of pUL17 in “light” particles which contain tegument proteins but lack 
capsids (214).  De-envelopment of the perinuclear virion results in cytoplasmic 
capsids which appear “naked” by electron microscopy.  Although they do not 
posses enough tegument to visualize, these capsids contain UL36, UL37, and 
US3 proteins as detected by immunogold electron microscopy (85).  The 
distribution of UL36 protein around the capsid may reflect the symmetry of the 
icosahedral capsid by association with the VP26-less pentons, although this 
symmetry is lost in more capsid-distal layers of the tegument (285). 
Physical interaction of the UL36 and UL37 gene products has been 
documented upon infection with PrV through immunoprecipitation studies and 
in both PrV and HSV yeast-two hybrid screens (123, 263).  The interaction, 
confirmed by reciprocal immunoprecipitations, was mapped to the N terminus 
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 of pUL36 (123).  Both pUL36 and pUL37 are essential virion proteins.  Despite 
successful C capsid formation and nuclear egress, ultrastructural studies of a 
UL36-null infection demonstrated the accumulation of cytoplasmic capsids and 
abrogated production of enveloped virions (65). Incorporation of UL37 protein 
in the tegument was found to be independent of pUL36 (123).  More recently 
live-cell microscopy studies using a UL37-GFP recombinant virus indicate 
pUL37 is trafficked to the Golgi in a pUL36-dependent, capsid-independent, 
manner (64).  These results suggest interplay between pUL36 and pUL37 is 
necessary for Golgi-recruitment of pUL37 possibly defining a crucial role for 
pUL37 in cytoplasmic envelopment. 
Beyond the inner layer the organization of the tegument becomes much 
less ordered and less well understood.  Two independent yeast two-hybrid 
screens have been performed to reveal structural interactions creating the 
network of tegument proteins (138, 263).  This quest is encumbered by the 
redundancy and flexibility of the tegument.  Reports indicate that deletion of 
the tegument protein VP22 creates a void in which other tegument as well as 
cellular proteins are over-represented in the virion presumably as a 
compensatory mechanism (61).    Whether reported tegument interactions are 
merely structural or whether they have functionally relevant purposes is still 
largely unknown.   
The functions of many tegument proteins appear to be redundant.  No 
single tegument-glycoprotein interaction appears to be essential for assembly 
of the tegument; in fact, a PrV virus with UL46, UL47, UL48, and UL49 all 
deleted can replicate although level of replication is impaired (86). Viruses 
deficient in either UL46 or UL49 were unattenuated; however, deletion of UL47 
or UL48 impaired replication (85, 126).  Not only are some tegument proteins 
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 redundant in function, their interactions with glycoproteins may also share 
redundancy further complicating the study of secondary envelopment.  Studies 
deleting both gM and gE found infection was only mildly hampered (26).  
 HSV tegument proteins are diverse, serving roles in viral transcriptional 
regulation, degradation of mRNA, inter- and intra-cellular trafficking, and 
induction of the NFkappaB pathway. One aspect all tegument proteins share is 
the potential to function immediately upon cell entry instead of relying on 
productive transcription and synthesis.  This suggests that tegument proteins 
may have either early or high priority functions in terms of replication.  
However, the function of many tegument proteins remains an enigma at the 
present. 
For example, one tegument protein, VP16 (UL48), is known to promote 
transcription of viral genes.  Although VP16 itself is not a transcription factor in 
that the protein is not capable of binding DNA directly, it promotes transcription 
through the assistance and interactions with the cellular protein, Oct-1, that 
recognizes a specific immediate early gene promoter sequence.   The 
consensus sequence, TAATGARAT, is recognized by Oct-1 which in 
combination with VP16 forms a complex (157, 189, 198).  Transactivation of a 
CAT construct linked to a TAATGARAT promoter element has demonstrated 
the recognition sequence alone is sufficient for activation (90).  
Another tegument protein with an established functional role in infection 
is pUL41, also coined vhs for virion host cell shut-off protein.  This protein 
appears to degrade or destabilize both viral and host mRNAs early in infection 
thereby shutting down protein synthesis so that cellular translation machinery 
can be used primarily by viral transcripts.  Early reports using a UL41 mutant 
suggested that this protein is necessary for incorporation of the transactivator, 
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 VP16, into the virion (201).  A VP16-binding domain was mapped to 20 
particular amino acids of vhs in a yeast-two hybrid assay (215).  Clearly, 
however, interaction between these two proteins does not occur exclusively 
through this domain; in more recent studies deletion of the VP16 binding 
domain in vhs did not preclude co-immunoprecipitation from infected cells and 
only made a modest decrease in the amount of vhs assembled into the virion 
(233).   
 The UL49 tegument protein, VP22, is not essential in HSV, but in 
Marek’s disease virus (MDV) is indispensible (70).  In HSV, VP22 has been 
demonstrated to co-localize and co-purify with the HSV major transcriptional 
regulator, VP16 (UL48) through its activation domain (73, 173, 190).  In a 
complex with VP16, VP22 also works indirectly with vhs to regulate viral gene 
expression.  In the absence of VP16/VP22, vhs protein levels produced from 
solo transfection were lower compared to levels after co-transfection of 
VP16/VP22 with vhs (237).  Despite the difference in protein levels, amount of 
vhs mRNA was equivalent in the single and co-transfection samples, 
indicating ample transcription of vhs, but the vhs protein is unstable without 
VP16 and VP22 (237).  Thus VP22, like VP16, may play role in regulating the 
ribonuclease activity of vhs which is strong early in infection and inhibited late 
in infection, thus explaining why VP22 is needed for mRNA accumulation of 
specific viral proteins (71, 131). 
 Additionally, VP22 may aid in transport of virus particles both intra- and 
inter-cellularly.  Since it was found to hyperacetylate and rearrange 
microtubules into thick, resilient bundles, VP22 has been suggested to be a 
microtubule associated protein (MAP) (74).  Independent of the HSV virion, 
VP22 has also been reported to spread from one cell to another (75), 
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 however, later reports suggest the uptake of VP22 may be influenced by 
fixation parameters (149). 
 The pUL37 tegument protein has been shown to induce NFkappa 
activation (147).  The host cell uses the NFkappaB pathway to respond to 
many stimuli.  NFkappaB translocates to the nucleus or is “activated” when its 
repressor IkappaB is phosphorylated.  The phosphorylation event induces 
dissociation of IkappaB from NFkappaB thus exposing the NLS of NFkappaB.  
Upon HSV infection two distinct phases of reduction of IkappaB and 
NFkappaB activation can be detected.  The first is virus-independent and co-
incidental with infection and may be the result of gD signaling through TLR2; 
the second  is virus dependent and starts between 5-6 hours post-infection (6).  
In a proteome-wide screen of 70 ORFs, the tegument protein pUL37 
demonstrated the strongest ability to activate NFkappaB (147).  This function 
was also determined to be TLR-independent (147). 
  
Secondary envelopment/cellular egress: 
Many outer tegument proteins interact with the cytoplasmic tails of 
glycoproteins present in cytoplasmic membranes which act as targets for sites 
of secondary envelopment.  Many organelle membranes have been proposed 
as secondary envelopment sites including the endoplasmic reticulum-Golgi 
intermediate, the Golgi, the trans-Golgi network (TGN), aggresomes, 
tegusomes, endosomes, and multi-vesicular bodies.  However, more recent 
reports support the TGN as the most likely candidate.  Infection with a 
temperature-sensitive protease mutant to block capsid egress, targeted 
glycoproteins gD, gE, gH, gI and gL specifically to the TGN at the restrictive 
temperature, which is in congruence with the idea that the TGN is the primary 
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 site of secondary envelopment (257).  With a shift to the permissive 
temperature the egress block was reversed and capsids were found to co-
localize with viral glycoproteins at the TGN (257).   
Some direct tegument-glycoprotein interactions have been reported, for 
example, the tegument protein VP16 (UL48) has been shown to interact in the 
cytoplasm with the gH glycoprotein using a GST-fusion of VP16.  This 
interaction was further substantiated with the in vivo co-immunoprecipitation of 
the two proteins (103).  Curiously, the PrV homolog of UL49 has not been 
shown to interact with gD; rather, yeast two hybrid studies suggest that in PrV 
this tegument protein can interact with gM and gE glycoproteins (87).   
The functional redundancy of tegument proteins and membrane-bound 
glycoproteins complicates the study of secondary envelopment.  Analysis of a 
single outer tegument protein, VP22 (UL49), and its multiple interactions with 
glycoproteins provides an excellent example of redundancy involved in the 
mechanism for secondary envelopment.  Using an in vitro assay, VP22 was 
shown to interact with the cytoplasmic tail of gD in two separate studies, one 
reacting cellular extracts with a GST-gD fusion protein and the second using 
tandem-affinity purified (TAP) cytoplasmic gD tail to capture VP22(44, 79).  
However, VP22 is also capable of interacting with the cytoplasmic tail of gE 
(79, 234).   
During secondary envelopment the virus particle obtains its final 
membrane from the compartment into which it buds.  Virus export to the 
extracellular space continues through the secretory system. 
 
 
 
 68
 Cytoplasmic capsid transport:  
 Cytoplasmic, anterograde transport of exiting virus particles occupying 
cytoplasmic compartments appears also to be mediated by microtubules.  
Using cytoplasmic organelles purified by sucrose-gradient that contain GFP-
VP26 recombinant HSV, time-lapse microscopy demonstrated ATP-
dependent, microtubule-based transport.  Movement rates along microtubules 
were calculated to average approximately 0.58 um/second (137).  In these 
studies, two types of motion were observed, short distance with highly variable 
speed and long distance with constant speed.  When kinesin motor inhibitors 
were used such as AMP-PNP (adenosine 5’-(β, γ-imido) tri-phosphate) and 
vanadate only the constant-speed, long-distance moving particles were 
stopped (137).  This argues that progressive anterograde transport of HSV is 
through kinesin motor transport on microtubules.  The force behind the other 
class of saltatory moving particles remains unknown.   
 
Roles of the UL17 protein: 
In the chapters that follow I explore structural and functional roles of the 
essential HSV protein pUL17.  Electron microscopy indicates pUL17 is 
multivalently present on the external surface of the HSV capsid.  Biochemical 
and immunofluorescent studies support the Trus et al hypothesis that pUL17 
and pUL25 form a heterodimer on the capsid (254).  pUL17 also appears to 
have DNA-binding properties similar to pUL25 (191).  Consistent with its 
capsid surface positioning, pUL17 also appears to interact with tegument 
proteins VP11/12 and VP13/14.  Both pUL17 and pUL25 as well as every other 
DNA cleavage and packaging protein are not essential to the intranuclear 
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 dynamics of capsids despite potential ATPase activity displayed with purified 
UL17 protein. 
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CHAPTER II: 
 
The Herpes Simplex Virus 1 DNA packaging proteins encoded by UL15, 
UL17, UL28, and UL33 are located on the external surface of the viral 
capsid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Portions of this chapter are published in Wills, E., L. Scholtes, and J. D. 
Baines. 2006. Herpes simplex virus 1 DNA packaging proteins encoded by 
UL6, UL15, UL17, UL28, and UL33 are located on the external surface of the 
viral capsid. J Virol 80:10894-9. 
 71
 Abstract: 
 Herpes simplex virus capsids were purified and were reacted with 
antibodies directed against the portal protein encoded by UL6, the putative 
terminase components encoded by UL15, UL 28, and UL33, the minor capsid 
proteins encoded by UL17 and UL33 protein, and the major scaffold protein 
ICP35.  The presence of bound antibodies in intact and sectioned capsids was 
revealed by immunoelectron microscopy.  Epitopes of the scaffold protein, 
ICP35, were more readily reactive after capsids were embedded and 
sectioned, indicating that, as expected, this protein was located exclusively 
within the capsid interior.  Epitopes of pUL6, pUL17, pUL33 and pUL15 were 
present at the capsid surface as revealed by the immunoreactivity of intact 
capsids reacted with antibodies directed against these proteins.  Epitopes of 
pUL15 were also recognized in sectioned capsids suggesting that portions of 
this protein were present at both the capsid exterior and interior.   
 
Introduction: 
 Capsids form in the nuclei of cells infected with all herpesviruses.  
Herpes simplex virus capsid pentons and hexons form spontaneously from 
five and six molecules of ICP5 respectively; these capsomeres are linked by 
triplexes consisting of two molecules of VP23 and one molecule of VP19C to 
form a porous procapsid (183, 228, 251).  ICP5 is also associated with ICP35 
that forms an internal shell or scaffold within the procapsid.  The procapsid is 
believed to give rise to the three other types of capsids seen in HSV-infected 
cells, designated A, B, and C.  All of these differ internally but contain identical 
outer shells as determined by cryoelectron microscopy (180, 216, 288).  Type 
B capsids retain the scaffold  internal to the outer shell, type A capsids only 
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 contain the outer shell, and type C capsids lack the internal scaffold but 
contain viral DNA (98).  Type C capsids then bud from the nuclear membrane 
in a reaction termed primary envelopment (163, 210). 
 One of the vertices of A, B, and C capsids is biochemically and 
structurally unique and has been designated the portal vertex.  Thus, the UL6 
encoded protein (pUL6) forms a dodecameric ring with an internal diameter of 
at least 65 Å, i.e. sufficiently wide to accommodate DNA as it is packaged into 
the capsid (252).  Critical to the discovery of the portal was the observation 
that an antibody to the C-terminus of pUL6 recognized epitopes on a single 
vertex of type B capsids, thus showing that at least the C-terminus of pUL6 is 
located at the capsid exterior in a position to access incoming viral DNA (182, 
241).   
 It has also been shown that HSV-1 B capsids contain a number of 
capsid proteins in addition to pUL6, ICP5, and ICP35.  These include 
approximately 1.2 copies of pUL15, 2.4 copies of pUL28, 40 copies of pUL25, 
and an undetermined number of copies of pUL17 and pUL33 (17, 18, 99, 194, 
213, 246, 283). By analogy to extensive studies of bacteriophage capsid 
assembly, one might predict that some of these minor capsid proteins would 
be involved in processing concatemeric DNA and threading the DNA into the 
portal through the hydrolysis of ATP (36).  Such a complex, termed the 
terminase, remains somewhat enigmatic in HSV, but a variety of indirect 
evidence suggests that it comprises at least the UL15, UL28, and UL33 
proteins.  Specifically, (i) all three proteins are among seven required for viral 
DNA packaging (3, 197, 243), (ii) the UL15 protein contains a conserved P-
loop ATPase motif and mutation of this motif precludes DNA packaging (54, 
282), (iii) the UL28 protein can specifically bind DNA sequences known to be 
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 required for correct cleavage of  concatemeric viral DNA (2), (iv) the UL15, 
UL28, and UL33 proteins interact in vitro and can be purified from lysates of 
infected cells by co-immunoprecipitation (1, 19, 127), (v) in vitro, both pUL28 
and pUL15 can interact with the portal protein encoded by UL6 (269).  
 Although it is also required for DNA packaging, the precise function of 
pUL17 is unknown (214).  Analysis of a UL17 deletion mutant revealed 
alteration of the normal intranuclear distributions of capsids, and a number of 
viral proteins including pUL6, ICP35, and ICP5 (241).  These observations 
suggest that UL17 protein is involved in capsid assembly, the reorganization of 
the infected cell nucleus, or directly or indirectly in capsid or protein transport 
within the nucleus.  Relevant to this last possibility is the observation that HSV 
capsids are actively transported in the nucleus and this transport is both 
energy and actin-dependent (82).   
 The hypotheses that the UL15, UL28, and UL33 proteins form the HSV 
terminase, and pUL17 acts directly or indirectly to mediate transport of capsids 
within the nucleoplasm predict that at least portions of these proteins would 
localize on the external surfaces of capsids.  This study was undertaken to test 
this possibility.  
 
Production and specificity of novel chicken antiserum against pUL17: 
 Because a previously described pUL17 antibody produced using a 
DNA vaccine did not recognize small quantities of UL17 protein (214) (data not 
shown), pUL17 was fused to DNA encoding a 6X Histidine tag and a 
recombinant baculovirus was generated that expressed the fusion protein. The 
UL17 fusion protein was purified from lysates of insect cells infected with the 
recombinant baculovirus by affinity chromatography on Ni++-containing 
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 Sepharose beads as described previously (18).  Immunization of chickens with 
the purified fusion protein was followed by purification of IgY from the eggs of 
immunized hens.    
To test the antisera for specificity, Hep-2 cells were mock infected or 
infected with HSV-1 (F) or a UL17 null virus at an MOI of 5 pfu per cell.  
Lysates from approximately 1.3 x106 cells were prepared by denaturation and 
boiling in 1% SDS and 5 mM beta mercaptoethanol.  Denatured proteins were 
electrophoretically separated on an 8% SDS polyacrylamide gel and 
transferred electrically to a nitrocellulose membrane.  The nitrocellulose 
membrane was blocked overnight at 4oC in PBS supplemented with 5.0% milk 
and 0.2% Tween-20.  The membrane was rinsed twice with room temperature 
PBS and 0.2% Tween-20 and was further blocked by immersion in a 1:10 
dilution of Block Hen (Aves labs) for 15 minutes.  Polyclonal anti-pUL17 IgY 
was diluted 1:500,000 into PBS with 1% BSA and 0.2% Tween-20 and applied 
overnight.   After extensive washes in PBS containing 0.2% Tween-20, the 
membrane was incubated with horseradish peroxidase-conjugated anti-
chicken antibody diluted 1:5,000 in PBS containing 5.0% milk and 0.5% 
Tween-20.  Bound IgY was detected using a five minute incubation with ECL 
Plus reagents (Amersham) and flash exposure to Fuji autoradiographic film.  
As shown in Figure 2.1, the anti-pUL17 antiserum recognized a 79,000 
apparent Mr protein that was not present in lysates of mock infected Hep2 cells 
or cells that were infected with the UL17 deletion virus.  This size is consistent 
with a previous study reporting an apparent Mr of 77,000 in virions (214).  We 
did not detect the previously reported 72,000 apparent Mr protein that was 
previously identified in virion lysates by mass spectrometry,  
 75
  76
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 2.1.  Chicken anti-pUL17 antibody immunoblotting.  Digitally 
scanned image of immunoblot of lysates of infected and uninfected cells 
reacted with pUL17 specific antiserum.  Lysates of cells that were 
uninfected (left lane) or infected with a UL17 deletion virus (center lane), 
or wild type virus HSV-1(F) (right lane) were electrophoretically 
separated on an SDS polyacrylamide gel, transferred to nitrocellulose 
and reacted with purified  IgY obtained from a chicken immunized with 
purified  pUL17.  Bound IgY was revealed as indicated in the text. 
 suggesting that the smaller protein may be highly enriched in virion 
preparations (214). 
 
Immunogold labeling of wild type and mutant capsids: 
Using standard procedures, capsids were purified from nuclear lysates 
of cells infected with wild type HSV-1(F), and viruses respectively lacking the 
UL6, UL15, UL17, UL28 and UL33 genes (10, 53, 195, 213, 243). Capsids were 
either attached to Formvar carbon-coated electron microscopic grids, or were 
placed into microdialysis tubes (200 μm diameter), subsequently embedded in 
LRWhite and sliced with a diamond knife into 60 nm sections that were then 
placed on EM grids.   
Previously described rabbit antisera directed against pUL6, pUL15, 
pUL28 and pUL33 were prepared by adsorption against capsids purified from 
Vero cells infected with 5.0 PFU/ml of the appropriate viral null mutant (8, 10, 
195, 206, 240, 241, 243).  The adsorbed antisera were then diluted 1:50 in 
PBS supplemented with 1% triton-100 and 1% fish gelatin and applied directly 
to the EM grids, followed by extensive washing.  Experiments performed with 
the pUL17-specific chicken IgY were similar except that the antibody was not 
preadsorbed and was diluted 1:5,000 for reaction with capsids.   As a control, 
the capsid samples were also reacted separately with a polyclonal antiserum 
directed against the internal scaffold protein ICP35 (48) (NC 3-4) (kindly 
provided by Roselyn Eisenberg and Gary Cohen).  Bound immunoglobulins 
remaining after the washing were recognized by goat anti-rabbit 
immunoglobulin conjugated to 12 nm gold beads, or goat anti-chicken IgY 
conjugated to 12 nm gold beads.  After further washing, the grids were viewed 
in a Philips 201 electron microscope after counterstaining with 2% aqueous 
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 uranyl acetate and 0.5% Reynold’s lead citrate.  Capsids were scored as 
positively immunolabeled only when a gold bead was observed in direct 
association with an observed capsid.   
 The results are summarized in table 2.1, and representative examples 
of immunostained capsids are shown in Figure 2.2.   
Examination of at least 400 capsids in each treatment group revealed 
the following:   
(i)  Background levels of immunostaining with the pUL15, pUL17,  pUL28 
and pUL33-specific antisera, as revealed by the number of appropriate mutant 
capsids bearing gold beads, was significantly below (All P values < 0.001 as 
assessed with the Fisher exact T test) similarly stained wild type HSV-1(F) 
capsids.   
(ii) As shown previously (182), pUL6-specific epitopes were recognized 
on the surface of the capsid inasmuch as significantly more (P < 0.001)  gold 
beads were present in intact wild type capsids reacted with the pUL6-specific 
antiserum than were present in capsids lacking pUL6.  These epitopes were 
detected more frequently in intact capsids than in sectioned capsids (p < 
0.001) suggesting that the bulk of the epitopes were available primarily for 
reaction at the capsid surface rather than internal to the capsid shell. 
Approximately 16.3% (53 of 325) of capsids were labeled suggesting either 
that the immunogold staining was insensitive and did not detect portal protein 
in many capsids, or that many capsids lack portals.  Biochemical studies 
showing that populations of B capsids have on average 14.8 +/- 2.6 copies of 
pUL6 per capsid (182), coupled with the high likelihood  that the portal ring 
contains 12 copies of pUL6 (252),  argue against the latter possibility.   
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Table 2.1.  Capsids were purified from cells infected with wild type viruses 
or viruses lacking the indicated open reading frames.  In some experiments 
(intact), capsids were attached to grids and reacted with the indicated 
antibodies.  In other experiments capsids were embedded and sectioned, 
followed by reaction of the thin sections with the indicated antibodies.  The 
number of immunolabeled capsids vs. number of capsids examined is 
indicated and the resulting percentage of labeled capsids shown. 
 
1The amount of immunoreactivity with a given antibody was greater (P < 
0.001) in wild type capsids than in the corresponding deletion mutant 
capsids. 
2The immunoreactivity of sectioned capsids was greater than intact capsids 
(p < 0.001) 
3Immunoreactivity of intact capsids was greater than sectioned capsids (p  
< 0.001) 
4 Immunoreactivity of intact capsids was greater than sectioned capsids (p 
= 0.01) 
5Immunoreactivity of sectioned capsids vs. intact capsids (p = 0.06) 
All P values were obtained with Fisher’s exact T test 
    
                Table 2.1. Percent capsids Immunolabeled with monospecific 
antisera 
 
Antibody Virus Intact 
Sectioned 
    
ICP35 HSV-1(F) (18/1007)  1.8%2 (115/413)  27.8%2 
    
pUL61 HSV-1(F) (53/325)  16.3%3 (48/1181)    4.0%3 
pUL6 UL6-   (4/945)      0.4% (3/929)        0.3% 
    
pUL171 HSV-1(F) (97/714)  13.5%3 (134/2447)  5.4%3 
pUL17 UL17- (0/1000)     0.0% (2/969)        0.2% 
    
pUL331 HSV-1(F) (25/281)   8.8%3 (35/1644)    2.1%3 
pUL33 UL33- (9/1155)     0.8% (4/1042)      0.3% 
    
pUL281 HSV-1(F) (33/378)   8.7%4 (43/960)      4.4%4 
pUL28 UL28- (8/1074) )   0.7% (3/973)        0.3% 
    
pUL15C1 HSV-1(F) (40/847)   4.7%5 (35/595)      5.8%5 
pUL15C UL15- (6/571)       1.0% (2/1000)      0.7% 
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Figure 2.2.  Capsid electron micrographs labeled with various antibodies.   
Capsids were purified from cells infected with HSV-1(F).  These were 
attached to copper mesh grids (left column), or were embedded in Lowicryl 
and sectioned (right column).  Each row shows intact capsids and thin 
sections reacted with antisera directed against the indicated proteins.  
Bound immunoglobulin was identified by reaction with appropriate antisera 
conjugated to 12 nm gold beads.  Arrowheads indicate gold beads 
associated with capsids. 
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 (iii) As expected, the ICP35-specific antiserum did not recognize the 
external surface of capsids to an appreciable extent inasmuch as only 18 
capsids were labeled with the NC 3-4 antibody of 1007 examined (1.8%).  
Upon sectioning the capsids however, ICP35-specific epitopes were rendered 
significantly more immunoreactive with the antiserum (P < 0.001) as revealed 
by an increased number of labeled sectioned capsids [115 (28%) of 413 
sectioned capsids].  These observations indicated that, as expected, ICP35 
was present in the capsid interior rather than the capsid surface, and verified 
that the inner surfaces of unsectioned capsids were sequestered from the 
applied antibodies under the experimental conditions. 
  (iv) Epitopes from pUL17, pUL28 and pUL33 localized at the surface of 
the capsid as revealed by immunoreactivity of intact capsids significantly 
above background levels obtained upon reaction with the corresponding 
deletion virus capsids. (All P values were less than 0.001 by Fischer’s exact T 
test.)  In all three cases, although immunoreactivity was present in sectioned 
HSV-1(F) capsids, the level of immunoreactivity was significantly less than that 
obtained using  intact capsids, presumably because a given thin section 
contains only a limited portion of the  capsid surface.  More capsids (13%) 
labeled with the pUL17-specific antibody than with either the pUL28 or pUL33 
specific antibodies (8.7% and 8.9%, respectively). 
 (v)  Antisera directed against C-terminal epitopes of pUL15 were 
recognized on the external surface of capsids as revealed by increased 
immunoreactivity of intact capsids over that of pUL15 negative capsids.  Unlike 
the case with pUL6, pUL33, pUL28 and pUL17-specific antibodies,  however, 
immunoreactivity of the pUL15-specific antibody  was increased in sectioned 
capsids, but the observed increase over immunoreactivity obtained with 
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 unsectioned capsids was not statistically significant (p = 0.06).  Because so 
little of the surface of the capsid is available for reaction in a thin section, the 
preservation of reactivity in sectioned capsids suggests that   pUL15 C-
terminal epitopes are available on both the surface and within the capsid 
interior. Thus, pUL15 is apparently located in a position such that some 
epitopes exterior and some epitopes exposed to the capsid interior.   
Alternatively, multiple copies of pUL15 may be present at different locations 
within the capsid.   Assuming that all B capsids are biochemically identical (an 
assumption that has not been tested), the observation that each B capsid 
contains only 1.2 copies of pUL15 (18) argues against this possibility. 
Rabbit skin cells infected with wild-type virus at an MOI of 5 were 
embedded and thin-sectioned (as described above).  Immunolabeling with 
anti-pUL17 antisera diluted 1:100 and subsequently reacted with a 1:50 
dilution of goat anti-chicken IgY conjugated to 12 nm gold beads.  
Immunostaining revealed multiple binding sites on individual intranuclear 
capsids (Figure 2.3).  Thus we were also able to conclude that multiple 
epitopes of pUL17 are present on the surface of intranuclear capsids.  
We conclude from these data that at least some epitopes of pUL6, pUL15, 
pUL17, pUL28, and pUL33 are located at the capsid surface.  The data also 
suggest that some epitopes in the C-terminus of pUL15 are sequestered from 
antibody unless the capsids are sectioned.  One model, consistent with 
previous observations showing that A capsids contain approximately 12 copies 
pUL15  but less than one copy of  pUL28 (18), is that pUL15 is more intimately 
associated with the capsid whereas pUL28 is more peripheral.   Whether or not 
this conclusion is correct, the localization of portions of pUL15, pUL17, pUL28 
and pUL33 at the capsid surface places these proteins in a position to engage  
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Figure 2.3  ImmunoEM labeling of pUL17 upon infection.  Capsids were 
observed with multiple beads indicating multiple sites of  occupancy on the 
capsid surface. 
 DNA as it is being packaged.  Alternatively, such a position might serve to 
engage molecular motors for capsid transport either within the nucleoplasm, or 
along microtubules in the cytoplasm. 
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CHAPTER III: 
 
Effects of major capsid proteins, capsid assembly, and DNA cleavage 
and packaging on the pUL17/pUL25 complex of herpes simplex virus 1  
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 Abstract: 
The UL17 and UL25 proteins of herpes simplex virus 1 (HSV-1) are 
located at the external surface of capsids and are essential for DNA packaging 
and DNA retention in the capsid, respectively.  The current studies were 
undertaken to determine how these proteins become associated with capsids 
by examining their interactions in cells infected with wild-type, VP5-null, VP23-
null, UL15-null and UL32-null viruses.  We found that pUL17 and pUL25 co-
immunoprecipitated from cells infected with wild type virus whereas the major 
capsid protein, VP5, did not co-immunoprecipitate with these proteins. In 
addition, pUL17 (i) co-immunoprecipitated with pUL25 in the presence or 
absence of VP5 (ii) did not co-immunoprecipitate efficiently with pUL25 in the 
absence of the triplex protein VP23, (iii) required pUL25 for proper 
solubilization and localization within the replication compartment, (iv) was 
essential to the nuclear retention of pUL25 and (v) required capsid proteins 
VP5 and VP23 for nuclear localization and normal levels of immunoreactivity 
in an indirect immunofluorescence assay.  Proper intranuclear localization of 
pUL25 required pUL17, pUL32, and the major capsid proteins VP5 and VP23, 
but not the DNA packaging protein pUL15.  The data suggest that VP23 and 
VP5 induce conformational changes in  pUL17/ pUL25, exposing epitopes that 
are otherwise partly masked in infected cells. These conformational changes 
can occur in the absence of DNA packaging. The data indicate that the pUL17/ 
pUL25 complex requires multiple viral proteins and functions for proper 
localization and biochemical behavior in the infected cell.   
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 Introduction: 
Immature herpes simplex virus capsids, like those of all herpesviruses, 
consist of two protein shells.  The outer shell comprises 150 hexons, 
composed of six copies of VP5, and 11 pentons, each containing five copies of 
VP5 (216, 286).  One vertex of five-fold symmetry is composed of 12 copies of 
the protein encoded by UL6 and serves as the portal through which DNA is 
inserted (182).  The pentons and hexons are linked together by more than 320 
triplexes composed of 2 copies of the UL18 gene product, VP23, and 1 copy of 
the UL38 gene product, VP19C (183, 288).  Each triplex arrangement has two 
arms contacting neighboring VP5 subunits (288).  The internal shell of the 
capsid consists primarily of more than 1,200 copies of the scaffold protein 
ICP35 (VP22a) (183), and a smaller number of protease molecules encoded 
by the UL26 open reading frame which self-cleaves to form VP24 and VP21 
derived from the amino and carboxyl termini, respectively (55, 59).  The outer 
shell is virtually identical in the three capsid types found in HSV infected cells, 
termed types A, B, and C (98).  It is believed that all three are derived from the 
immature procapsid (184).  Type C capsids contain DNA in place of the 
internal shell; type B contain both shells, and type A consist only of the outer 
shell (98).  Only C capsids go on to become infectious virions (80).  
The outer shell also contains minor capsid proteins derived from the 
UL25 and UL17 open reading frames (99, 245).  These proteins are located on 
the external surface of the viral capsid and are believed to form a heterodimer 
arranged as a linear structure, termed the C capsid specific complex (CCSC), 
located between pentons and hexons of C capsids (254).  This is consistent 
with the observation that levels of pUL25 are increased in C capsids as 
opposed to B capsids (217). On the other hand, other studies have indicated 
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 that at least some pUL17 and pUL25 associate with all capsid types, and 
pUL17 can associate with enveloped light particles, which lack capsids but 
contain a number of viral structural proteins (245, 246).  How the UL17 and 
UL25 proteins attach to capsids is not currently known although the structure 
of the CCSC suggests extensive contacts with triplexes (254).  It is also 
unclear when pUL17 and pUL25 become incorporated into the capsid during 
the assembly pathway.  Less pUL25 associates with pUL17(-) capsids 
suggesting that the two proteins bind capsids either cooperatively or 
sequentially, although this could also be consequential to the fact that less 
pUL25 associates with capsids lacking DNA (245).   
Both pUL25 and pUL17 are necessary for proper nucleocapsid 
assembly, but their respective deletion generates different phenotypes.  
Deletion of pUL17 precludes DNA packaging and induces capsid aggregation 
in the nuclei of infected cells suggesting a critical early function (214, 241), 
whereas deletion of pUL25 precludes retention of full length cleaved DNA 
within the capsid (47, 158, 231), thus suggesting a function late in the 
assembly pathway.   
The current studies were undertaken to determine how pUL17 and 
pUL25 associate with capsids by studying their interactions in the presence 
and absence of other capsid proteins. 
 
Materials and Methods: 
Cell Lines and Viruses-  Vero and Hep2 cells were obtained from the 
American Type culture association and were propagated in DMEM 
supplemented with 10% newborn calf serum (NBCS) and antibiotics as 
described previously (278). 
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 A UL18 deletion virus (delta 18) virus was constructed to remove the 
entire open reading frame of UL18 and replace it with an FRT-flanked 
Kanamycin resistance (KanR) cassette as follows.  A gene encoding KanR was 
PCR amplified with the following primers containing sequences homologous to 
the flanking regions UL18 ORF and KanR cassette:  (del18F, #64) 
CCCCCGTGGGTCTAGCCGGGCCGTGTAGGCTGGAGCTGCTTC; (del18R, 
#65) CCCTGCCGCGTGGATCGGCGCCATTCCGGGGATCCGTCGAC  
(KanR homology underlined).  Amplicons were transformed into EL250 cells 
containing a chloramphenicol–resistant (CmR), wild-type HSV-1(F) BAC and 
CmR/KanR recombinants were selected on agar plates (238).  Extracted BAC 
DNA was transfected with SuperFect (Qiagen) into and propagated on G5 
cells complementing the HSV genome UL16 to UL21 region (62).  Stocks were 
obtained from G5 cells infected at an MOI of 0.01 and grown in 890 cm2 roller 
bottles. 
 Delta 17 (described in Chapter IV) and delta 25 (KUL25NS)(158) 
viruses were described previously and contain a Kanamycin cassette inserted 
into UL17 and stop codon inserted into UL25, respectively.  Delta 17 and delta 
25 were grown on CV1-17 and 8-1 cells complementing UL17 and UL25, 
respectively (158).  Stocks were obtained from cells infected at an MOI of 0.01 
and grown in 890 cm2 roller bottles. 
 To rescue the UL17 deletion, the delta 17 BAC and a UL17-expression 
vector (pRB457) were co-transfected into non-complementing (Vero) cells.  
After plaques had begun to spread 10 days post transfection virus was 
harvested. Several plaques from this virus preparation yielded plaques on 
Vero cells.  For stock preparation after a second round of plaque picking, Vero 
cells were infected with the virus at 0.01 PFU/cell. The repaired virus, 
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 designated pUL17R, was verified both by its competency to infect non-
complementing cells and by expression of pUL17 as assessed by 
immunoblotting.    
 
Immunoprecipitation Assay -  Vero cells in 10 cm or 15 cm dishes were 
infected with various viruses at 5 PFU per cell and incubated at 370C.  Sixteen 
hours following infection, cells were removed by scraping, transferred to 15 ml 
conical tubes, and pelleted at 4000 rpm in an Eppendorf 5810R centrifuge with 
an A-4-62 rotor at 40C.  Supernatants were discarded and pellets were 
resuspended in 5 ml PBS with Complete protease inhibitors (Roche).  Again, 
samples were centrifuged at 4000 rpm at 40C for 10 minutes and supernatants 
were decanted.  Cell pellets were stored at -800C overnight.  After thawing, the 
infected-cell pellets were lysed in RIPA buffer (1.0% NP40, 0.25% sodium 
deoxycholate, 50 mM Tris-HCl pH 7.4, 150mM NaCl, 1mM EDTA pH 8.0, 1 
μg/ml aprotinin, 1 μg/ml leupeptin, 1 μg/ml pepstatin, 1mM PMSF, 1mM 
Na3VO4) on ice for at least 20 minutes.  Infected-cell lysates were centrifuged 
to pellet insoluble material at 40C for 10 minutes in a microcentrifuge and 
supernatants were transferred to new tubes.  One twentieth of each soluble 
lysate volume was removed and combined with 2x SDS-PAGE  (100mM Tris-
HCl pH 6.8, 4.0% SDS, O.2% bromophenol blue, 20% glycerol, 200mM fresh 
DTT) to assess protein expression in the lysates.  The remaining lysate was 
pre-cleared by reaction with normal mouse IgG with constant rotation at 40C 
for 30-60 minutes after which Gamma Bind G beads (GE lifesciences) in a 
50% PBS slurry was added.  The mixture was then constantly rotated at 40C 
for 1 hour after which samples were centrifuged for 5 minutes at 40C to 
remove the beads, normal mouse IgG, as well as any proteins capable of non-
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 specific binding.  Pre-cleared lysates were then reacted with the target 
antibody (anti-pUL25 or anti-pUL17) for 30-60 minutes at 40C with constant 
rotation before Gamma Bind G beads were added.  (Immunoprecipitation with 
anti-pUL17 required an additional incubation with a rabbit anti-IgY bridging 
antibody to adhere to the Bind G beads (as described in Chapter IV)  The 
beads were then allowed to react with antibody complexes for 2 hours at 40C 
with constant rotation, after which time they were pelleted at 40C for 5 minutes, 
resuspended in RIPA solution, and rotated for 10 minutes at 40C.  This 
washing step was repeated three more times before elution of proteins by 
boiling in 2x SDS-PAGE denaturation buffer for 5 minutes.  Soluble lysate 
samples and immunoprecipitation samples were electrophoretically separated 
on an 10% polyacrylamide gel and transferred to nitrocellulose at 30V for 5 
hours at 40C.    
 
Transfections-  Adherent Hep2 cells were transfected with the indicated 
expression plasmids using Lipofectamine 2000 (Invitrogen) according to the 
protocol of the manufacturer. 
 
Immunofluorescence Assay (IFA) –  Hep2 cells were seeded onto glass 
coverslips and cultured in DMEM with 10% supplemental NBCS (newborn calf 
serum).  Cells were either transfected in Opti-MEM (Invitrogen) media or 
infected with 5 PFU per cell using low serum-containing media (1% NBCS).  At 
various times following transfection or infection, cells were briefly washed with 
PBS and fixed with 3% paraformaldehyde in PBS for 15 minutes at room 
temperature.  Fixed cells were washed with PBS before quenching 
autofluorescence with a 15 minute incubation in 50 mM ammonium chloride.  
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 Cells were then washed with PBS and permeabilized for 5 minutes in 1.0% 
Triton X-100, washed again with PBS, and then incubated for 30 minutes in 
PBS with 1.0% BSA, 5% donkey serum, and 5% human serum to block non-
specific antibody binding.  Primary antibody was diluted in blocking solution at 
the following concentrations: anti-pUL17 between 1:1,000 and 1:500, anti-
pUL25 (25E10) 1:200, anti-capsid 8F5 monoclonal antibody (253) 1:100.  After 
reaction of the primary antibodies with the fixed, permeabilized cells for 45 
minutes unbound antibody was removed by washing in PBS.  The coverslips 
were then reacted for 45 minutes with the indicated fluorescent-conjugated 
secondary antibodies diluted 1:1,000 in blocking solution.  Subsequently, cells 
were washed extensively with PBS, dipped briefly in dH20 to remove any 
excess salt, and mounted on glass slides with Vectashield mounting media.  
Mounted coverslips were sealed with nail polish. 
 
Immunoblotting – Immunoblots were blocked in PBST with 5% milk for 20-30 
minutes and rinsed with PBST.  Primary antibodies were diluted in PBST with 
1%BSA to the following concentrations (anti-pUL17, 1:10,000; anti-pUL25, 
1:1,000; anti-VP5 (Virusys), 1: 500; anti-VP23 (NC-5), 1:2,000; anti-VP19C 
(NC-2).  (NC-2 and NC-5 antibodies were gifts from Gary Cohen and Roselyn 
Eisenberg).  Excess antibody was removed with 3, 10 minute washed in 
PBST.  Horseradish peroxidase-conjugated secondary antibodies were diluted 
1:5,000 in to PBST with 5% milk and allowed to react with immunoblots for at 
least 1 hour.  Excess antibody was again removed with PBST washes and 
conjugate-binding was detected with Pierce chemiluminescent ECL and 
subsequent exposure to x-ray film.  Bound antibody was stripped from 
membranes with 2% SDS and 0.71% β-mercaptoethanol in 62.5 mM Tris pH 
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 6.8 at 500C for 15-20 minutes and membranes were washed extensively with 
PBST before reprobing.  
 
Results:   
pUL17 and pUL25 interact in the absence of assembled capsids: 
In preliminary studies we found that pUL17 co-immunoprecipitated with 
VP5, which was not surprising given several lines of evidence indicating pUL17 
associates with capsids.  In this study, we wanted to further investigate the 
relationship between pUL17 and nucleocapsid assembly of HSV.   
First, we sought to determine whether pUL17 interacted with all or a 
subset of major capsid constituents. To this end, cells were infected with HSV-
1(F), and deletion mutants lacking functional UL17 (delta 17), UL25 (delta 25), 
UL18 (delta 18; VP23), UL19 (delta 19; VP5) or UL32 (delta 32).  The infected 
cells were lysed at 16 hours post-infection and lysates were subjected to 
immunoprecipitation with anti-pUL17 antibody and a rabbit anti-IgY bridging 
antibody (described in Chapter IV).   Immunoprecipitated material and aliquots 
of soluble cell lysates were electrophorectically separated on a denaturing 
polyacrylamide gel, transferred to nitrocellulose, and probed with antibodies to 
pUL17, the major capsid protein VP5, triplex proteins VP23 and VP19C, and 
the minor capsid protein pUL25.  
As shown in figure 3.1 A, pUL17 was immunoprecipitated specifically 
from lysates of cells infected with HSV-1( F), delta 25, delta 18, delta 19 and 
delta 32 at levels that reflect their relative amounts in the respective cell 
lysates.  The absence of a signal from the immunoprecipitation with a delta 17 
virus indicated that the signal examined represented UL17 protein.   
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Figure 3.1  Co-immunoprecipitation with pUL17 in F and capsid deletion 
viruses.  Panel A shows immunoblotting with anti-pUL17.  Amounts of 
pUL17 immunoprecipitated (on the right) reflect the relative levels of pUL17 
present in the lysates (shown on left).  pUL25 immunoblotting indicates that 
this protein co-immunoprecipitates with pUL17 in F, delta 19, and delta 32 
infected cells (Panel C).  A barely detectable band of pUL25 was also 
present in the delta 18 lane (Panel C).  Capsid proteins VP5 and VP23 did 
not co-immunoprecipitate in any sample, including wild-type (F)-infected cell 
lysates (Panels B and D).   
 Immunoblotting pUL17 co-immunoprecipitated material with mouse 
monoclonal anti-pUL25 antibody indicated that pUL25 co-immunoprecipitated 
with pUL17 from lysates of cells infected with HSV-1(F), delta 19, and delta 32 
(Figure 3.1 C).  Lesser amounts of pUL25 were co-immunoprecipitated from F  
and delta 19 infected cell lysates compared to that from lysates of cells 
infected with delta 32.  No pUL25 was immunoprecipitated from lysates of 
delta 17 infected cells despite high levels of expression in soluble lysates,  
indicating that pUL25 was specifically co-immunoprecipitated through 
interactions with pUL17 (Figure 3.1 C).  These data suggest that pUL17 and 
pUL25 interact independently of assembled capsids and the major capsid 
protein VP5.  
 We also noted variable expression of pUL25 and VP23 in our infections.  
Higher levels of pUL25 were noted in delta 32 and HSV-1(F) (to a lesser 
extent) infected cell lysates compared to levels of pUL17 and VP23 (Figure 3.1 
C vs. Figure 3.1 A, D) .  We currently do not understand whether these 
discrepancies are a specific effect related to each deleted gene or whether 
they reflect protein expression variation from different viral strains.  VP23, in 
contrast, was specifically decreased to an undetectable level only upon delta 
19 infection. 
 
 pUL17 and pUL25 interaction occurs independently of VP5, the major 
capsid protein:  
We also wanted to determine whether or not  the pUL17/ pUL25 
complex was dependent on major capsid proteins. To address this question 
we re-probed the pUL17 immunoprecipitation blot for the capsid protein VP5 
(Figure 3.1 B), VP23 (Figure 3.1 D), and VP19c (data not shown).  (The triplex 
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 protein VP19C co-migrated with the heavy chain of the rabbit bridging 
antibody and therefore higher levels of overlapping background signal was 
observed in immunoblots probed with VP19C-specific antibody.)  In all cases, 
VP5 was not co-immunoprecipitated with pUL17, suggesting that the pUL17/ 
pUL25 complex forms independently of capsid formation, and of the major 
component of the outer capsid shell.   
 
Reciprocal immunoprecipitation of pUL17 with anti- pUL25: 
 To confirm the capsid-independent interaction of pUL17/pUL25 cells 
were infected with HSV-1(F), delta 17, delta 25, delta 18, delta 19, and delta 
32 viruses, and lysates prepared at 16 hours post-infection were reacted with 
a pUL25-specific monoclonal antibody, 25E10.  The presence of various 
proteins in immunoprecipitated material was then determined by 
immunoblotting with monospecific antibodies.  The results are shown in figure 
3.2. 
Readily detectable amounts of the UL25 protein were 
immunoprecipitated from HSV-1(F)-infected lysates, whereas significantly less 
pUL25 was detected in delta 18 samples despite the fact that ample pUL25 
was present in the delta 18 infected cell lysate (Figure 3.2 A).  Moreover, 
pUL25 was not immunoprecipitated  with its cognate monoclonal antibody from 
delta 19 (VP5-null) infected cell lysates to detectable levels.  To explain the 
lack of immunoprecipitated pUL25 in these samples we hypothesize that 
pUL25 adopts at least two conformations, one of which is accessible to 
reactivity with the monoclonal 25E10 antibody and one that is not.  Moreover, 
the conformational change revealing the epitope recognized by 25E10 
requires the major capsid proteins VP5.  
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Figure 3.2  Reciprocal immunoprecipitation of pUL17 with anti-pUL25.  Panel 
A shows immunoblotting with anti-pUL25.  Despite high concentrations of 
soluble pUL25 in all lysates except delta 25 and mock, only pUL25 in F, 
delta 18 and delta 32 is immunoprecipitated. Panel B shows pUL17 co-
immunoprecipitates only from F-infected cells. 
 When the immunoblot of 25E10-immunoprecipitated proteins was reacted with 
anti-pUL17 antibody, co-immunoprecipitation of pUL17 was noted only from 
HSV-1(F)-infected cell lysates (Figure 3.2 B).  These data confirmed the 
interaction between pUL17 and pUL25 from cells infected with wild type virus.  
Conclusions concerning pUL17/ pUL25 interaction in the other cell lysates was 
hampered by the poor immunoprecipitation of pUL25 with monoclonal antibody 
25E10 in most of these lysates, and the relatively low amounts of pUL17-
specific immunoreactivity detected.    
 
Solubility of pUL17 in the absence of pUL25 and capsids: 
The above experiment indicated that less pUL17 was present in lysates 
of cells infected with viruses lacking  UL19 or UL18  (see figure 3.2 A).   To 
determine whether this reflected lower levels of pUL17 in cells infected with 
these mutant viruses, or a difference in solubility, cells infected with HSV-1(F) 
or the UL25, UL18, or UL19 null virus infected cell lysates were denatured and 
subjected to immunoblotting with pUL17-specific antibodies.  As shown in 
figure 3.3 A , despite the lower levels of these proteins in soluble lysates, 
steady state levels of pUL17 in total lysates did not vary significantly in the 
cells infected with the different viruses.  We conclude that at least VP23, VP5, 
and pUL25  contribute to the solubility of pUL17 seen in cells infected with wild 
type viruses.   
 
Distribution of both pUL17 and pUL25 are each altered in the absence of 
the other: 
Having established pUL17 and pUL25 association, we next asked 
whether the distribution of either protein affected the location of the other in 
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Figure 3.3  Immunoblot of whole cell lysates from infected cells.   Panel A, 
overlaid images of anti-pUL17 and  anti-pUL25 immunoblots.  Panel B 
overlaid images of immunodetection of anti-ICP8 and Lamin A/C  from the 
same blot.  
 infected cells.  To assess this possibility, we infected Hep2 cells with 5.0 PFU 
per HSV-1(F), delta17 or delta 25 viruses, fixed and permeabilized the cells at 
various times after infection, and reacted the cells with chicken polyclonal 
antibody to pUL17 and the 25E10 monoclonal antibody directed against 
pUL25.  After extensive washing, bound immunoglobulins were revealed by 
reaction with appropriately conjugated antibodies, and the cells were 
examined by confocal microscopy.    
As shown in figure 3.4, upon infection with wild-type HSV-1(F) virus, 
pUL17- and pUL25-specific immunostaining co-localized extensively in nuclei 
both at 12 and 16 hours post infection (fig 3.4 C, F). Cytoplasmic staining of 
both pUL17 and pUL25 increased slightly by 16 hours after infection, although 
the great majority of immunoreactivity remained in the nucleus.  Of the 
cytoplasmic signals, very little colocalized.   
Immunostaining for either pUL17 or pUL25 in the absence of the other 
was different from that seen in cells infected with wild type HSV-1(F) virus.  
Specifically, (i) in delta 17-infected cells, pUL25-specific immunostaining was 
generally at a much lower intensity (fluorescence intensity in Figure 3.4 G-I 
was adjusted to illustrate the distribution pattern). (ii) The distribution of pUL25-
specific immunoreactivity in delta 17 infected cells was nearly equal between 
the nucleus and cytoplasm. (iii) In cells infected with the UL25 null virus, the 
majority of pUL17 was mislocalized to intensely staining foci near the periphery 
of the nucleus at both 12 and 16 hours post-infection; however, this 
distribution was more pronounced at the earlier (12 hour) time point, 
presumably due to increased levels of immunoreactivity at 16 hours that  
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Figure 3.4 Colocalization of pUL17/pUL25 and co-dependent localization.  
Confocal microscopy of immunofluorescently-stained pUL17 (Texas Red) 
and pUL25 (FITC) in F-infected cells shows extensive co-localization of 
pUL17 and pUL25 in the replication compartment at 12 (A-C) and 16 (D-F) 
hours post-infection.  pUL25 in the absence of pUL17 stains diffusely 
throughout the nucleus and cytoplasm (G-I).  pUL17 is mis-localized into 
intensely staining aggregates along the periphery of the nucleus in the 
absence of pUL25 (J-O) that were more easily observed at 12 hours rather 
than 16 hours post-infection.  Images were captured under 600x 
magnification with an additional 3x digital zoom.  
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obscured the foci (fig 3.4 J, M).  We conclude from these data that the proper 
localization of both pUL17 and pUL25 is co-dependent.  
 
pUL17 colocalizes with capsids in delta 25 infection: 
 The pUL17-containing foci at the nuclear periphery of delta 25-infected 
cells were reminiscent of capsid aggregates observed upon infection with a 
UL17 null virus (241).  To determine whether the foci containing pUL17 were 
also associated with capsids, we immunostained delta 25 infected cells with 
pUL17-specific antibody and a monoclonal antibody (8F5), which recognizes 
VP5 in capsid pentons (253).  As shown in figure 3.5, HSV-1(F)-infected cells 
displayed both pUL17-specific and capsid-specific staining in the replication 
compartment as previously observed (figure 3.4 panel A, (241)) (fig 3.5 A-C).  
However, in delta 25-infected cells, both capsid- and pUL17-specific 
immunoreactivity were observed to co-localize at the nuclear periphery (fig. 
3.5 D-F, arrows).  Examination at higher magnification revealed that pUL17 
and 8F5 immunostaining co-localized not only in the intensely-staining 
peripheral regions, but also in smaller puncta distributed throughout the central 
intranuclear replication compartment.  The smaller puncta were of a size and 
distribution similar to those of capsids (Figure 5.2, (82)). This result was 
expected given the association of pUL17 and pUL25 with capsids (254) but 
was potentially incongruent with the observation that anti-pUL17 antibody did 
not co-immunoprecipitate VP5, the major capsid protein (fig 3.1).  We favor the 
hypothesis that  pUL17 interacts with wild type capsids in the presence and 
absence of pUL25, but the interaction is of low affinity such that capsid  
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Figure 3.5 Peripheral nuclear aggregates in delta 25 infection contain 
pUL17 and completely assembled capsids.  Fields of wild-type (F) 
infected cells (A-C) and delta 25 infected cells (D-F) immunostained for 
assembled capsids and pUL17 with mouse monoclonal 8F5 (FITC) and 
chicken polyclonal anti-pUL17 (Texas Red) antibodies, respectively.  
Arrows indicate pUL17 associated with capsids aggregated in the nuclear 
periphery in delta 25 infection.  Panels G-H show high magnification of a 
single cell to demonstrate co-localization of pUL17 with individual 
intranuclear capsids as well as capsid in peripheral aggregates upon 
delta 25 infection.  Images A-F were captured under 600x magnification, 
G-I with an additional 5.33x digital zoom.  
  proteins do not co-immunoprecipitate with pUL17 under the conditions 
employed.   
 
Capsid formation, but not DNA encapsidation, aids nuclear retention of 
pUL17 and pUL25: 
 Since pUL17 and pUL25 are both capsid-associated and necessary for 
cleavage and packaging, we questioned whether the mislocalization of these 
proteins in delta 25 and delta 17 infections was a specific effect, or a general 
effect of either capsid malformation or lack of DNA encapsidation.  To 
distinguish between these possibilities, we determined the distribution of 
pUL17 and pUL25 upon infection with capsid-null and DNA encapsidation-
deficient viruses by indirect immunofluorescence. 
To address the effect of capsid formation upon pUL17/pUL25 
localization, we infected cells with delta 18 or delta 19 virus and fixed and 
stained  them to  reveal the cellular distribution of pUL17 and pUL25 proteins.   
Cells infected with wild-type HSV-1(F), delta 17, and delta 25 were processed 
in parallel as controls (fig. 3.6 A, B, M, N, P, Q) and all samples were stained 
with antibody against ICP8 to indicate that the cells were infected and to mark 
the DNA replication compartment (fig. 3.6 C, F, I, L, O, R). 
Surprisingly, the immunostaining of both pUL17 and pUL25  was 
significantly reduced in cells infected with the delta 18 and delta 19 viruses.  
Moreover, the relative amount of cytoplasmic staining of both pUL17 and 
pUL25 was increased relative to that seen in cells infected with wild-type virus 
(fig 3.6 D, E, G, H, and M).  Overall, the immunostaining of pUL25 in cells 
infected with the UL17, UL18 and UL19 null viruses was similar in distribution  
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Figure 3.6 Immunostaining of pUL17 and pUL25 with cleavage and 
packaging or capsid mutant viruses.  Infected cells were immunostained 
with anti-pUL17 (Texas Red) and anti-pUL25 antibodies (FITC) for cellular 
localization.  ICP8 immunostaining was used as a control for infection.  All 
images were captured under 600x magnification with an additional 3x digital 
zoom. 
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and intensity (fig. 3.6 D, G and M), thus indicating that appropriate capsid 
formation is required both for nuclear retention and optimal epitope recognition 
of pUL25.  In contrast, pUL17 immunostaining was greatly diminished in cells 
infected with the UL18 and UL19 null viruses whereas the staining was 
somewhat brighter in cells infected with the UL25 null virus although this may 
reflect protein concentration in the aggregates rather than overall levels.  
Moreover, the mislocalization of pUL17 into peripheral nuclear aggregates was 
seen only in delta 25-infected cells (fig. 3.6 Q).   
To test the hypothesis that encapsidation of viral DNA was also 
involved in proper localization of pUL25 and pUL17, cells were infected with a 
virus lacking pUL32, a protein required for DNA cleavage and packaging (132).  
In cells infected with delta 32, (figure 3.6 JOKE) the pUL17-specific signal 
localized in the intranuclear replication compartment in a pattern similar to  
that seen in infections with wild type virus.  Although pUL25 specific signals 
localized primarily in the nucleus, significant levels of pUL25-specific signal 
were also present in the cytoplasm. We also noted that pUL25 
immunoreactivity was greater in delta 32 infected cells compared to HSV-1(F) 
infected cells, whereas pUL17 immunoreactivity was roughly equal in the two 
sets of infected cells.   
To further test the role of DNA packaging in pUL25 and pUL17 
localization, these proteins were assayed by indirect immunofluorescence in 
cells infected with a virus lacking the terminase subunit encoded by UL15. As 
shown in figure 3.7, pUL25 and pUL17 colocalized within the nuclei of cells 
infected with the UL15 null virus in a pattern similar to that of ICP8, a marker of 
the replication compartment (fig. 3.7 (D-F).  The intensity of the  
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immunostaining of both proteins was similar to that in cells infected with wild 
type virus.  We conclude from these studies that proper localization of pUL17 
and pUL25 does not require the UL15 protein or the process of viral DNA 
cleavage and packaging.  
Cytoplasmic pUL25 in cells infected with mutant viruses could be the 
result of a failure to engage the nuclear import machinery or a failure to retain 
pUL25 in the nucleoplasm.  In support of the latter possibility, two canonical 
nuclear export sequences were noted in the UL25 ORF (data not shown).   To 
further understand the cytoplasmic distribution of pUL17 and pUL25, we 
investigated Crm-1-dependent nuclear export.  Previously, HSV was shown to 
use this cellular mechanism to shuttle the viral proteins VP13/14 (260). 
To test the possibility that these motifs were functional, cells infected 
with HSV-1(F) (data not shown) or the UL32 null virus were treated at 5 hours 
post infection with 10 nM leptomycin B, a Crm-1 inhibitor, and were fixed at 13 
hours post-infection and immunostained with pUL25-specific and pUL17-
specific antibodies.  As shown in figure 3.8 D, treatment with leptomycin B 
substantially increased the amount of pUL25-specific staining in the nuclei of 
cells infected with the UL32 null virus, and decreased cytoplasmic staining.  
This effect was not observed with anti-pUL17 immunostaining.  There was no 
observable effect of leptomycin B treatment on pUL25 localization in cells 
infected with wild type HSV-1(F) (data not shown) which is not surprising since 
the distribution of pUL17 and pUL25 in cells infected with wild-type virus is 
nearly exclusively nuclear.  We conclude that at least one of the Crm-1 motifs 
in pUL25 is functional and aids in nuclear retention of pUL25.  Thus the 
cytoplasmic localization of pUL25, but not pUL17, in the absence of pUL32 is 
partly dependent on the Crm-1 nuclear export pathway. 
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 pUL17 and pUL25 colocalize in the absence of other viral proteins:   
Given that pUL17 immunoprecipitates with pUL25 in delta 19 infected 
cells (and to a small extent in delta 18 infected cells), we conclude that pUL25 
and pUL17 associate independently of capsid assembly.  Next we asked 
whether expression of any other viral protein was necessary for pUL17/pUL25 
interaction.  For this, we transfected Hep2 cells on glass coverslips with 
expression constructs, pcDNA3-UL17 and pcDNA3-UL25 (pJB71), either alone 
or together, and 24-36 hours post-transfection cells were fixed and 
immunostained with anti-pUL17 and anti-pUL25 antibodies.  In a control 
experiment, cells were transfected with lipofectamine without plasmid DNA.   
Extensive co-localization of the pUL17 and pUL25 signals was noted in 
a mesh-like network throughout the cytoplasm (fig 3.8 C, F) as well as in 
intensely staining cytoplasmic foci (fig 3.8 C, F, I).  pUL17 was consistently 
more abundant in the nucleus than pUL25, although a few cells showed little 
nuclear pUL17 staining.  These data suggest that pUL17 and pUL25 can 
colocalize in infected cells in the absence of other viral proteins. 
 
Discussion:  
 As revealed by co-immunoprecipitation and co-localization in the nuclei 
of infected cells, the presented data indicate the conditions under which pUL17 
and pUL25 interact.  Their interaction can occur independently of capsid  
formation and in the absence of the major capsid protein VP5 or viral DNA 
cleavage and packaging.  Moreover, VP5 was not co-immunoprecipitated with 
pUL17.  Because it is known that pUL17 and pUL25 associate with capsids the 
observations suggest that the immunoprecipitation conditions employed in the 
current studies were stringent and did not detect lower affinity interactions with 
 114
  115
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 Cells co-expressing pUL17 and pUL25.  Lipofectamine 
transfected cells stained for pUL17 (FITC) and pUL25 (Texas Red) .  
Extensive cytoplasmic colocalization (yellow) was observed both in 
aggregates and network-like structures.  Images were captured under 600x 
magnification with an additional 3x digital zoom.   
 pUL17.  Indeed, we have noted that overnight incubation with pUL17 antibody 
can co-immunoprecipitate VP5 and other capsid proteins (data not shown).  
The studies described here were intended to detect direct rather than indirect 
interactions.  
 In contrast to the result with VP5, the triplex protein VP23 was 
essential for the pUL17/pUL25 interaction under the conditions employed.  This 
observation is potentially consistent with the tight association of pUL17/pUL25 
and triplexes on the capsid surface (254).  We also showed that  the major 
capsid proteins, VP5 and VP23, were necessary for normal localization of 
pUL17 and pUL25 in infected cell nuclei, for proficient immunoreactivity with 
pUL17 and pUL25-specific antibodies, and for solubility of pUL17.  Thus the 
absence of capsid-binding alters immunoreactivity in immunoprecipitation and 
immunofluoresence, potentially reflecting an altered conformation of pUL17 
and pUL25.  To explain the phenomenon that the pUL17/ pUL25 complex 
requires the presence of capsids for their proper intranuclear localization, we 
suggest that both proteins when free from capsids may be exported to the 
cytoplasm but are retained within the nucleus in the presence of capsids.  The 
functional significance of the nuclear export activity during the viral life cycle is 
unclear.  Nuclear export may be involved in capsid egress, or may assist the 
fidelity of capsid assembly by exporting misfolded complexes to the cytoplasm. 
 The data presented herein also document unprecedented effects of 
pUL32 on the pUL17/ pUL25 complex.  Because the role of pUL32 in DNA 
packaging is unknown, these observations are the first to shed light on its role 
in the DNA packaging reaction.   Perhaps the most striking of the observations 
was the greatly increased ratio of soluble pUL25 to pUL17 in cells infected with 
the pUL32 deletion virus.  Although pUL17 and pUL25 interacted in the 
 116
 absence of pUL32, the latter was found to be necessary for retention of pUL25 
in the nucleus, and this role could be rescued by inhibition of the Crm1 nuclear 
export pathway.  The precise mechanism by which pUL32 mediates its effects 
is unknown.  The possibilities range from effects on pUL25 expression to 
chaperone like functions that augment pUL17 solubility.  Further studies will be 
necessary to distinguish between these and other possibilities. 
 Finally, the proper nuclear localization of both pUL17 and pUL25 
requires the expression of the corresponding interacting protein.   
 These observations suggest that multiple functions are required to 
mediate the proper behavior, interactions, and localization of the pUL17/ pUL25 
complex in the infected cell.   
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CHAPTER IV: 
 
pUL17 binds a DNA fragment with the HSV packaging site, pac-1 
 118
  
Introduction: 
Given that pUL17 and pUL25 interact independently and form a 
heterodimer on the external surface of the capsid (254) (discussed in Chapter 
III), we hypothesized that these two proteins may share similar functional 
characteristics.  Specifically, evidence suggests that pUL25 is capable of 
binding DNA (191) a property that was hypothesized to be important in 
retaining genomic DNA in the capsid.  We wanted to know if pUL17 has the 
same property.   
 
Materials and Methods: 
Purification of pUL17-His protein from insect cells -  SF21 cells were 
infected with 5 PFU/cell UL17-His BacPak-derived virus.  Cells were collected, 
pelleted, and washed once with PBS.  The cells were then lysed in 50mM 
NaH2PO4/300mM NaCl/10mM imidazole/1% NP40 pH 8.0 by sonication for 15 
seconds on ice.  Insoluble material was removed by centrifugation for 10 
minutes at 4000 rpm in an Eppendorf 5810R centrifuge with an A-4-62 rotor at 
40C.  A 50% slurry of nickel-nitrilotriacetic acid (Ni-NTA) resin in PBS was 
added to the solubilized proteins and mixed by rotation at 40C for 90 minutes.  
pUL17-His-bound Ni-NTA resin was pelleted and washed twice in 50mM 
NaH2PO4/300mM NaCl/20mM imidazole (pH 8.0).  Protein was eluted with 
50mM NaH2PO4/300mM NaCl/250mM imidazole (pH 8.0).   
 
Dialysis of purified pUL17-His - Eluted proteins were loaded into dialysis 
tubing and incubated in 1.0 L solutions at 40C with rotation.  The buffer was 
changed using step-wise increments from 300 mM to 200 mM, then 150 mM 
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 NaCl while in the constant presence of 50 mM NaH2PO4, 10% glycerol, and 
protease inhibitors. 
 
DNA Binding Assay  (EMSA)-  Ub upper, 
GCGCCGCCGCGCTTTAAAGGGCCGCGCGCGACCCCCGGGGGGTGTGTT
TCGGGGGGGGCCCGT and Ub lower 
ACGGGCCCCCCCCGAAACACACCCCCCGGGGGTCGCGCGCGGCCCTTT
AAAGCGCGGCGGCGC oligonucleotide primers were annealed by boiling for 
10 minutes followed by slow cooling.  Annealed probes were end labeled with 
γ32 ATP using T4 Polynucleotide Kinase (Promega) per the manufacturer’s 
protocol.  On ice, radiolabeled probe and purified, C-His-tagged pUL17 which 
was previously dialyzed into 150 mM NaCl, 50 mM NaH2PO4 and 10% 
glycerol were added to binding buffer (50 mM KCl, 10mM Tris-HCl pH 8.0, 0.5 
mM EDTA pH 8.0, 0.2 mM DTT, and 12% glycerol) at the molar ratios 
specified.  Samples were mixed and tubes were shifted to 37oC for 30 minutes 
to let the binding reaction take place.  Products were electrophoresed at 65V 
in non-denaturing 4.5% polyacrylamide gels at 4oC to separate the products.  
The non-denaturing gels were dried at 80oC for 2 hours and exposed to film. 
 
Results: 
Electrophoresis of PNK-labeled, pac-1-containing DNA is altered by 
purified pUL17-His: 
In parallel to the pUL25 study, we placed a C-terminal His tag on pUL17 
in a baculovirus expression vector and purified pUL17-His using Ni-NTA 
beads.  The His tag was previously shown not to cause DNA binding by using 
a baculovirus-expressed pUL32-His control that did not bind DNA (191).  To 
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 test DNA binding of purified pUL17-His we P32 end-labeled a complementary 
pair of annealed DNA oligonucleotides using T4 polynucleotide kinase (PNK).  
This DNA probe contains the pac1 site (Ub region).  EMSAs were executed as 
reported in the Materials and Methods section. 
Pilot experiments using various cation-containing buffers were 
performed to determine the optimal DNA-binding buffer.  The migration of 
DNA-protein complexes was reduced with buffers containing monovalent 
cations KCl, NaCl, and both KCl and NaCl, but was not significantly altered in 
the presence of divalent, Zn2+ or Mg2+ cation-containing buffers (data not 
shown).  The KCl-containing binding buffer (Materials and Methods) was 
determined to be the most effective and was used in all subsequent mobility 
shift assays. 
 Even with the lowest amounts of protein, 250 femtomoles of purified 
pUL17-His, mobility shifts were modest yet detectable.  We noted that in this 
assay virtually all free probe was bound by pUL17-His.  Through the addition of 
more protein up to 2.0 picomoles, DNA migration was even further retarded 
(fig 4.1).  The pUL17-His/DNA complex was never found to migrate to one or 
multiple discrete positions in the gel as is customary of a transcription factor 
binding a single site.  At higher concentrations, increasing amounts of pUL17-
His/DNA complexes could be found in the wells (fig 4.1, fig. 4.2).  Taken 
together, these data suggest that pUL17-His may have multiple occupancy on 
DNA.  Alternatively, some dissociation of pUL17-His may be occurring during 
electrophoresis. 
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Figure 4.1  Electrophoretic mobility shift assay (EMSA) of pac-1 containing 
DNA with purified pUL17-His.  Each lane contains 25 femtomoles of γP32-
labeled DNA oligonucleotides incubated with increasing amounts of pUL17-
His protein dialyzed into 150mM NaCl, 50mM NaH2PO4, with 10% glycerol.  
Protein:DNA molar ratios are shown at the top of each lane.  (1) probe only, 
no pUL17-His, (2) 10:1, (3) 20:1, (4) 30:1, (5) 40:1, (6) 60:1, (7) 80:1 such 
that the minimum pUL17-His loaded is 250 fmole (lane 2) and the maximum 
pUL17-His loaded is 2.0 pmole (lane 7).  Complexes were separated on a 
4.5% non-denaturing gel and electrophoresed in 0.5x TBE buffer.  
 Contaminating proteins are reflected in altered migration: 
In order to address the specificity of pUL17-His-DNA binding, uninfected 
insect cells were processed for Ni-NTA purification in parallel with pUL17-His.  
The rationale behind this experiment was to determine if contaminating insect 
cell proteins and/or imidazole from the elution buffer remaining after dialysis of 
pUL17-His were responsible for the DNA-binding effects observed.  Insect cell 
proteins non-specifically binding the nickel matrix were eluted in a volume 
equal to pUL17-His and elutions were assayed directly without buffer dialysis 
in order to more stringently test the effect of imidazole.  The results are shown 
in figure 4.2. 
As shown in the previous experiment pUL17-His again altered the 
mobility of the pac-1 containing DNA fragment.  We observed most 
protein/DNA complexes at or near the wells of the gel for reasons that are not 
yet clear.  In reactions with proteins eluted from the “purification” from 
uninfected insect cells altered DNA mobility was detected only in the sample 
with the highest protein:DNA molar ratio.  This shifting of DNA may be caused 
by imidazole from the elution buffer or from insect cell DNA-binding proteins 
non-specifically binding to the Ni-NTA matrix.  More to the point of this assay, 
the DNA-binding activity present even in the highest concentrations of 
uninfected cell lysate samples was significantly less appreciable than that of 
the lowest concentration of pUL17-His-containing sample, thus suggesting a 
role for pUL17-His in DNA-binding. 
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Figure 4.2  Electrophoretic mobility shift assay of pUL17-His and 
uninfected cell lysate samples.  10 femtomoles of γP32-labeled, pac-1-
containing, double-stranded DNA fragment was present in each sample.  
Probe alone was run in lane 1 as a control.  Samples in lanes 2-4 
contained non-dialyzed pUL17-His protein, with the molar ratios of 
protein:DNA indicated at the top of the lane.  Equivalent volumes from a 
parallel “purification” of uninfected insect were also assayed for non-
specific DNA binding.  Protein/DNA complexes were separated on a 4.5% 
non-denaturing gel and electrophoresed in 1.0x TAE buffer 
  
Discussion: 
The role of pUL17 DNA-binding activity in the viral life cycle is uncertain.  
One possibility is that  the protein in some way aids association of capsids with 
DNA pursuant to its eventual cleavage and packaging.  Such activities would 
not be expected to be specific for certain DNA sequences, because the 
terminase proteins likely provide the recognition of packaging signals.  Indeed, 
the DNA binding activity identified herein was not specific to certain sequences 
although this was not tested extensively (data not shown). 
    Another possible role for the DNA binding activity is one of 
reorganization of nuclear chromatin to augment gene expression, or to 
mediate heterochromatinization of host cell DNA.  Effects of pUL17 on 
formation of the DNA replication compartment or architecture of the nucleus 
might be warranted. 
    Finally, it is possible that the potential DNA binding activity simply 
reflects the basic nature of certain regions of pUL17 that mediate functions 
other than DNA association in the infected cell.  Further mutational analysis to 
identify DNA binding regions and testing the effects of mutations ablating DNA 
binding on viral replication, DNA packaging, and interactions with  proteins 
known to interact with pUL17 would help correlate DNA binding activity to 
functionality in the infected cell. 
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 CHAPTER V: 
 
The essential protein encoded by UL17 of herpes simplex virus 1 bridges 
capsid and tegument proteins 
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Abstract: 
The UL17 protein (pUL17) of herpes simplex virus 1 (HSV-1) likely 
associates with the surfaces of DNA-containing capsids in a heterodimer with 
pUL25.  pUL17 is also associated with viral light particles that lack capsid 
proteins, suggesting its presence in the tegument of the HSV-1 virion.  To help 
determine how pUL17 becomes incorporated into virions and its functions 
therein, we identified pUL17 interacting proteins by immunoprecipitation with 
pUL17-specific IgY at 16 hours post infection followed by mass spectrometry.  
Co-immunoprecipitated proteins included cellular histone proteins H2A, H3 
and H4, the intermediate filament protein, vimentin, the major HSV-1 capsid 
protein, and the HSV tegument proteins VP11/12 (UL46) and VP13/14 (UL47).  
The pUL17-VP13/14 interaction was confirmed by reciprocal co-
immunoprecipitation with a polyclonal anti-VP13/14 antibody, and by affinity 
co-purification of pUL17 and VP13/14 from lysates of cells infected with a 
recombinant virus encoding His-tagged pUL17.  The co-immunoprecipitation 
from infected cell lysates of VP13/VP14 and VP16, another major HSV-1 
tegument protein, required pUL17.  pUL17 and VP13/14-HA co-localized in the 
nuclear replication compartment, cytoplasm, and at the plasma membrane 
between 9 and 18 hours post-infection. The co-expression of pUL17 and 
epitope-tagged VP13/14 and VP11/12 caused all three proteins to partially co-
localize in cytoplasmic aggregates. Immunoelectron microscopy of cells 
infected with a virus encoding VP13/14-HA and reacted with HA-specific 
antibody revealed immunoreactivity distributed in short linear arrays at the 
nuclear periphery, occasionally with perinuclear virions, and frequently with 
virions in the cytoplasm and extracellular space.  Taken together, these data 
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 suggest that although some VP13/14 associates with perinuclear virions, most 
becomes incorporated into virions by interaction with pUL17 in the cytoplasm 
at the surface of de-enveloped nucleocapsids.   
 
Introduction:   
Herpesvirus virions are composed of a double-stranded DNA genome 
encapsidated into an icosahedral shell, an amorphous proteinaceous network 
surrounding the capsid termed the tegument, and a glycoprotein-decorated 
envelope surrounding the tegument [reviewed in (164, 165, 230)].  The 
predominant model of virion assembly involves primary envelopment of the 
nucleocapsid at the inner nuclear membrane (INM), fusion of this nascent 
virion envelope with the outer nuclear membrane (ONM), and subsequent 
attachment of tegument proteins to the de-enveloped nucleocapsid in a region 
of the cytoplasm derived from the Golgi apparatus and/or trans-Golgi network 
(165).  That the bulk of the tegument is applied at a step after primary 
envelopment is consistent with the relatively sparse electron microscopic 
appearance of the perinuclear virion tegument as opposed to the dense 
tegument of the extracellular virion (9, 100).  This model of virion egress 
suggests opportunities for a subset of tegument proteins to attach directly or 
indirectly to the nucleocapsid in either the nucleosol, cytosol, or during 
budding through nuclear or cytoplasmic membranes.  Supporting the idea that 
at least some tegumentation occurs in the nucleoplasm are the observations 
that pUL36 and vhs (the UL41 gene product) are associated with intranuclear 
capsids (27, 202).  Budding through the INM likely causes incorporation of 
another set of proteins into the tegument, including the peripheral membrane 
proteins pUL11 and pUL31, the viral kinase encoded by US3, and the 
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 nucleoplasmic protein VP16 (the UL48 gene product) (12, 162, 176, 209).  Of 
these, only the UL31 gene product is absent from extracellular virions 
indicating its loss at the de-envelopment step (148, 209). 
Major tegument components include the products of the UL46 gene 
(VP11/12) and UL47 gene (VP13/14), present in 400-600 and 1400-1880 
copies per virion, respectively (107, 284).  Although neither protein is essential 
for viral replication, they play augmentary roles in VP16-dependent viral 
transcription (284).   Perhaps related to this observation, yeast two hybrid 
studies detected interactions of VP11/12 with either VP13/14 or VP16 (263).  
The VP11/12-VP16 interaction was further confirmed in a pull down assay 
(263).  HSV-1 VP13/14 shuttles from the nucleus to cytoplasm during the 
course of infection (69, 260), a feature shared by the VP13/14 homolog of 
bovine herpesvirus (261).  Localization in both nucleus and cytoplasmic 
compartments makes it challenging to determine when and where VP13/14 
becomes associated with virions.   As evidence supporting a cytoplasmic role 
in tegumentation, cells infected with a pseudorabies virus mutant lacking the 
homolog of UL47 contain increased numbers of cytoplasmic capsids lacking 
electron density attributable to the tegument (126).  
The role of VP11/12 in virion assembly is even less clear because viral 
mutants lacking this protein are unimpaired in virion egress through the 
nucleus or cytoplasm in all systems studied (13, 70, 126).  VP11/12 can 
associate with membranes, and a VP11/12 /GST fusion protein can associate 
with capsids purified from infected cell nuclei when added in vitro (174).  
These data are consistent with functions of VP11/12 in bridging the membrane 
and capsid in the virion structure, and perhaps during virion budding.   
 129
 Although the precise contribution of HSV-1 UL17 protein (pUL17) to viral 
replication remains unclear, its role as a structural component of capsids is 
well documented.  Originally classified as a DNA cleavage and packaging 
protein due to the exclusive production of concatemeric DNA and capsids 
lacking DNA in cells infected with a UL17 deletion virus, pUL17 was found later 
to be necessary for proper capsid distribution within the intranuclear replication 
compartment (214, 241).  pUL17 interaction with capsids was further 
supported by biochemical and electron microscopy studies showing 
association with the external surfaces of capsids (245, 274).  The herpes 
simplex virus capsid shell is composed of 12 pentons and 150 hexons 
composed of the major capsid protein VP5 (encoded by UL19), 375 triplexes 
made up of two molecules of VP23 (encoded by UL18) and one molecule of 
VP19C (encoded by UL38), and 900 copies of VP26 (UL35) which localize atop 
each of 5 VP5 molecules in each hexon.  Recent cryoelectron microscopy 
studies have identified a heterodimer of pUL25/pUL17, termed the C Capsid 
Specific Component (CCSC) that bridges pentons and adjacent hexons in 
DNA-containing (type C) capsids (254).  These observations are consistent 
with other data indicating that pUL17 localizes on the capsid surface and 
enhances association of pUL25 with capsids (245, 274).  In addition to the 
capsid association studies, pUL17 is a component of viral light particles, which 
contain tegument and membrane associated proteins but lack capsids (246).  
Thus, pUL17 can become incorporated into tegument-like structures in the 
absence of capsids. 
To clarify specific capsid and tegument protein interactions with pUL17, 
we performed co-immunoprecipitations with a pUL17-specific antibody and 
have identified interactions with the major capsid protein VP5, as well as 
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 tegument proteins VP11/12 and VP13/14.  In light of these and previous data, 
we suggest two possibly related structural roles for pUL17 in virion assembly: 
to ensure that the capsid is competent structurally to package viral DNA, and 
to serve as sites of attachment for a subset of virion tegument proteins that 
include pUL47 and associated proteins.   
 
 
Materials and Methods: 
Cell lines and viruses -  Vero and Hep2 cells were obtained from the 
American Type culture association and were propagated in DMEM 
supplemented with 10% newborn calf serum (NBCS) and antibiotics as 
described previously (277).    
A novel cell line CV1-17, specifically engineered to support replication 
of UL17 null viruses, was created using the Flp-In system from Invitrogen.  
Briefly, the UL17 open reading frame was cloned into the FRT-containing 
expression vector pcDNA5/FRT and verified by DNA sequencing.  The 
pcDNA5/FRT-UL17 plasmid was co-transfected with pOG44, a Flp 
recombinase-encoding plasmid, into CV-1 cells previously selected for an 
integrated FRT locus to support recombination of the transfected DNA.  Site-
specific recombination resulted in a change of cell line phenotype from Zeocin 
resistance to Hygromycin (Hyg) B resistance.  Hygromycin-resistant colonies 
resulting from the transfection were amplified and grown into cellular 
monolayers.  Expression of UL17 in these cells was determined by 
immunoblotting with anti-pUL17 antibody, and plaque formation by the UL17 
null virus.  One such cell line was designated CV1-17 and was used for further 
studies.  CV1-17 cells were maintained in Dulbecco’s modified Eagle’s 
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 medium (DMEM) supplemented with 10% fetal bovine serum and 200 μg/ml 
Hyg B.   
The wild type HSV-1(F) strain was used in these studies and  has been 
described previously (72).  HSV-1(F) was propagated on Vero (African green 
monkey kidney) cells.  
A new UL17-null virus was constructed by integration and subsequent 
selection of a Kanamycin resistance (KanR) cassette into the UL17 open 
reading frame (ORF) as follows.  A gene encoding KanR was PCR amplified 
with the following primers containing sequences homologous to the UL17 ORF 
and KanR cassette:   
(del17F, #11) CAAACTTCCAG GTCGAAATCCAG ACTCGGGCTCATG 
CCACCGGCGACTG TA CGTGTAGGCTGGAGCTGCTTC; (del17R, #12) 
TTCCGTAGT GGTGGCGCA GGACCACGGAG ATAGAACGACG 
GCTCCACAGCC AGTCATTCCGGGGATCCGTCGAC  (KanR homology 
underlined).  Amplicons were transformed into EL250 cells containing a 
chloramphenicol–resistant (CmR), wild-type HSV-1(F) BAC (238).   CmR/KanR 
recombinants were selected on agar plates.  Extracted BAC DNA was 
transfected with SuperFect (Qiagen) into CV1-17 cells and after 3 rounds of 
viral plaque purification, CV1-17 cells grown in 890 cm2 roller bottles were 
infected with 0.01 PFU per cell for propagation of viral stocks. 
A recombinant HSV-1(F) BAC encoding a UL17 ORF in frame with 6 
histidine codons (His) at the 3’ end was created by PCR using the following 
primers: 
 (ORF17 3’HisF, #28) GCCGCT GTCCTTAGGTTTT GTCGCA AGGTGTC 
GTCCGGG AACGGCCGT TCTCGCCACCAC CACCACCA CCACTAGCGT 
GTAGGCTGGA GCTGCT TC and (ORF17 3’HisR, #29) CAACGG CGCGG 
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 GGAGGAG TGGATG GGCGAG GTGGCC GGGGGA AGGCGC CCGATT 
CCGGG GATCC GTCGAC (where the six His codons are italicized, the stop 
codon indicated in bold, and homology to the KanR cassette underlined).  PCR 
amplicons that contained the 6X His tag immediately before UL17’s stop 
codon, and the KanR cassette 3’ of the TAG flanked by FRT sites were 
electroporated into HSV-1(F) BAC-containing EL250 cells.   CmR/KanR clones 
were identified on selective media.  Overnight cultures of CmR/KanR colonies 
were grown in the presence of 10% arabinose to induce expression of the FRT 
recombinase, driving recombination at the FRT sites and resulting in the loss 
of KanR.  Purified BAC DNAs from CmR/KanS clones were transfected by the 
CaCl2/Na2HPO4 method into individual wells containing Vero cells and after 3 
rounds of plaque picking, viral stocks were grown on Vero cells inoculated at 
0.01 PFU per cell.   
Two additional HSV-recombinant viruses, one with DNA encoding a 
FLAG epitopic tag fused to the 5’ end of UL46 (FLAG-VP11/12) and another 
encoding an influenza hemagglutinin (HA) tag in frame with the 3’ end of UL47 
(VP13/14-HA) were created by en passant mutagenesis, a previously 
described markerless BAC mutagenesis technique (247).  Thus, gel purified 
primers (EP FLAG46F, #60) GCGGCA TAACTC CGA CCGGCGGGTCCCG 
ACCGAACGGGCGT CACCATG GATTACAAGGAT GACGACGATAAG and  
(EP FLAG46R, #61) GCACCG CGCCA GCCGCA GGGAGCTCGCG 
CCGCGCG TCCGGCGCTG CTTATC GTCGTCA TCCTTG TAATC 
CATGGTGA CGCCC GTTCGC AACCA ATTAT CCAAT TCTGAT TAG (FLAG 
tag italicized, start codon in bold;  pEP Kan cassette homology underlined) 
were used to make FLAG-VP11/12.  Primers (EP 47HAF, #62) GTGTCGG 
GGAGGCG CGCGACC GGGCTGG GAGGCCC GCCACGC CCATACC 
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 CATACGA CGTCCCA GACTACG CTTAAAG GATGA CGACG ATAAGT 
AGGG and (EP 47HAR, #63) TATGC CGCGT CCAGG GCCATC GGGGCG 
CTTTTTA TCGGGA GGAGC TTAAG CGTAGT CTGGG ACGTC GTATG 
GGTAT GGGCG TGGCG GGCCC AACCA ATTAA CCAAT TCTGAT (HA tag 
italicized, stop codon in bold, pEP Kan cassette homology underlined) were 
used to generate a VP13/14-HA recombinant BAC.  Recombinant BAC DNAs 
were purified and transfected into Vero cells with SuperFect (Qiagen) for virus 
propagation. 
A recombinant UL17-His virus was also made by BAC mutagenesis. 
 A carboxy-terminal 6x His tag was added to the UL17 ORF by PCR with 
primers (CHis17F, LDS#9) 
CGGGATCCACCATGAACGCGCACTTGGCCAACGAG and (CHis17R, 
LDS#10) 
GGAATTCCTAGTGGTGGTGGTGGTGGTGGCGAGACCGGCCGTTCCCGG
A (UL17 homology underlined, 6xHis tag italicized, stop codon in bold).   
Digestion at the flanking BamHI and EcoRI restriction sites allowed for 
subcloning into the pCR2.1 vector.  PCR products were electroporated into 
HSV BAC containing EL250 cells.  Recombinant clones were selected with 
Chloramphenicol (Cm) and Kan.  Overnight cultures of CmR/KanR were grown 
in the presence of 10% Arabinose to recombine FRT sites for the loss of Kan.  
Maxi-preps of CmR/KanS BAC clones were transfected into Vero cells and 
after 3 rounds of plaque picking, viral stocks were grown in roller bottles on 
Vero cells inoculating at an MOI of 0.01.    
 
Immunoprecipitation Assay - A previously described anti-pUL17 chicken IgY 
antibody (35) was used to co-immunoprecipitate proteins interacting with 
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 pUL17 as follows.  Approximately 8.0 x108 rabbit skin cells (RSC) were 
infected with 5 plaque forming units of HSV-1(F) or UL17 null virus per cell.  
Cells were collected at 16 hours post-infection, pelleted by centrifugation, and 
lysed in NP40 lysis buffer (1.1% NP40, 100 mM Tris pH7.7, 300mM NaCl, 
1mM EDTA pH 8.0, 1mM PMSF, 1μg/ml Aprotinin, 1μg/ml Pepstatin, 1μg/ml 
Leupeptin, Sigma Protease Inhibitor cocktail (P8340), 1mM Na3VO4) on ice.  
Lysates were clarified by a 10 minute, 4000 RPM centrifugation in an 
Eppendorf 5810R centrifuge with an A-4-62 rotor at 40 C 4 times to ensure 
removal of all cellular debris.  In a pre-clearing step, Gamma Bind G beads 
which contain a recombinant form of streptococcal Protein G covalently bound 
to Sepharose 4B (GE Healthcare Bio-Sciences AB) were washed with PBS, 
brought to a 50% slurry in PBS, and reacted with the solubilized cellular 
proteins for one hour at 40C and then were pelleted for 10 minutes at 8000 
rpm in a F34-6-38 rotor.  The pre-cleared lysates were transferred to new 
tubes and subsequently reacted for 1.5 hours at 40C with rabbit anti-IgY IgG 
plus Gamma Bind G beads with constant rotation to further remove any non-
specific binding.  After removal of the bead/rabbit IgG mix by centrifugation at 
8000 RPM in a F34-6-38 rotor at 40C and transfer to new tubes, the 
supernatants were reacted with chicken anti-pUL17 IgY for 2 hours at 40C, 
followed by reaction with rabbit anti-IgY IgG for 2 hours at 40C, and finally with 
Gamma G bind beads overnight.  The beads with bound proteins were 
pelleted, washed 4 times with ice-cold NP40 lysis buffer, and protein was 
eluted from the beads in 150 μl 2X SDS-PAGE buffer (100mM Tris-HCl pH 
6.8, 4.0% SDS, O.2% bromophenol blue, 20% glycerol, 200mM fresh DTT).  
Samples were separated on both 8% and 15% SDS polyacrylamide gels and 
stained with Coomassie blue.   
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MALDI-MS -  Proteins of interest were cut from the polyacrylamide gel, 
digested with trypsin, and the masses of peptides determined by Matrix-
Associated Laser Desorption Ionization time of flight mass spectrometry 
(MALDI-TOF MS).  The top 10 scoring peptide matches for each band are 
reported in table 4.1. 
 
Immunofluorescence Assay (IFA) – Hep2 cells grown on glass coverslips in 
6-well dishes to approximately 80-100% confluence were infected by 
incubation with 5.0 PFU/cell in 199V media (DMEM with 1% NBCS) with 
rocking for 1 hour, and then returned to stationary incubation.  At various times 
after infection, the cells were fixed in 3% paraformaldehyde in PBS for 15 
minutes.  Cells infected with virus VP13/14-HA were fixed with ice cold 
methanol for 10 minutes at 40C.   Autofluorescence was quenched with 50 mM 
ammonium chloride for 15 minutes; cells were washed with PBS and 
permeabilized in 1.0% Triton-X 100 for 5 minutes followed by washing in PBS.  
PBS supplemented with 1% BSA, 5% donkey serum and 5% human serum 
was used to block non-specific antibody binding for 20-30 minutes at room 
temperature.  Primary antibodies were diluted in this blocking solution as 
follows: anti-pUL17 between 1:1000 and 1:500, anti-acetyl K9 Histone H3 
(Upstate) 1:100, anti-ICP5 (VP5) (Virusys) 1:100, anti-ICP8 1:1,000 (a kind gift 
of Bill Ruyechan), anti-FLAG (M2) 1:200, and anti-HA (Santa Cruz) 1:100.  
After the 30-60 minute incubation with primary antibody, cover slips were 
washed at least 3 times with PBST [PBS supplemented with 0.2% Tween-20 
(Sigma)] and secondary antibodies were diluted 1:1,000 in blocking solution 
and reacted for 30-60 minutes.  Cover slips were washed at least 4 times in 
 136
 PBST then briefly in dH20, mounted on glass slides with Vectashield mounting 
medium (Vector Laboratories) containing a UV protectant, and sealed with nail 
polish. 
 
Transfections for transient expression-  Adherent Hep2 cells were 
transfected with the indicated expression plasmids using Lipofectamine 2000 
(Invitrogen) according to the protocol of the manufacturer and were processed 
for indirect immunofluorescence 36-48 hours after transfection as indicated 
above.   
 
Ni-NTA Protein Purification -  Vero cells were infected with 5 PFU/cell UL17-
His virus.  Cells were collected, pelleted, and washed once with PBS.  The 
cells were then lysed in 50mM NaH2PO4/300mM NaCl/10mM imidazole/1% 
NP40 pH 8.0 by sonication for 15 seconds on ice.  Insoluble material was 
removed by centrifugation for 10 minutes at 4000 rpm in an Eppendorf 5810R 
centrifuge with an A-4-62 rotor at 40C.  A 50% slurry of nickel-nitrilotriacetic 
acid (Ni-NTA) resin in PBS was added to the solubilized proteins and mixed by 
rotation at 40C for 90 minutes.  pUL17-His-bound Ni-NTA resin was pelleted 
and washed twice in 50mM NaH2PO4/300mM NaCl/20mM imidazole (pH 8.0).  
Protein was eluted with 50mM NaH2PO4/300mM NaCl/250mM imidazole (pH 
8.0).  Eluted proteins were electrophoretically separated on SDS 
polyacrylamide gels, transferred electrically to nitrocellulose, and probed with 
various antibodies as described below. 
 
Immunoblotting – Vero cells were collected and pelleted at 4000 rpm for 10 
minutes.  Cell pellets were resuspended and lysed in 2x SDS-PAGE sample 
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 buffer.  Associated proteins were electrophoretically separated on SDS 
polyacrylamide gels and transferred to nitrocellulose at 25-30 amps for 5-6 
hours at 40C.  Membranes were blocked in 5% dried milk in PBST, rinsed with 
PBST, and probed with antibody diluted in PBST supplemented with 1.0% 
BSA.  Primary antibodies were diluted as follows: anti-pUL17, 1:10,000; anti-
VP5, 1:1,000; anti-vimentin, 1:1,000; anti-HA, 1:1,000; anti-VP13/14, 1:1,000; 
anti-FLAG (M2), 1:2,500; anti-VP22, 1:10,000; anti-VP16, 1:1,000. Excess 
primary antibody was removed with 3, 10-minute washes in excess PBST.  
Secondary HRP-conjugated antibodies were diluted 1:5,000 in PBST with 5% 
milk and rocked for 1 hour at room temperature.  Excess antibody was again 
removed by washing in excess PBST 3 times for 10 minutes each.  Bound 
immunoglobulin was revealed by chemiluminescence using Pierce ECL 
detection agent exposure to X-ray film for approximately 2 minutes.   
 
Immunogold electron microscopy - Hep2 cells were infected with HSV-1(F) 
or a recombinant virus bearing a UL47 gene fused to DNA encoding an HA 
epitopic tag.  At 16 hours after infection the cells were fixed, embedded, and 
thin sectioned as previously described (3, 24).  Thin sections were reacted 
with rabbit anti-HA antibody diluted 1:50 in PBS supplemented with 0.5% 
Tween 20 and 1% fish gelatin, followed by extensive washing and reaction 
with goat anti-rabbit immunoglobulin conjugated to 12 nm gold beads (Jackson 
ImmunoResearch catalog #111-205-144).  Electron microscopy, and 
photography was performed essentially as described (209).  
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 Results: 
Construction of a new UL17 expressing cell line and viral deletion 
mutant:  
Since pUL17 is essential for viral replication, propagation of viral null 
mutants lacking this gene requires complementing cell lines engineered to 
express UL17.  Because the previously described G5 complementing cells 
harbored a 16.2 kb fragment of the HSV genome (62), recombination between 
homologous HSV sequences in the virus and cell line often resulted in genetic 
reversion of the UL17 deletion to wild type sequences (data not shown).   
To overcome this difficulty, a new cell line, CV1-17, containing only 
UL17 was created through the use of the Flp-In system (Invitrogen) as outlined 
in Materials and Methods.  During the course of these efforts, the UL17 ORF 
from HSV-1(F) was subcloned and sequenced.  This sequence analysis 
revealed differences between the UL17 ORFs in HSV-1(F) and the published 
HSV-1(17) sequences (156).  Specifically, a +1 insertion mutation in HSV-1(F) 
UL17 was predicted to causes a frame shift relative to HSV-1(17) at codon 11 
(Fig. 5.1 A).  The open reading frames then realign at codon 21 by a 
compensatory -1 deletion in UL17 of HSV-1(F).  These mutations are predicted 
to produce ten distinct amino acids at the N-termini of the two otherwise 
identical genes.   Other silent mutations were observed (data not shown), as 
well as a single amino acid change at codon 352 (Fig. 5.1B).   
After obtaining a UL17-specific cell line, a novel HSV-1(F) BAC was 
generated in which a central portion of UL17 ORF was replaced with a 
Kanamycin resistance cassette (detailed in Materials and Methods).  This 
deletion of 912 base pairs (bps 212-1,123 with 1 representing the A in the start  
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Figure 5.1  UL17 sequences in different HSV-1 strains.  Panel A.  An 
insertion between codons 10 and 11 cause a frameshift in the HSV-1(F) 
sequence compared to the published HSV-1(17) sequence.  A deletion 
between codons 21 and 22 in the HSV-1(F) bring the two UL17 genes back 
into frame.  Panel B.   A point mutation changes a single amino acid in the 
HSV-1(F) UL17 compared to the HSV-1(17) UL17 sequence.  
 codon) retained 989 base pairs of the 3’ end of the UL17 coding sequence to 
preserve the UL16 promoter region.  Transfection of this BAC into supporting 
CV1-17 cells resulted in a UL17 deletion virus (designated delta 17) with 
significantly reduced rates of reversion (data not shown).  
Identification of UL17 interacting proteins: To clarify pUL17’s putative 
roles in virion assembly as both a tegument and capsid protein, we used co-
immunoprecipitation to identify pUL17 interacting proteins.   
In our first approach to discover protein-protein interactions involving 
pUL17 we employed 35S metabolic labeling of cells infected with  recombinant 
UL17-His, F, and delta 17 viruses.  Both uninfected and mock infected cells 
were used as controls.  Immunoprecipitation with subsequent autoradiography 
indicated a substantial amount of two proteins was enhanced specifically in 
the 17-His-infected sample (Figure 5.2)  Of the two the fast migrating species 
electrophoresed to the expected zone of pUL17.  The slower migrating 
species, of approximately 160 kDa was presumed to be VP5. 
  To specifically identify proteins co-immunoprecipitating with pUL17 we 
performed an immunoprecipitation with an anti-pUL17 antibody and identified 
co-immunoprecipitating proteins by MALDI-TOF MS. Specifically, cells were 
infected with HSV-1(F) or the novel deletion mutant lacking UL17.  The 
proteins in each lysate were reacted separately with pUL17-specific IgY 
antibody, and immune complexes were purified by reaction with a rabbit anti-
IgY bridging antibody that could subsequently be captured with Gamma Bind 
G Sepharose beads.  Immunoprecipitated proteins were eluted and 
electrophoretically separated on both 8% and 15.0% denaturing 
polyacrylamide gels to resolve both high and low molecular weight proteins, 
respectively. The results are shown in figures 5.3 A and 5.3 B.   
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Figure 5.2  Anti-His immunoprecipitation from pUL17-His-infected cells.  
Autoradiogram of 35S metabolically labeled cells immunoprecipitated with 
penta anti-His antibody.  Two major species migrating at 160 kDa and 85-
90 kDa were immunoprecipitated more efficiently from pUL17-His infected 
cells. 
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Figure 5.3.  Co-immunoprecipitation of proteins with pUL17-specific 
antibody.  Cells were infected with HSV-1(F) or the UL17 deletion virus, and 
pUL17 was immunoprecipitated.  Immunoprecipitated proteins were 
electrophoretically separated on a 15% (panel A) or 8% SDS 
polyacrylamide gels (Panels B and C) and were stained with Coomassie 
brilliant blue (panels A and B), or were subjected to immunoblotting with 
pUL17-specific antibody (panel C).  Proteins unique to or highly enriched in 
immunoprecipitations performed with HSV-1(F) infected cells are indicated 
with arrows, and their identities are indicated in the text. 
 Four bands in the 8% polyacrylamide gel (indicated in figure 5.2 B and 
corresponding to apparent Mr’s 62,000, 85,000, and 95,000, and 160,000) and  
three bands from the 15% polyacrylamide gel (Figure 5.3 A; corresponding to 
apparent Mr’s 15,000, 17,500 and 19,000) were exclusive to or greatly 
enhanced in lanes containing immunoprecipitations from lysates of HSV-1(F), 
as opposed to immunoprecipitations from lysates of cells infected with the 
UL17 deletion virus.  These bands were cut from the gel and subjected to 
trypsin digestion.  The masses of the resulting peptides were determined by 
MALDI- TOF mass spectrometry and were compared to available databases 
of vertebrate proteins.   
As shown in table 5.1, bands from the 8% gel of apparent Mrs 85,000 
and 95,000 contained tryptic peptides with masses consistent with the UL46 
and UL47 gene products of HSV-1 (predicted MW 73,771 and 78,195, 
respectively).  In addition to these species, eight other peptide matches from 
the 85,000 apparent Mr band matched glycoprotein E peptides.  This was not 
surprising inasmuch as gE/gI complexes have been shown to bind the Fc 
domain of IgG immunoglobulins (120).  Because this complex efficiently binds 
rabbit immunoglobulins, we expect that the rabbit anti-chicken IgG antibody, 
used to bridge the IgY and Sepharose beads in this experiment, was 
responsible for immunoprecipitation of the gE/gI complex.  Tryptic peptides 
from the VP11/12-containing band also included one match to a Zinc-finger 
protein homolog, and seven other peptides attributable to spindle-like 
microcephaly-associated proteins (ASMPs). 
The three bands from the 15% gel containing proteins of apparent Mrs 15,000, 
17,500 and 19,000 most abundantly contained peptides consistent with 
cellular histone proteins H4 (predicted MW 11,236), H2A (predicted MW 
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13,927), and H3 (predicted MW 15,498), respectively (Figure 5.3 A and Table 
5.1).  These masses matched tryptic peptides from a number of animal 
histones due to the high conservation of these proteins (data not shown).      
 A predominant band of 62,000 apparent Mr was detected in both the 
8% and 15% SDS polyacrylamide gels.  This band was much more intense in 
the HSV-1(F) immunoprecipitation reactions and contained tryptic peptides  
 with masses consistent with those from the human intermediate filament 
protein vimentin and vimentin homologs, which comprises intermediate 
filaments in several animal species.  The other two most highly ranked 
matches included unnamed human proteins, both with homology to the N-
terminal head region of intermediate filament proteins (data not shown) 
The slowest migrating band in this experiment produced tryptic peptides 
consistent with the major capsid protein from a variety of herpesviruses with 
human herpesvirus 1 and 2 scoring the highest and second-highest, 
respectively.  This was consistent with pUL17 association with capsids, which 
contain abundant amounts of VP5. 
Because none of the harvested gel slices contained pUL17, we 
transferred the electrophoretically separated proteins immunoprecipitated with 
anti-pUL17 antibody to nitrocellulose and probed the proteins with anti-pUL17 
antibody.  Bound immunoglobulin was revealed by reaction with horseradish 
peroxidase conjugated anti-chicken antibody followed by chemiluminescence 
as detailed in Materials and Methods. As shown in figure 5.3 C, pUL17 was 
immunoprecipitated by its cognate antibody inasmuch as it was present in the 
HSV-1(F) sample.  Subsequent experiments demonstrated nearly identical co-
migration between pUL17 and VP13/14 and this is most likely the reason why 
pUL17 was not represented in our MALDI-TOF analysis.     
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 To confirm the putative pUL17 interaction with VP13/14, lysates of cells 
infected with HSV-1(F) and the UL17 deletion virus were reacted with 
polyclonal antibody directed against VP13/14 (a kind gift from the laboratory of 
David Meredith) and the presence of pUL17 in immunoprecipitated material 
was assessed by immunoblotting.  As shown in Figure 5.4 C, approximately 
equal amounts of VP13/14 were immunoprecipitated from cells infected with 
either the UL17 deletion or wild type viruses.  More important to the purposes  
of this report, however, pUL17 was readily co-immunoprecipitated with the 
VP13/14-specific antibody (fig. 5.4 A).  These data therefore confirmed the 
interaction between pUL17 and VP13/14.   
Because VP13/14 had been reported to interact directly with VP16 in a 
yeast two-hybrid screen and to enhance VP16-mediated transcription, we 
were interested to know whether VP16 co-immunoprecipitated with VP13/14 
and/or pUL17.  To test this possibility, the immunoblot of VP13/14 
immunoprecipitated from lysates of cells infected with wild type and UL17 
deletion viruses was probed with VP16-specific antibody.  As shown in figure 
5.4 B, VP16 was readily co-immunoprecipitated with VP13/14 from cells 
infected with HSV-1(F).  In contrast to this result, however, VP16 was not co-
immunoprecipitated by the VP13/14-specific antibody from lysates of cells 
infected with the UL17 deletion mutant.  These data indicate that pUL17 is 
required for the interaction between VP13/14 and VP16 as detected by 
immunoprecipitation.   
In a second set of experiments to confirm the pUL17-VP13/14 
interaction, we sought to co-purify VP13/14 with pUL17 by means other than 
co-immunoprecipitation.   Therefore, a novel virus encoding pUL17 with 6 
histidine codons fused to its C-terminus (pUL17-His) was constructed as  
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Figure 5.4.  Co-immunoprecipitation of proteins with anti-VP13/14 antibody. 
Cells were mock infected, or were infected with HSV-1(F) or the UL17 
deletion virus and lysates were reacted with VP13/VP14-specific antibody.  
Immune complexes were purified, electrophoretically separated, subjected 
to immunoblotting with antibodies against pUL17 (Panel A), VP16 (Panel B) 
or VP13/14 (panel C).  Bound immunoglobulins were revealed by reaction 
with appropriately conjugated anti-immunoglobulins, followed by 
chemiluminescent exposure to X-ray film.
 
 described in Materials and Methods.  Cells were infected with this virus and 
sixteen hours later were lysed in 1% NP40.  pUL17-His was then purified from 
these lysates by affinity chromatography on Ni++-containing agarose beads.  
As a negative control, lysates of cells infected with HSV-1(F) were treated 
identically.  Proteins bound to the affinity matrix were eluted sequentially 4 
times in the presence of imidazole, denatured in SDS, electrophoretically 
separated, and transferred to nitrocellulose.  As shown in figure 5.5, probing 
the nitrocellulose with pUL17-specific antibody revealed pUL17-His within the 
eluates from pUL17-His infected cells but not from eluates derived from cells 
infected with HSV-1(F).  pUL17 was most concentrated in the first elution, with 
subsequent elutions diminishing in signal as expected (fig. 5.5 A lane 1, 3).   
The same immunoblot was then stripped and re-probed for the 
presence of VP13/14. As shown in fig. 5.5 B, although a background level of 
VP13/14 was detectable in the first elution from beads containing HSV-1(F) 
infected cell proteins, VP13/14 was clearly enriched in eluates derived from 
cells infected with the UL17-His virus.  Moreover, VP13/14 was readily 
detectable in the second elution from beads bearing proteins from cells 
infected with UL17-His virus, but not from cells infected with HSV-1(F).  These 
data therefore indicate that pUL17 and VP13/14 can be co-purified via the His 
tag incorporated into the C-terminus of pUL17, and further confirm the 
VP13/14-pUL17 interaction.   
To further investigate the relationship between VP16 and the VP13/14-
pUL17 complex, the affinity purified proteins were also probed with antibody 
directed against VP16.  As shown in figure 5.5 C, lanes 1 and 3, a significantly 
reduced amount of VP16 was affinity purified from lysates of cells infected with 
pUL17-His compared to the amounts eluted from the affinity matrix bearing  
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Figure 5.5. Affinity co-purification of VP13/14 and pUL17.  Hep2 cells were 
infected with either HSV-1(F) or a recombinant HSV-1 bearing a histidine 
tag fused to the C-terminus of pUL17.  Lysates of the cells were clarified 
and soluble proteins subjected to affinity chromatography on Ni++ 
containing beads. After extensive washing, proteins bound to the beads 
were eluted in SDS-PAGE sample buffer, electrophoretically separated, 
transferred to nitrocellulose, and subjected to immunoblotting with 
antibodies to pUL17 (panel A), VP13/14 (panel B), or VP16 (panel C).   
 proteins of HSV-1(F)  (fig. 5.5 C lanes 2 and 4).  Thus, VP16 binds the Ni++ 
beads nonspecifically and does not associate efficiently with the pUL17- His–
VP13/14 complex.  Although the reason for nonspecific association of VP16 
with the Ni++ beads remains unclear, we hypothesize that the presence of 
pUL17-His competes for non-specific interactions between VP16 and the 
charged Ni++ beads. Because VP13/14 and VP16 are known to interact, we 
speculate that the strong binding of VP16 to the affinity matrix might account 
for the small amount of VP13/14 in the HSV-1(F) eluate (Figure 5.5 B, lane 2).  
If this were the case, it would argue that relatively few molecules of VP16 
associate with VP13/14. 
 
Co-localization of pUL17, VP11/12 and VP13/14 in infected cells:  
Given the results of our immunoprecipitation data, we next asked if 
VP13/14 and pUL17 co-localize in infected cells.  Because the polyclonal 
antibody directed against VP13/14 was not useful for indirect 
immunofluorescence (data not shown), we constructed a recombinant virus 
placing an HA tag at the C terminus of VP13/14.   
Cells were infected with the VP13/14-HA virus, fixed at various times 
after infection, and immunostained with anti-pUL17 and anti-HA antibodies.  
Bound immunoglobulins were revealed by reaction with anti-immunoglobulins 
conjugated to different fluorescent markers.  The results, shown in figure 5.6, 
indicate that pUL17 and VP13/14 (as indicated by reaction with the anti-HA 
antibody) are detectable by 6 hours after infection.  At this time point, both 
pUL17 and VP13/VP14 co-localized in either the cytoplasm in a perinuclear 
region of cells or at low levels in the nucleus.  By 9 hours, both pUL17 and 
VP13/14 were predominantly located in the intranuclear replication 
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Figure 5.6.  Immunofluorescence staining time-course from infection with an 
HA-tagged VP13/14 virus.  At the indicated hours post-infection Hep2 cells  
were fixed, permeabilized, and reacted with antibodies to pUL17 (leftmost 
column), HA (indicating VP13/14 localization; second column to left), or 
ICP4 (rightmost column).  Third column from the left is a merge of the two 
columns to its left.  Arrows indicate regions of the plasma membrane 
bearing pUL17 and VP13/14-HA-specific signals.  Images were captured 
under 600x magnification with an additional 3x digital zoom. 
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 compartment as determined by their distribution in a pattern identical to that 
obtained upon immunostaining with ICP4 specific antibody (57).  Some cells 
contained more pUL17 specific staining than VP13/14 staining, whereas others 
contained more VP13/14- than pUL17-specific immunostaining.  Although 
previous reports indicated that pUL17 localized to intranuclear aggregates 
containing VP5 and ICP35, such distribution was seen only rarely in the 
current study (99).  At 12-15 hours post infection, small amounts of 
immunoreactivity attributable to both VP13/14 and pUL17 co-localized at the 
plasma membrane (fig. 5.6 M, N, O, Q, R, S and figure 5.7).  These data 
indicate that, at least as viewed by immunofluorescence, VP13/14 and pUL17 
localize at later times post infection in the replication compartment of the 
nucleus, and eventually at the plasma membrane. 
 A recombinant 47HA delta 17 virus was constructed to survey whether 
the pUL17 deficiency could alter the distribution of HA-tagged VP13/14.  
Immunofluorescent studies were repeated with VP13/14-HA and VP13/14-HA 
delta 17 in parallel and no significant difference was observed in the intensity 
or distribution of VP13/14 (data not shown).  Late in infection, HA staining was 
still readily apparent in the nucleus, the cytoplasm, and at nuclear and plasma 
membranes.  Thus we conclude that the interaction of pUL17 with VP13/14 in 
not necessary to maintain either VP13/14-HA expression or localization.  
 
Co-expression of VP11/12, VP13/14 with  pUL17 results in cytoplasmic 
co-localization: 
In order to determine whether pUL17, VP11/12, and VP13/14 co-
localize in the absence of other viral proteins, expression constructs encoding 
pUL17, VP13/14-HA and FLAG-VP11/12 were transfected in various  
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Figure 5.7  Co-localization of pUL17 and VP13/14.  Sixteen hours post-
infection co-localization can be seen in the replication compartment, at the 
nuclear and plasma membrane and in the cytoplasm.  pUL17 (Texas Red), 
anti-HA (FITC).  Images were captured under 600x magnification with an 
additional 7x digital zoom.  
 combinations into Hep2 cells.  Approximately 36-48 hours later, the cells were 
reacted with anti-FLAG (M2), anti-pUL17 and anti-HA antibodies.  The results 
are shown in figure 5.8.   
The distribution of pUL17 expressed in the absence of other viral 
proteins varied from cell to cell.  In some cells, immunoreactivity attributable to  
pUL17 accumulated in the cytoplasm almost exclusively, with very light 
staining in the nucleus (fig. 5.8, panel 1, cell on left).  In many cells, pUL17 was 
distributed roughly equally in both the cytoplasm and nucleus (fig 5.8, panel 1, 
cell on right). 
Solely expressed VP13/14-HA localized predominantly (although not 
exclusively) within the nucleoplasm in a smooth pattern exclusive of the  
nucleolus, with very little immunostaining detectable in the cytoplasm (fig. 5.8, 
panel 2). 
In contrast, FLAG-VP11/12 expressed in the absence of other viral 
proteins localized exclusively in the cytoplasm and primarily in perinuclear 
aggregates (fig. 5.8, panel 3).  We note that this exclusively cytoplasmic 
pattern was similar to that expressed by a virus encoding VP11/12-GFP (174, 
273) and VP11/12 fused to an HA epitope tag (174). Thus, the punctate 
distribution of FLAG-VP11/12 in this study was consistent with that seen in 
previous studies using different fusion partners.   
Co-expression of UL17 and FLAG-VP11/12 caused the encoded 
proteins to partially co-localize in some perinuclear aggregates (fig. 5.8, panel 
6); however, the general pattern of immunostaining of both proteins remained 
unaltered from that obtained upon expression of the individual proteins.  Co-
expressed pUL17 and VP13/14-HA co-compartmentalized (fig. 5.8, panel 9) in 
the nucleus. Co-expression of FLAG-VP11/12 with VP13/14-HA resulted in a  
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Figure 5.8.  Immunofluorescent staining of singly and co-expressed pUL17,  
VP13/14-HA,  and VP11/12-FLAG.  Expression of each protein alone is 
shown (1-3): VP13/14-HA (Texas Red, red), FLAG-VP11/12 (Cy5, white), 
and pUL17 (FITC, green).  Co-transfection indicates cytoplasmic co-
localization of pUL17 with FLAG-VP11/12 (6), and FLAG-VP11/12 with 
VP13/14- HA (12).  Images were captured under 600x magnification with 
an additional 3x digital zoom. 
 slight increase in the amount of VP13/14-HA immunoreactivity in the 
cytoplasm (fig. 5.8, panel 10).  Although most VP13/14-HA and VP11/12-
specific staining did not co-localize, some of the more intensely staining 
cytoplasmic foci of VP13/14-HA contained FLAG-VP11/12 (fig. 5.8, panel 12).  
Lastly, cells receiving all three expression constructs exhibited more 
cytoplasmic VP13/14-HA, and some cytoplasmic foci contained all three 
proteins (fig 5.9, panels 4 and 8).  Based on these collective data, we 
conclude that (i) co-expression of VP11/12 and VP13/14 results in a greater  
cytoplasmic localization of VP13/14 and (iii) co-expressed pUL17, VP11/12, 
and VP13/14 co-localize to a limited extent in the cytoplasm. 
    
Assembly of VP13/14 into virions: 
Having established collectively in this and previous studies that (i) pUL17 is 
located on the surface of nucleocapsids, (ii) VP13/14 and pUL17 interact and 
(iii) that both VP13/14 and pUL17 co-localize in the nucleus and cytoplasm at 
late times post infection, we wanted to determine at what point during egress 
VP13/14 becomes incorporated into virions.  Preliminary experiments to 
demonstrate unequivocally the presence of VP13/14-HA in association with 
intranuclear capsids were unsuccessful because VP13/14-HA migrated 
throughout sucrose gradients, even when capsid assembly was precluded by 
deletion of UL18, which encodes one of the triplex proteins critical to capsid 
formation (not shown).  We therefore used immunogold electron microscopy 
as an alternative approach.  Thus, cells were infected with HSV-1(F) or the 
VP13/14-HA virus at 5 PFU per cell.  Sixteen hours after infection, the cells 
were fixed, embedded in Epon plastic, and thin sections were reacted with 
anti-HA antibody.  Bound immunoglobulin was revealed by reaction with 
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Figure 5.9  VP11/12-FLAG, VP13/14-HA, and pUL17 triple transfection.   
Co-expression of all three proteins: VP13/14-HA (Texas Red, red), FLAG-
VP11/12 (Cy5, white), and pUL17 (FITC, green) and cytoplasmic co-
localization.  Images were captured under 600x magnification with an 
additional 3x digital zoom. 
 goat anti-rabbit immunoglobulin conjugated to 12 nm colloidal gold beads.  
Representative results are shown in figure 5.10.   
 Immunoreactivity in thin sections of cells infected with the VP13/14 HA 
was most intensely associated with virions in the cytoplasm and extracellular  
space.  This was expected inasmuch as VP13/14 is known to accumulate 
abundantly in virions.  In contrast, colloidal gold beads reflecting localization of  
VP13/14-HA were not associated to an appreciable extent with intranuclear 
capsids. We also noted many gold beads arranged in short linear or curved 
arrays at the nuclear periphery.  Importantly for the purposes of this study, 
some perinuclear virions were also decorated with gold beads, but the 
immunolabeling was not as consistent nor as intense as that of virions in the 
cytoplasm or extracellular space.  In the control experiment performed in 
parallel, virtually no immunoreactivity was observed in thin sections of cells 
infected with HSV-1(F) reacted with the HA antibody.  This was the case 
despite the ample presence of virions within these sections (not shown).    
We interpret these data as indicating that the bulk of VP13/14-HA is 
incorporated into de-enveloped virions in the cytoplasm, whereas small 
amounts may become associated with capsids at the nuclear periphery, 
presumably at or near the time of budding through the INM.   
 
Discussion:    
   The main goal of this study was to identify pUL17 interacting proteins to 
shed light on its role in tegument and capsid assembly.  The studies were 
initiated by co-immunoprecipitation with pUL17 antibody, followed by analysis 
of bands predominantly or exclusively visualized in electrophoretic profiles of 
proteins immunoprecipitated from lysates of wild type virus as opposed to 
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Figure 5.10. Immunogold electron microscopy with HA-specific antibody.  
Cells were infected with a recombinant virus bearing the HA epitopic tag 
fused to VP13/14, and were embedded 16 hours later.  Thin sections of the 
infected cells were reacted with HA specific antibody and bound antibody 
was recognized with goat anti-rabbit IgG conjugated to 12 nm colloid gold 
beads.  Panel A.  Gold beads arranged in curved linear arrays at the 
nuclear periphery, and with cytoplasmic virions. Panel B. A single labeled 
perinuclear virion. Panel C. Gold beads associated with cytoplasmic virions 
and with the cytosol. Panel D. Gold beads (i) arranged in a curved linear 
array at the nuclear periphery and (ii) in association with  cytoplasmic 
virions.  Onm, outer nuclear membrane; nuc, nucleus; cyto, cytoplasm.  As 
a size standard, HSV-1 capsids are 125 nm in diameter. 
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 those from a UL17 deletion virus.   Although this approach might preclude 
detection of interesting interacting proteins if they were to co-migrate with (i) 
proteins immunoprecipitated nonspecifically or (ii) the heavy or light chains of 
the IgY and IgG antibodies, we were able to identify interactions between 
pUL17 and vimentin, cellular histone proteins, the capsid component VP5, and 
the tegument proteins VP13/14 and VP11/12.   
Histone proteins that co-immunoprecipitated with pUL17 included H4, 
H2A, and H3, which represent core proteins of the nucleosome.  The 
exclusion of histone H2B from this group may reflect the fact that the encoding 
gene is transcriptionally down-regulated in lytic HSV infection as a 
consequence of competition by HSV-1 VP16 for the transcription factor Oct1 
(135).  Whether the interaction between pUL17 and histones actually occurs in 
vivo remains uncertain, however.  Such an interaction was not supported by 
indirect immunofluorescence studies inasmuch as pUL17 and histone H3 did 
not co-localize to any appreciable extent in infected cell nuclei (data not 
shown).  We remain similarly skeptical of the pUL17/vimentin interaction 
inasmuch as vimentin is a common contaminate of affinity purification and 
vimentin is mostly cytoplasmic, whereas pUL17 is largely nuclear in infected 
cells.  Thus, the significance of the histone/pUL17 and vimentin/pUL17 co-
immunoprecipitations requires further verification.   
The co-immunoprecipitation with VP5 is perhaps not surprising given 
previous observations that pUL17 localizes on the external surface of the 
capsid shell, which is largely composed of VP5 (274).  It remains unclear, 
however, whether pUL17 interacts with monomeric, pentameric or hexameric 
forms of VP5.  The deduced presence of pUL17 in a heterodimer with pUL25 
atop triplexes bridging capsid pentons to adjacent hexons was observed 
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 exclusively in DNA-containing capsids (i.e. in the CCSC) (254), whereas 
others using biochemical techniques have detected pUL17 on all capsid forms 
including procapsids (246).  Reconciling these observations will require further 
studies, but one possibility is that some triplexes bearing pUL17 are 
incorporated into the procapsid, whereas structural changes induced by DNA 
insertion promote the optimal conformation to promote pUL17/pUL25 binding.  
(We note that although pUL25 was not detected in these studies, we would 
expect the protein to co-migrate with the IgY heavy chain and therefore be 
unapparent in the analysis.)  Given that the triplex proteins VP19C and VP23 
were also unapparent by Coomassie-staining in the immunoprecipitation with 
anti- pUL17 antibody, it is possible that we are detecting pUL17 interactions 
with VP5 prior to capsid formation or after lysis of procapsids.  Further studies 
will be required to determine whether other capsid proteins interact directly or 
indirectly with pUL17. 
It is likely that the tegument is anchored to the capsid by a series of 
interactions.  Previous work to identify such anchoring points on the capsid 
focused on the pentonic vertices which bear densities of primary tegument 
when viewed in intact virions (285).  The precise identities of the proteins 
responsible for the penton-associated densities are unknown.  pUL36 has 
been shown to interact with HSV nucleocapsids and to interact with pUL25 in 
the pseudorabies system, suggesting its role as a primary tegument protein 
(27, 49).  The current study suggests another anchoring point of tegument on 
the capsid, specifically through the interactions between pUL17 on the capsid 
surface, and VP11/12 and VP13/14 in the next layer of tegument.  Thus, it is 
possible that the interaction between capsid-associated pUL17 and tegument 
proteins VP11/12 and VP13/14 helps capsids engage secondary envelopment 
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 sites in the cytoplasm.  That VP11/12 and VP13/14 associate with cytoplasmic 
capsids primarily is supported by (i) our immunogold study in which 
cytoplasmic virions were more frequently decorated by gold beads indicative 
of VP13/14-HA than were intranuclear capsids or perinuclear virions and (ii) 
the observation that co-localization of co-expressed pUL17, VP11/12 and 
VP13/14 only occurs in the cytoplasm. 
We also noted that co-immunoprecipitation of VP13/14 and VP16 does 
not occur in lysates of cells infected with a UL17 null virus, suggesting that 
pUL17 is necessary for the interaction between VP13/14 and VP16 in vivo. 
Although it is tempting to speculate that this observation reflects pUL17’s 
effects on the conformation of the tegument, and VP13/14-VP16 in particular, 
it is unclear whether this is a direct or indirect effect.  For example, if 
engagement of VP16 with VP13/14 required the presence of DNA-containing 
capsids in the cytoplasm, the absence of such capsids in cells infected with 
the UL17 null could explain the failure of VP16 and VP13/14 to interact.  
Further studies will be required to distinguish between this and other 
possibilities. 
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  CHAPTER VI: 
 
Encapsidation of Herpes simplex virus 1 DNA is not responsible for 
intranuclear movement of capsids 
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Abstract: 
Previous studies indicate that herpes simplex virus (HSV) capsids move 
in a directed, energy, and actin-dependent fashion in the nuclei of infected 
cells.  Because DNA packaging also requires substantial amounts of energy, 
we sought to test the hypothesis that energy-dependent movement was linked 
to DNA packaging. To this end capsid movement of viruses deficient for the 
essential DNA cleavage and packaging proteins, pUL6, pUL15, pUL17, pUL25, 
pUL28, or pUL33 was examined by time lapse microscopy.  In all cases, 
capsids moved with similar rates as those of wild type virus. We therefore 
conclude that capsid movement occurs independently of successful viral DNA 
cleavage and packaging.   
 
Introduction: 
HSV capsid proteins assemble 125 nm shells in the nucleus into which 
newly replicated HSV DNA is packaged.  The precursor capsid type, or 
procapsid, consists of two shells.  The inner shell is composed of scaffold 
proteins.  The outer capsid shell has T=16 symmetry and is mainly composed 
of the VP5 protein which can form two types of capsomeres of five-fold 
(termed pentons) and six-fold (termed hexons) symmetry (253, 262).  
Individual capsomeres are separated by triplexes, which comprise two VP23 
molecules and one molecule of VP19C (183, 228, 251).  VP26, the 12 kDa 
capsid protein encoded by UL35 (160), is external to the core capsid shell 
(178).  The protein is assembled onto the tips of hexons, but is excluded from 
pentons (25, 287)  By analysis of synchronized capsid maturation, it was 
determined that VP26 is added to the capsid in an ATP-dependent manner 
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 after angularization of the capsid from a spherical precursor or procapsid to 
more mature forms (45, 184). 
After capsid assembly is complete, a group of proteins encoded by UL6, 
UL15, UL17, UL25, UL28, UL32, and UL33 mediates packaging of nascent viral 
genomes.  The terminase, comprising subunits encoded by UL15, UL28, and 
UL33, is the protein complex thought to be responsible for recognizing, 
binding, and ultimately cleaving HSV DNA at Pac sites in the terminal repeats 
of the genome (19, 127, 259).  In this complex, UL15 protein (pUL15) likely 
encodes the ATPase, pUL28 contributes specific DNA binding activity, and 
pUL33 stabilizes the interaction between pUL15 and pUL28 (2, 277, 282).  
During the packaging reaction, the terminase proteins associate with a 
specialized portal vertex of the capsid comprising 12 copies of the UL6 protein 
(32, 182, 269, 278).  The UL17 and UL25 genes appear to play a structural role 
as they encode minor capsid proteins that are added to the external surface 
and border hexons and pentons (245, 254, 274).  pUL25 is dispensable for 
cleavage of genomes of less than full length, but in full length genomes is 
essential for maintenance of one end of the packaged genome.  This indicates 
that either pUL25 (i) is required for accuracy of the final DNA cleavage event 
that releases the genome from the concatemer or (ii) ensures proper capsid 
conformation to ensure that the genome stays in the capsid to avoid 
degradation (158, 231).  Potentially consistent with either role is the 
observation that pUL25 is present in greater amounts on DNA-containing 
capsids.  
GFP from the bioluminescent jellyfish, Aequorea Victoria, has been 
used extensively in both prokaryotic and eukaryotic systems as a molecular 
reporter for gene expression and cellular localization (reviewed in (37)).  
 168
 Because its fluorescence is independent of other co-factors, GFP facilitates 
live-cell analysis of proteins and organelle dynamics (38).  This characteristic 
of GFP and other chromophore derivatives (RFP, YFP etc) has been useful in 
labeling and monitoring HSV capsids (58, 63, 82) tegument proteins (58, 76), 
and glycoproteins (10, 18) by live cell microscopy.  
In HSV infection, VP26 is not essential for viral replication or proper 
tegumentation (42) and thus can be tagged and used to track capsids in living 
infected cells without substantially disturbing virion assembly.  Baculoviruses 
co-expressing the triplex proteins, scaffold protein, and the major capsid 
protein of HSV or Marek’s disease virus (another alphaherpesvirus) have been 
shown to produce large-cored B capsids in the absence of VP26 although 
assembly is facilitated in the presence of VP26 (130, 239, 244).   
Previous studies have shown that intranuclear capsids produced by 
HSV-1 strain  KOS labeled with GFP-VP26 move in a directed but erratic 
manner, and that this movement is both energy- and actin-dependent (82).   
The motor responsible for movement in the nucleus has yet to be identified.  
Although capsid movement was halted with myosin inhibitor 2,3-butanedione 
monoxime (BDM), this drug has effects on the cell other than myosin inhibition 
(82).  It is also unclear what advantage, if any, such movement serves in the 
viral life cycle.     
A simple hypothesis is that intranuclear capsid movement is driven by 
the HSV DNA packaging motor.  The packaging motor must be sufficiently 
powerful to encapsidate viral DNA under extreme pressure, at near liquid 
crystalline density, thus it is a good candidate to support capsid movement.  It 
is conceivable that the terminase motor could be used to move capsids along 
bound DNA in search for packaging signals prior to DNA cleavage/packaging.  
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 As an approach to address whether DNA packaging can account for capsid 
movement, we characterized the nuclear movement of GFP-labeled capsids in 
cells infected with a variety of DNA cleavage and packaging mutants.   
Intranuclear capsids were observed to move in cells infected with all the 
mutant viruses tested.   We therefore conclude that intranuclear capsid 
movement can occur independently of the DNA encapsidation process. 
 
Materials and methods: 
Production of a novel VP26-GFP expressing cell line - A GFP-UL35-
expressing pcDNA3 clone was created through an intermediate pCR2.1-UL35 
subclone derived from a KOS GFP-VP26 virus previously reported by Desai et 
al (63).  This fusion was formed by ligating a 711 base pair NcoI/BsrGI 
fragment of EGFP from pEGFP-N1 (Clontech) into the UL35 open reading 
frame such that EGFP started at the fifth codon of UL35 (63).  A GFP-UL35 
DNA fragment and linear pcDNA3 vector were obtained by EcoRI digestion 
and ligated to yielded a GFP-UL35 expression clone.  Hep2 cells were 
transfected with GFP-UL35-pcDNA3 and GFP positive clones were sorted by 
an ExCalibur FACS (fluorescence activated cell sorter) to enrich for FITC+ 
cells.  Cells were pooled and selected for stable expression of GFP-UL35. 
 
Production of a novel UL17 expressing cell line - A novel cell line CV1-17, 
specifically engineered to support replication of UL17 null viruses, was created 
using the Flp-In system from Invitrogen.  Briefly, the UL17 open reading frame 
was cloned into the FRT-containing expression vector pcDNA5/FRT and 
verified by DNA sequencing.  The pcDNA5/FRT-UL17 plasmid was co-
transfected with pOG44, a Flp recombinase-encoding plasmid, into CV-1 cells 
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 previously selected for an integrated FRT locus to support recombination of 
the transfected DNA.  Site-specific recombination resulted in a change of cell 
line phenotype from Zeocin resistance to Hygromycin (Hyg) B resistance.  
Hygromycin-resistant colonies were amplified and grown into cellular 
monolayers.  Expression of UL17 in these cells was determined by 
immunoblotting with anti-pUL17 antibody, and plaque formation by the UL17 
null virus.  One such cell line was designated CV1-17 and was used for further 
studies.  CV1-17 cells were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum and 200 μg/ml 
Hyg B. 
 
Live-cell microscopy of GFP-VP26 cells infected with DNA packaging-
deficient viruses - GFP-VP26 Hep2 cells were infected with viruses deleting 
individual DNA cleavage and encapsidation proteins.  Nine hours post-
infection the glass cover slips containing infected cells were mounted into a 
Bioptics flow cell and the intranuclear movement of GFP-labeled capsids was 
assayed by confocal time-lapse microscopy as was done previously (82).  
Multiple cells were analyzed for each infection.  Scan zones were cropped to 
isolate individual nuclei allowing for higher laser scanning frequencies ranging 
from 0.366 to 1.08 seconds per frame. 
 
Production of a BAC derived GFP-VP26 virus - Since our assay of infecting 
GFP-VP26 cells with deletion viruses results in two populations of VP26, non-
labeled and GFP-labeled, reporting capsid dynamics by GFP only represents 
a portion of total VP26.  In order to ensure that we were not missing an effect 
on capsid dynamics in our unlabeled population, we recreated a GFP-VP26 
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 virus through recombinant BAC technology.   This virus was engineered to 
mimic the K26GFP virus (63) including the previously reported 50 base pair 
deletion of non-coding sequence upstream of UL35 (175) leaving only a small 
FRT scar upstream of the GFP-UL35 coding region.  Briefly, primers LDS #36 
CCATGGTGAGCAAGGGCGAGGAG and TF #79 GCGTTATCCGCCGATGA 
with EGFP and VP26 homology, respectively, were used to amplify the GFP-
VP26 fusion protein from K26GFP viral DNA.  In an independent reaction, 
primers LDS #38 
GCACCGCCGCCCTAATCGCCAGTGCGTTCCGGACGCCTTCGCCCCACTC
GACCCGTGTAGGCTGGAGCTGCTTC (Kan homology underlined) with 
flanking oligonucleotides homologous to sequence upstream of UL35 and 
LDS#39 
AGCTCGACCAGGATGGGCACCACCCCGGTGAACAGCTCCTCGCCCTTG
CTCACCATATTCCGGGGATCCGTCGAC (Kan homology underlined) with 
flanking oligonucleotides homologous to the N terminus of GFP were used to 
amplify a FRT-KAN-FRT cassette.  In a subsequence stitching PCR reaction, 
products were annealed and the complete construct: upstream UL35 sequence 
/ FRT-KAN-FRT / GFP–UL35 was amplified with LDS #38 and TF #79 primers.  
This construct was sub-cloned into pCR2.1 and sequenced to ensure proper 
junctions.  EcoRI digestion of subclones released the KAN / GFP-UL35 fusion 
fragment with flanking UL35 sequence which was transformed into EL250 cells 
with a chloramphenicol-resistant, HSV-containing, bacterial artificial 
chromosome (BAC) (238) and recombinants were selected on Kan/Cm agar 
plates.  DNA extracted from resulting colonies was verified by electrophoresis 
of restriction digest.  Overnight cultures were grown in the presence of 0.1% 
arabinose to induce FRT-mediated recombination resulting in release of the 
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 Kan gene and the following day bacteria was struck on Cm plates for single 
colonies.  A selected group of resulting single colonies were replica-plated, 
first inoculating a Kan/Cm plate and subsequently a Cm only plate.  All 
selected colonies grew only on the Cm plate, indicating induction was 
complete and the Kan gene was lost through recombination.  These results 
were verified through successful colony PCR with upstream UL35 and internal 
UL35 primers [LDS #31 GAACGACAAACGGTGAATAGGTG (internal) and 
LDS #32 TATTTGGTGGGTGGTTGGTGCTGGCG (upstream)].  Three 
colonies were chosen for further analysis by BAC DNA extraction and BamHI 
digestion.  DNA from one clone, 38-2-11, was co-transfected by SuperFect 
(Qiagen) into rabbit skin cells with pCAGGS, a Cre recombinase-containing 
plasmid, to excise the BAC backbone.  Three rounds of plaque purification on 
Vero cells produced our GFP-VP26 virus.  The GFP-VP26 recombinant virus 
demonstrated wild-type growth properties. 
To knock-out one of the proteins essential for cleavage and packaging, 
UL17, in the context of this novel GFP-VP26 virus, electrocompetent EL250 
cells harboring the GFP-VP26 BAC were electroporated with a Kanamycin 
resistance cassette (KanR).  A gene encoding KanR was PCR amplified with 
the following primers containing sequences homologous to the UL17 ORF and 
KanR cassette:   
(del17F, #11) CAAACTTCCAG GTCGAAATCCAG 
ACTCGGGCTCATG CCACCGGCGACTG TA 
CGTGTAGGCTGGAGCTGCTTC; (del17R, #12) TTCCGTAGT GGTGGCGCA 
GGACCACGGAG ATAGAACGACG GCTCCACAGCC 
AGTCATTCCGGGGATCCGTCGAC  (KanR homology underlined).  Amplicons 
were transformed into EL250 cells containing a chloramphenicol–resistant 
 173
 (CmR) GFP-VP26 BAC (238).   CmR/KanR recombinants were selected on 
agar plates.  BAC DNA isolated from selected recombinants was co-
transfected with pCAGGS into CV1-17 cells to yield GFP-VP26 delta 17 virus. 
 
Capsid purification - Two roller bottles of Vero cells (approximately 4.0 x108) 
were infected with GFP-VP26 virus at an MOI of 5 and collected at 16 hours 
post-infection.  Cells were pelleted at 4000 rpm for 10 minutes, and pellets 
were resuspended in 16 mls dH20 and stored at -800C overnight.  Infected cell 
pellets were thawed, dounce homogenized with 15 strokes to lyse, and nuclei 
were pelleted at 4000 rpm for 15 minutes.  Pellets were resuspended in 8 mls 
of 1.0% TritonX100 in dH20 and sonicated for 45 seconds, before pelleting 
debris for 10 minutes again.  The supernatant was transferred to new tubes 
and returned to -800C.  Capsid containing supernatents were thawed and 
sedimented by ultracentrifugation at 20K rpm for 1 hour through a 35% (w/v) 
sucrose cushion.  After capsid were pelleted the cushion was carefully 
discarded and capsids were resuspended in 500 μl of STE buffer, sonicated 
for 3 seconds, and loaded onto the top of a 20% to 50% continuous sucrose 
gradient.  Capsid bands were formed upon ultracentrifugation at 23-25K for 1 
hour.  The entire sucrose gradient was fractioned into 500 ml aliquots with 
number 1 and number 22 representing the top and bottom fractions, 
respectively.   Aliquots of each of the 22 fractions were mixed with 2X SDS-
PAGE sample buffer, electrophoretically separated on an 8% SDS 
polyacrylamide gel, and transferred to nitrocellulose.  The membrane was 
blocked with 5% milk in PBST (PBS with 0.2% Tween-20) for 30 minutes and 
reacted with a 1:2,000 dilution of rabbit anti-GFP antibody (Molecular Probes 
A-11122) for 2 hours, washed 3 times with PBST for 5-10 minutes each, and 
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 incubated with a 1:5,000 dilution of HRP-conjugated anti-rabbit secondary 
antibody.  Excess secondary was washed from the membrane with another 3 
PBST washes and bound antibody was detected with a 1 minute incubation of 
(Pierce) ECL.  Fluorescence was captured on film.  
 
ATPase Assay:  C-His-tagged pUL17 expressed in insect cells was purified 
with Qiagen Ni-NTA beads as previously described (Chapter 4).  500 nM or 
1μM pUL17 were incubated with γP32-labeled ATP in BTR buffer (50 mM Tris 
pH 7.5, 10 mM MgCl2, 0.5 mM EDTA, 0.02% β-mercaptoethanol) at 37oC for 
60 minutes.  Samples were spotted on Whatman paper and dried with heat.  
Chromatography proceeded in a TLC chamber using a 50 ml solution 
containing 1.05g of lithium chloride and 2.6 mls of formic acid as a solvent.  
Chromatography was stopped before the migration front reached the end of 
the paper.  The paper was dried and exposed to film. 
  
Results:   
Verification of the GFP-VP26 virus: 
A recombinant BAC was generated that encoded GFP-VP26 virus in 
place of the UL35 gene.  To ensure that GFP-VP26 was able to bind to 
capsids, capsids were purified and subjected to immunoblotting with GFP-
specific antibody.  An identical peak in signal from fractions 13-15 was also 
seen with VP5 immunoblotting.  As shown in figure 1A, a band containing GFP 
immunoreactivity was detected that contained protein with a relative molecular 
weight (Mr) of 34.6 kDa in capsid fractions 10-22, with peak intensities in 
fractions 13-15 (fig 6.1). This was in close agreement with the calculated 
molecular weight, 38,170 of the GFP/VP26 fusion protein.  Bound IgG was 
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 removed chemically, and the nitrocellulose was re-probed with a 1:1,000 
dilution of anti-VP5 antibody (Virusys) followed by reaction with an  
HRP-linked anti-mouse secondary conjugate (Pierce) and fluorography. As 
shown in figure 6.1, the capsid-containing fractions as revealed by those with 
intense VP5 immunostaining corresponded to those containing VP26/GFP (fig 
6.1). 
To determine whether GFP labeling was uniform among capsids,  and 
that the observed capsids were consistent in fluorescent intensity compared to 
those reported in our previous studies, ten microliter aliquots of sucrose 
gradient fractions, 2, 7, 10, 14, 16, 18, 20, and 22 were spotted on glass slides 
and covered with coverslips.  Capsid fraction aliquots were analyzed on an 
Olympus confocal microscope at 600x and representative fields of capsids 
were photographed.  Fraction 14, corresponding to the fraction with the most 
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Figure 6.1  GFP-VP26 capsid isolation. GFP-VP26 purified from infected 
cell nuclei was separated in a sucrose gradient that was fractioned into 500 
μl aliquots numbered 1-22 with #1 and #22 representing the top and bottom 
of the gradient, respectively.  Separate immunoblotting with anti-GFP and 
anti-VP5 antibodies each shows a peak of capsids in fractions 13-15.  
(Images are overlaid)  The Mr of GFP-VP26 was calculated to be 34.6 kDa. 
 VP26/GFP immunoreactivity, demonstrated the highest density of GFP foci 
(fig. 6.2).  Labeled foci were determined to be fundamentally uniform in size 
and GFP intensity.  These were approximately equal in fluorescence intensity 
compared to labeled capsids seen in previous live-cell microscopy 
experiments (78, 82, 150).  Larger fluorescent foci, which have been termed 
assemblons, were not detected in any sampled fraction including the bottom-
most fraction, #22, where cell debris might accumulate (fig 6.2). 
 
Live-cell microscopic analysis of GFP-UL35 infection indicates different 
phases of capsid movement during the course of infection: 
Initial experiments to characterize intranuclear movement of capsids 
revealed multiple phases of capsid dynamics upon infection.  Specifically, 
most cells assayed prior to 8 hours post infection showed diffuse, hazy GFP 
staining without obvious single bright foci.   Subsequent to this, and starting 
around 9 hours post-infection, bright foci could be distinguished within the 
infected cell nucleus. These foci moved very rapidly in a seemingly random 
pattern (fig. 6.3). Measuring the rate of movement was hampered by the 
diffuse signal, high rate of  movement, and the fact that individual foci moved 
in and out of the focal plane very rapidly, precluding tracking of individual foci 
for significant lengths of travel.  By 10 hours post-infection additional larger 
fluorescent areas because apparent.  These were relatively immobile 
compared to the smaller foci.   The large fluorescent areas corresponded in 
size and position to previously identified assemblons (as shown in movies 
below Figures 6.4, 6.5, 6.6, 6.7, 6.8 , 6.9) and referred to as assemblons 
hereafter).  The assemblons remained essentially static during observation 
periods on the order of minutes, and only occasionally merged.  Smaller foci  
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Figure 6.2  Confocal immunofluorescence of purified GFP-VP26 
capsids.  Numbers along the side represent the gradient fraction from 
which the sample was taken.  Note the uniform size and intensity of 
particles.  Images were captured under 600x magnification. 
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Figure 6.3  Confocal time-lapse microscopy of BAC-derived GFP-VP26 
recombinant virus.  At earlier times in infection capsids displayed rapid 
movement in the absence of assemblons.  Images were cropped to 3.6771 
μm x 4.5057 μm and captured at 0.60 frames/second under 600x 
magnification.  Dynamics were such that only short paths of movement from 
individual particles could be traced, as indicated by white circles. 
 indicative of capsids were observed both entering and exiting the assemblon 
like structures, but entering was observed more frequently.   At later times 
after infection starting at 15 hours, movement of the small foci slowed 
considerably and became traceable over longer trajectories, with individual 
capsids moving at rates similar to those reported previously (82).  This type of 
movement was previously shown to be dependent on both energy and intact 
actin inasmuch as it was inhibited by depletion of ATP and depolymerization of 
F-actin with latrunculin B (82). 
 
Movement of capsids without DNA cleavage and packaging: 
To analyze movement of capsids in the absence of DNA cleavage and 
packaging, Hep 2 cells were infected with a recombinant virus bearing a 
deletion in UL17 and in which UL35 was replaced with a fused gene encoding 
GFP-VP26.  Similar to observations of wild type capsids tagged with GFP, 
fluorescent UL17-null capsids were first observed at 9 hours post infection.  
Much like wild-type capsids, rapid migration of labeled capsids and virtual 
stasis of assemblons was observed, thus indicating that, at least with respect 
to the UL17 deletion mutant, capsid movement could still occur in the absence 
of DNA packaging (fig 6.4).   
To ensure that DNA packaging proteins other than pUL17 are not 
involved in the intranuclear movement of viral particles, we sought to examine 
the movement of capsids in cells infected with viruses lacking other DNA 
packaging proteins.  To expediently address this issue, a cell line expressing 
GFP-VP26 was constructed and infected with various mutant and wild type 
viruses.  At 9-10 hours post-infection many assemblons and hundreds of 
individual capsids were discernable in individual nuclei in all infected cells.   
 181
  182
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4  Confocal time-lapse microscopy of GFP-VP26 delta 17 infection.  
Between 9-10 hours post-infection many dynamic capsids were discernable 
as well as the large assemblons.  Images were cropped to 5.3344 μm x 
4.9201 μm and captured at 0.50 frames/second under 600x magnification.  
An individual capsid moving within the focal plane is indicated in circles. 
 The movement of individual capsids of each virus could be traced and was 
found to be similar to wild type virus, despite the fact that DNA cleavage and 
packaging were precluded (Figures 6.5 – 6.10).  Intranuclear capsid 
movement was maintained even in the absence of the UL15 gene that 
encodes the ATPase subunit of the terminase, and in capsids that lacked the 
portal protein pUL6 (Figures 6.8, 6.7).  These observations suggest that 
capsids move through the nucleus by a mechanism that is completely 
independent of the individual viral proteins necessary to cleave and package 
the HSV genome as well as the action of DNA encapsidation mechanism. 
 In contrast to individual capsid movement, the brightly fluorescent 
assemblon-like structures were found to be relatively static during the course 
of both wild-type and DNA packaging-deficient infections.  Capsids were 
observed to migrate towards and enter assemblons (Figure 6.9).  However, 
only rarely were capsids observed leaving assemblons.  This suggests 
assemblons may be inactive depots where capsids accumulate; alternatively, 
capsids may have exited assemblons in focal planes other than those 
observed.  Only once were two assemblons observed to merge over a longer 
period of observation of a delta 17 infection (fig. 6.11).  When the same cell 
was assayed two minutes later the assemblons still remained merged.  
Examination of these bright foci by electron microscopy revealed that only 
some contained capsids (data not shown), indicating that the aggregates 
mostly represent accumulation of VP26/GFP.    
 
ATP hydrolysis with purified pUL17-His: 
 Although our data clearly show that cleavage and packaging proteins 
are not needed for capsid movement, we hypothesized that in addition to the  
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Figure 6.5  Confocal time-lapse microscopy of delta 17 infection in pJB193 
cells.  Images were cropped to 6.5773 μm x 3.6771 μm and captured at 
0.29 frames/second under 600x magnification.  An individual capsid moving 
within the focal plane is indicated in circles. 
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Figure 6.6  Confocal time-lapse microscopy of delta 25 infection in pJB193 
cells.  Images were cropped to 14.657 μm x 14.242 μm and captured at 
0.92 frames/second under 600x magnification.  An individual capsid moving 
within the focal plane is indicated in circles. 
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Figure 6.7  Confocal time-lapse microscopy of delta 6 infection in pJB193 
cells.  Images were cropped to 18.593 μm x 15.485 μm and captured at 
0.99 frames/second under 600x magnification.  An individual capsid moving 
within the focal plane is indicated in circles. 
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Figure 6.8  Confocal time-lapse microscopy of delta 15 infection in pJB193 
cells.  Images were cropped to 5.5415 μm x 4.9201 μm and captured at 
0.38 frames/second under 600x magnification.  An individual capsid moving 
within the focal plane is indicated in circles.  An assemblon which was not 
detected at the start of the movie was observed to appear within these 
frames. 
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Figure 6.9  Confocal time-lapse microscopy of delta 28 infection in pJB193 
cells.  Images were cropped to 12.585 μm x 14.035 μm and captured at 
0.91 frames/second under 600x magnification.  An individual capsid moving 
within the focal plane is indicated in circles. 
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Figure 6.10  Confocal time-lapse microscopy of delta 33 infection in pJB193 
cells.  Images were cropped to 15.692 μm x 16.935 μm and captured at 
1.08 frames/second under 600x magnification.  Individual capsids moving 
within the focal plane are indicated in circles. 
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Figure 6.11 Converging assemblons in delta 17 infection of pJB193 cells.  
Individual time-lapse microscopy frames from delta 17 movie show two 
assemblons in close proximity that appear to merge (frame 9 of this panel), 
into one, larger assemblon (lower right corner).  The field was cropped to 
6.5773 μm x 4.7129 μm and imaged at 0.37 frames/second under 600x 
magnification. 
 putative ATPase, pUL15, other cleavage and packaging proteins may have the 
ability to hydrolyze ATP which may aid in genomic encapsidation.  Specifically, 
we tested whether or not one of the outer capsid proteins, pUL17 has the 
ability to hydrolyze ATP.  A recombinant baculovirus was used to express 
pUL17 with a C-terminal 6x-(His) tag in SF21 insect cells.  Soluble pUL17-His 
was purified by affinity chromatography with Ni-NTA beads, eluted in 50mM 
NaH2PO4/300mM NaCl/250mM imidazole (pH 8.0), dialyzed into 50mM NaCl 
/50 mM NaH2PO4 and stored briefly at 4oC before use.  Purified protein was 
mixed with γP32-radiolabeled ATP at modest concentrations, 0.5-1.0 μM, and 
thin layer chromatography (TLC) was used to separate hydrolyzed free γP32 
phosphate from γP32-labeled ATP. 
 Assays comparing pUL17-containing samples to buffer only controls in 
the presence or absence of HSV-1(F) BAC DNA indicated hydrolysis was 
taking place specifically in the presence of pUL17 and independent of HSV 
DNA (Figure 6.12).  Hydrolysis of ATP was readily apparent in all pUL17-
containing samples.  Quantitative analysis of these data was performed using 
the Storm phosphoimager.  The percentage of free phosphate compared to 
the total radioactivity of the lane ranged from 31.9% - 39.2% in lanes 3, 4, 7 
and 8.  Quantization of negative samples (buffer only and buffer + DNA) 
ranged from 3.8% - 5.9%.   
 Having established that pUL17-containing samples were capable of 
hydrolyzing ATP, we next wanted to show that this activity was specific to 
pUL17.  To specifically block the hydrolysis of ATP we employed two 
antibodies that recognize purified pUL17-His, a commercial monoclonal anti-
penta His antibody (Qiagen) and a polyclonal chicken anti-pUL17-His (Figure 
6.13).  The assay was performed with 500 nM pUL17 as it proved sufficient for  
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Figure 6.12  ATPase assay of purified pUL17-(His).  The drawn line 
indicates the point of origin before TLC separation was applied.  Lower 
migrating species are indicative of γP32 labeled ATP whereas the upper 
species represents free phosphate.  Lanes 1-4 are as follows, (1) buffer 
only, (2) buffer + HSV BAC DNA, (3) buffer + 500 nM purified pUL17, (4) 
buffer + 500 nM purified pUL17 + HSV BAC DNA.  Lanes 5-8 repeat these 
samples, only pUL17 was added at 1.0 μM where applicable. 
  
hydrolysis in preceding experiments.  The result of this assay was that neither 
antibody was capable of inhibiting ATP hydrolysis of pUL17; ATP hydrolysis 
occurred in all pUL17-containing samples. 
 There are a number of reasons why the inclusion of antibody did not 
preclude ATP-hydrolysis.  It is not surprising that the anti-His antibody did not 
inhibit ATPase activity because it is a monoclonal antibody and thus directed 
at only a single epitope of the pUL17 protein.  In addition, the effective 
concentration of anti-His used was nearly 50-fold less than the anti-pUL17 
antibody.  Thus, it is possible that either an insufficient amount was added, or 
more likely that the His epitope is distinct from any putative ATPase domain on 
pUL17. 
 The anti-pUL17 chicken polyclonal antibody was also incapable of 
inhibiting ATPase activity in pUL17-containing samples.  Since (i) ample 
antibody (>10 ug) was added to the pUL17 + anti-pUL17 Ab reaction and (ii) 
this antibody has the potential to bind multiple epitopes on pUL17, the lack of 
an effect with its addition was unexpected.  Therefore, we must address the 
possibility that this hydrolytic function may be coming from another 
contaminating protein in our purification of pUL17. 
 To address the issue of protein purity we processed uninfected SF21 
cells and cells infected with another baculovirus expressing an unrelated His-
tagged protein (Stu2) with no known ATPase activity (a kind gift from T. 
Huffaker) in parallel with pUL17-His .  Elutions of Stu2 yielded 3- fold lower 
protein concentrations than that of pUL17.  ATPase assays were then 
performed with 500 nM concentrations of pUL17-His and Stu2-His.  No 
concentration could be assigned for the proteins binding non-specifically to the  
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Figure 6.13  ATP hydrolysis in the presence of pUL17-His antibodies.  
Lanes are as follows: buffer only (1), pUL17 (2), pUL17 + α-His Ab (3), α-His 
Ab (4), pUL17 + α-pUL17 Ab (5), α-pUL17 Ab (6).  Hydrolysis of ATP is not 
inhibited by either antibody; instead, hydrolysis is observed in all pUL17-
containing samples. 
 
 Ni-NTA matrix from the uninfected sample, so to be conservative we used the 
same volume of uninfected “purification” elution as was used for the less 
concentrated Stu2-His protein.  The results are shown in Figure 6.14. 
As previously shown, pUL17-His hydrolyzed ATP; however, levels of 
ATPase activity in both Stu2-His and uninfected purification samples 
exceeded that of pUL17.   Although it is likely that the pUL17-His extraction 
contains a contaminating protein with ATPase activity, this may not account for 
all activity observed.  Due to the lower concentration of Stu2-His recovered 
from purification, 3-4 fold larger volume of both Stu2-His and proteins eluted 
from uninfected-cell lysate was added compared to that of pUL17-His.  The 
intensities of free phosphate species in Stu2-His and uninfected samples do 
not appear to have a 3-4-fold increase over hydrolyzed phosphate in the 
pUL17-His, which suggests pUL17-His maybe be contributing to the ATPase 
activity observed.   
 
Discussion: 
 The HSV DNA packaging motor  must be powerful enough to overcome 
charge effects as it packages viral DNA into the capsid at near liquid 
crystalline density.  In order for the genome to be inserted, either the  DNA 
moves into a relatively stationary capsid, the capsid moves along fixed DNA,  
or both  relationships occur at different stages.  Since intranuclear capsid 
dynamics had already been observed, we chose to address the hypothesis 
that these capsid dynamics were linked to DNA encapsidation.    We found 
that precluding DNA cleavage and packaging did not stop the motility of 
capsids, indicating that the movement of capsids does not reflect activity of the 
DNA packaging reaction.  Additionally, none of the essential encapsidation  
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Figure 6.14  ATP hydrolysis with pUL17-His, Stu-2, and non-specific purified 
proteins.  Lanes are as follows: buffer only (1), pUL17-His (2), Stu2-His (3), 
“uninfected” (non-specific binding proteins) (4). 
   
proteins tested, including the ATPase-containing terminase complex, was 
individually required for capsid movement.  
In our assays in both wild-type and mutant-infected cells, assemblons 
were readily observed.  These large aggregates were nearly static during the  
course of infection.  Rarely, perceptible but slow movement of these structures 
was observed.  Due to their intensity which precluded detection of labeled 
capsids within them, no conclusions could be made about the dynamics of 
capsids within these structures.   
The role of assemblons in viral assembly is controversial (132, 266).  
The relatively uncommon detection of capsids within these structures indicates 
that they mostly represent deposition of GFP-VP26, rather than capsids, a 
conclusion consistent with the notion that  DNA packaging occurs elsewhere in 
the nucleus. 
We extended our investigation of the mechanisms underlying cleavage 
and packaging by assaying for energy production from pUL17, a minor capsid 
protein that is essential for cleavage and packaging.   Purified pUL17 samples 
were consistently able to hydrolyze the third phosphate of ATP into free 
phosphate in γP32 ATPase assays.  This function was shown to be 
independent of HSV DNA.  However, a monoclonal and polyclonal antibody 
against the His tag and pUL17-His, respectively, were unable to preclude the 
reaction, and non-specifically purified proteins were also shown to have the 
same activity.  Thus, pUL17 may function as an ATPase but the possibility that 
a contaminating protein in the purification is responsible for the hydrolysis of 
ATP has not been eliminated. 
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CHAPTER ViI: 
 
CONCLUSION 
 
Implications and Future Studies: 
In probing for protein interactions this work establishes pUL17’s 
relationship to both capsid and tegument proteins.  The first clues to a 
structural role for pUL17 were revealed by immunoelectron microscopy studies 
presented in Chapter II which suggested that pUL17 lies on the external face 
of the capsid.  To address this question, a high-affinity anti-pUL17 serum was 
generated which has proved to be invaluable to further studies.  
More precise capsid interactions between pUL17 and pUL25, which 
form a heterodimeric complex, were discussed in Chapter III.  
Immunoprecipitation assays suggest that these two proteins dimerize even in 
the absence of capsids.  Additionally, each protein requires its partner for 
proper distribution in infected cells.  Our results also suggest that pUL25 and 
pUL17 may undergo a conformational change independent of other capsid 
proteins. 
Many avenues of novel investigation of the pUL17/pUL25 heterodimer 
are opening  Future studies involving monoclonal antibodies or structure 
determination may pin-point the exact physical changes in these proteins, the 
timing of these conformational changes, and any functional implications.  
Although this complex is essential for DNA packaging, it is unclear if 
pUL17/pUL25 play only a structural role in preparing or in stabilizing capsid 
conformation, or if they are active participants in the encapsidation process.  
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 Recent studies are beginning to investigate the role this heterodimer plays in 
acquisition of tegument .  It also remains to be seen if the heterodimer may 
also be important in selection of C capsids for primary envelopment. 
 The observations described here also suggest that pUL17 makes 
contact with tegument proteins, specifically VP11/12 and VP13/14, to bridge 
the capsid and tegument layers.  Chapter IV investigates the requirements for 
the interaction of pUL17 and VP13/14.  Although pUL17 is not necessary for 
localization of VP13/14, the two proteins were observed to co-localize in the 
cytoplasm when in the presence of VP11/12.  The question remains whether 
these cytoplasmic aggregates represent tegumentation sites, or are artifacts of 
enhanced protein expression.   
  In addition to establishing a structural role for pUL17, this work 
investigates potential functional roles pUL17 may play.   We clearly 
demonstrated that pUL17, along with other cleavage and packaging proteins, 
was not responsible for intranuclear capsid movement.  However, other 
functional assays, such as DNA-binding and ATP hydrolysis show indications 
of pUL17 activity in preliminary experiments.  To perform these in vitro assays, 
a baculovirus expressing pUL17-His was engineered.  Upon infection of insect 
cells pUL17 was highly expressed and soluble protein was readily purified, a 
tool that no doubt will prove beneficial in subsequent functional assays.  As 
Chapter V illustrates pUL17 may posses the ability to hydrolyze ATP, although 
more stringent purification perhaps through TAP will be necessary before this 
can be concluded.  In electrophoretic mobility-shift assays, purified pUL17 also 
showed potential to bind both single and double-stranded DNA in a 
concentration dependent manner.  Difficulties in resolving a discrete migrating 
species most likely indicate that pUL17 has multiple binding sites on DNA.  
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 Further studies will be needed to determine if the 6x-Histidine tag allows 
electrostatic interactions with DNA or if pUL17 binds DNA independently of the 
epitope tag.  Also, chromatin immunoprecipitation assays may prove useful as 
a survey to find if pUL17 binds specifically to a region of the HSV genome. 
 To conclude, although no precise functional role for pUL17 was 
determined, these investigations have illuminated specific associations 
between pUL17 and capsid structure, tegumentation, and intranuclear capsid 
transport.    
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